

10/507,510

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 207/26, 403/06, 409/12, 207/40, 233/78, 231/08, 401/12, A61K 31/40, 31/41, C07D 413/12, 417/06</p>	<p>A1</p>	<p>(11) International Publication Number: WO 97/32846 (43) International Publication Date: 12 September 1997 (12.09.97)</p>
<p>(21) International Application Number: PCT/US97/02568 (22) International Filing Date: 3 March 1997 (03.03.97) (30) Priority Data: 60/013,098 8 March 1996 (08.03.96) US (71) Applicant (for all designated States except US): PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): JACOBSEN, E., Jon [US/US]; 74 South Lake Doster Drive, Plainwell, MI 49080 (US). (74) Agent: YANG, Lucy, X.; Pharmacia & Upjohn Company, Intellectual Property Legal Services, 301 Henrietta Street, Kalamazoo, MI 49001 (US).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: HYDROXAMIC ACID DERIVATIVES FOR USE WITH THE TREATMENT OF DISEASES RELATED TO CONNECTIVE TISSUE DEGRADATION</p>		
<p>(57) Abstract</p> <p>The present invention provides novel hydroxamic acid derivatives represented by the compound of formula (I), or pharmaceutical acceptable salts thereof, wherein the compounds of the present invention inhibit various enzymes from the matrix metalloproteinase family, including collagenase, stromelysin, and gelatinase, and hence are useful for the treatment of matrix metallo endoproteinase diseases such as osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as osteoporosis, tumor metastasis (invasion and growth), periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, and other diseases related to connective tissue degradation.</p> <div data-bbox="665 1155 1136 1407"> <p style="text-align: right;">(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

HYDROXAMIC ACID DERIVATIVES FOR USE WITH THE TREATMENT OF DISEASES RELATED TO CONNECTIVE TISSUE DEGRADATION**FIELD OF THE INVENTION**

5 The present invention relates to novel hydroxamic acid derivatives or pharmaceutically acceptable salts thereof, their preparation, and pharmaceutical compositions containing them. Particularly, the present invention relates to hydroxamic acid derivatives substituted by a series of 2-pyrrolidinones, hydantions, and pyrazolidinones, which are useful in the treatment of diseases related to
10 connective tissue degradation.

BACKGROUND OF THE INVENTION

Loss of connective tissue integrity occurs in many disease processes, including osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as
15 osteoporosis, tumor metastasis (invasion and growth) periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, and other diseases related to connective tissue degradation. Although there is a high incidence of these diseases in the developed world, there is no treatment that prevents the tissue damage that occurs. Considerable lines of scientific evidence indicate that
20 uncontrolled connective matrix metalloproteinase (MMPs) activity is responsible for the damage, and as a consequence the inhibition of these enzymes has become the target for therapeutic intervention (see Matrisian, L. M., Bases, Vol. 14, pp 445-463, (1992); Emonard, H. et al., Cellular and molecular Biology, Vol. 36, pp 131-153, (1990); Docherty, A. J. P. et al., Annals of the Rheumatic, Vol. 49, pp 469-479,
25 (1990)).

The compounds of the present invention inhibit various enzymes from the matrix metalloproteinase family, including collagenase, stromelysin, and gelatinase, and hence are useful for the treatment of matrix metallo endoproteinase diseases such as osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as
30 osteoporosis, tumor metastasis (invasion and growth), periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, and other diseases related to connective tissue degradation. These compounds may also inhibit the release of cytokines including tumor necrosis factor (TNF α) and hence may also be useful in the treatment of inflammation, fever, acute infections and shock.

35

INFORMATION DISCLOSURE

International Publication No. WO95/09841 discloses new hydroxamic acid derivatives of amino acid amide compounds useful as TNF release and matrix metalloprotease inhibitors, e.g., for treating inflammation, fever or arthritis.

5 International Publication No. WO95/04033-A1 discloses new succinimide derivatives useful as gelatinase and collagenase inhibitors.


International Publication No. WO93/21942 discloses matrix metallo protease inhibitors for promoting tumour regression by inhibiting cancer cell proliferation and angiogenesis, atherosclerosis, ovarian carcinoma, melanoma and sarcoma.

10 European Patent Publication 0,574,758A discloses new hydroxamic acid derivatives useful as collagenase inhibitors for the treatment of arthritis, tumours, atherosclerosis, etc.

UK Patent Application GB2,282,598A discloses hydroxysuccinyl hydroxyamines useful in the prophylaxis or treatment of diseases or conditions
15 mediated by metalloproteinases and/or tumour necrosis factor.

SUMMARY OF THE INVENTION

The present invention provides novel hydroxamic acid derivatives represented by the formula I:



I

or pharmaceutical acceptable salts thereof wherein

X is

- 30 a) $-(CH_2)-$,
b) $-NR_5-$, or
c) $-C(=O)-$;

Y is

- a) $-(CH_2)-$, or
35 b) $-NR_5-$;

with the proviso that when X is $-NR_5-$ then Y is $-(CH_2)-$;

R₁ is

- 5
- a) H,
 - b) C₁₋₂₀ alkyl,
 - c) -(CH₂)_i -Aryl,
 - d) -(CH₂)_i -O-R₅,
 - e) -(CH₂)_i -Het,
 - f) -(CH₂)_i -CO₂ R₅,
 - g) -(CH₂)_i -C(=O)NHR₅,
 - h) -(CH₂)_i -NR₆R₇,
 - 10 i) -(CH₂)_i -SO₂-Aryl,
 - j) -(CH₂)_j cycloalkyl, or
 - k) -(CH₂)_j-Aryl-Aryl;

R₂ is

- 15
- a) H,
 - b) C₁₋₂₀ alkyl,
 - c) -(CH₂)_j -R₈,
 - d) -(CH₂)_j -OR₅,
 - e) -CHCR₅=CR₅R₅,
 - f) -NHR₅,
 - 20 g) -(CH₂)_jNR₆R₇,
 - h) -NHSO₂R₅,
 - i) -(CH₂)_j -C(=O)NR₆R₇,
 - j) -(CH₂)_j -NR₅C(=O)R₅,
 - k) -(CH₂)_j-NR₅SO₂R₅, or
 - 25 l) -(CH₂)_j -N(COR₅)₂;


R₃ is

- 30
- a) H,
 - b) C₁₋₆ alkyl,
 - c) -(CH₂)_j -Aryl,
 - d) -(CH₂)_j -Het,
 - e) -(CH₂)_j -C₃₋₆ cycloalkyl, or
 - f) -C(=O)NHR₅;

R₄ is

- 35
- a) H,
 - b) -C(=O)NHR₅,
 - c) -C(=O)NR₆R₇,

- d) $-\text{C}(=\text{O})\text{NH}(\text{CH}_2)_k\text{NR}_6\text{R}_7$,
 e) $-\text{C}(=\text{O})\text{NH}(\text{CH}_2)_j\text{-Aryl}$,
 f) $-\text{C}(=\text{O})\text{NH}(\text{CH}_2)_k\text{-O}-(\text{CH}_2)_k\text{NR}_6\text{R}_7$,
 g) $-\text{C}(=\text{O})\text{NH}(\text{CH}_2)_k\text{-S}-(\text{CH}_2)_j\text{NR}_6\text{R}_7$,
 5 h) $-\text{C}(=\text{O})\text{NH}(\text{CH}_2)_k\text{-NHSO}_2\text{-Aryl}$,
 i) $\text{C}(=\text{O})\text{NH}(\text{CH}_2)_k\text{-NHSO}_2\text{-NR}_6\text{R}_7$, or



10 R_5 is

- a) H,
 b) C_{1-6} alkyl,
 c) $-(\text{CH}_2)_j\text{-Aryl}$,
 d) $-(\text{CH}_2)_j\text{-Aryl-Aryl}$,
 15 e) $-(\text{CH}_2)_j\text{-Aryl}-(\text{CH}_2)_j\text{-Aryl}$,
 f) $(\text{CH}_2)_j\text{-Het}$, or
 g) $-(\text{CH}_2)_j\text{-cycloalkyl}$


R_6 and R_7 may be the same or differently

- a) H,
 20 b) C_{1-6} alkyl,
 c) $-(\text{CH}_2)_j\text{-Aryl}$,
 d) Q, or
 e) R_6 and R_7 taken together with the linking N-atom form azetidiny, pyrrolidiny, piperaziny, piperidiny, or morpholiny, optionally substituted with one
 25 or more C_{1-4} alkyl;


R_8 is

- a) $-\text{SR}_5$,
 b) $-\text{SO-R}_5$,
 c) $-\text{SO}_2\text{-R}_5$,
 30 d) $-\text{S}-(\text{CH}_2)_j\text{-Het}$,
 e) $-\text{NHCO}_2\text{R}_5$,
 f) piperidiny,


35 g)




5




10




15




20



25



30



35

R_9 is

- a) halogen,
- b) C_{1-6} alkyl,
- c) $-OR_5$,
- 5 d) $-NR_5R_5$,
- e) $-CONHR_5$,
- f) $-SO_2NHR_5$,
- g) $-NHSO_2R_5$,
- h) $-NO_2$,
- 10 i) $-CO_2R_5$, or
- j) $-CF_3$;

R_{10} is

- a) H,
- b) OH,
- 15 c) OR_5 ,
- d) NHR_5 , or
- e) $-(CH_2)_j-OR_5$;

Aryl is phenyl, optionally substituted with one or more of the following:

- a) halogen,
- 20 b) C_{1-10} alkyl,
- c) $-OR_5$,
- d) $-NR_5R_5$,
- e) $-CONHR_5$,
- f) $-SO_2NHR_5$,
- 25 g) $-NHSO_2R_5$,
- h) $-NO_2$,
- i) $-CO_2R_5$, or
- j) $-CF_3$;

Het is

- 30 a 5-, or 6-membered heteroaromatic moiety having one or more atoms selected from the group consisting of N, O, and S;

Q is

a saturated 5, or 6-membered heterocyclic moiety having 1-2 atoms selected from the group consisting of N, O, and S;

- 35 i is 1, 2, 3, 4, 5 or 6;

j is 0, 1, 2, 3, or 4;

k is 2, 3, or 4;

n is 0, 1, 2, 3, or 4;

- C₁₋₆ alkyl, C₁₋₁₀alkyl, or C₁₋₂₀alkyl in each of the above definitions, may be each and independently substituted with one to three halogen, hydroxy, or cyano; and
5 with the proviso that when R₁ is methylbutyl R₄ is other than H.

The present invention provides novel hydroxamic acid derivatives useful as preventatives and therapeutics for diseases related to connective tissue degradation.

DETAILED DESCRIPTION OF THE INVENTION

- 10 For the purpose of the present invention, the carbon content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C_{i-j} defines the number of carbon atoms present from the integer "i" to the integer "j" inclusive. Thus, C₁₋₄ alkyl refers to alkyl of 1-4 carbon atoms, inclusive, or methyl, ethyl,
15 propyl, butyl and isomeric forms thereof.

The terms "C₁₋₆ alkyl", "C₁₋₁₀ alkyl" or "C₁₋₂₀ alkyl", refers to methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, etc. and isomeric forms thereof, and preferably an alkyl group having 1 to 6 carbon atoms.

- The C₁₋₆ alkyl group may optionally be substituted by one or more
20 substituents selected from the group consisting of a halogen atom, a hydroxy group, or -CN group such as, for example, fluoromethyl, difluoromethyl, fluoroethyl, cyanomethyl and the like.

- The term "C₃₋₆ cycloalkyl" refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and isomeric forms thereof, and preferably an cycloalkyl group having 4
25 to 6 carbon atoms.

The term "halogen" refers to fluoro, chloro, bromo, or iodo, preferably fluoro and chloro.

- The term "Q" refers to a saturated 5-, or 6-membered heterocyclic moiety having 1-2 atoms selected from the group consisting of nitrogen, oxygen, and sulfur
30 forming such groups as, for example, dioxolane, imidazolidine, dithiolane, oxathiolane, oxazolidine, piperidinyl, piperazinyl, morpholino and thiomorpholino.

- The term "Het" refers to a 5-, 6-membered heteroaromatic moiety having one or more atoms selected from the group consisting of nitrogen, oxygen, and sulfur forming such groups as, for example, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-
35 pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, 3-pyrazinyl, 2-furanyl, 3-furanyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 1-pyrazolyl. A

preferred heteroaromatic ring within the definition is 2-thienyl and pyridyl.

Within the definition of the terms "Het", and "Q", the nitrogen atom forming the hetero rings may have a protective group such as an acetyl or hydroxyacetyl group.

5 The compounds of the present invention can be converted to their salts according to conventional methods.

 The term "pharmaceutically acceptable salts" refers to salts useful for administering the compounds of this invention and these include hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate,
10 mesylate, maleate, malate, succinate, tartrate, citrate, 2-hydroxyethyl sulfonate, fumarate and the like. These salts may be in hydrated form. Some of the compounds of this invention may form metal salts such as sodium, potassium, calcium and magnesium salts and these are embraced by the term "pharmaceutically acceptable salts".

15 Certain of the hydroxamic acid derivatives of the present invention are preferred.

 The preferred R_1 substituent is methylpropyl.

 The preferred R_2 substituent is H, methyl, 2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(1,3-dihydro-1,3-dioxo-2H-naphthoisoindol-2-yl)ethyl, 2-(4,5,6,7,-
20 tetrafluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(5,6-dichloro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(5-amino-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(4-nitro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(5-nitro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(4-fluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(4,7-difluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(5-
25 fluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl, 2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl, 2-(2-thienylthio)propyl, or 2-(2-thienylthio)methyl.

 The preferred R_3 substituent is H, 2-methylpropyl, cyclohexylmethyl, benzyl, or phenyl.

30 The preferred R_4 substituent is H or acetamide.

 The preferred absolute configurations of the compounds claimed in the present invention are as represented in the structures II - VII. The absolute configurations are determined under the Cahn-Ingold-Prelog nomenclature system. The compounds depicted in the Examples are racemic unless indicated otherwise by
35 R or S to refer their optical activity. The pure enantiomers possess higher inhibitory activities. The racemic mixtures are useful in the same way and for the same

purpose as the pure enantiomer, the difference is that more racemic material may be used to produce the same inhibitory effect. Optically pure material can be obtained by using chiral HPLC methods to provide the corresponding enantiomers as illustrated in Examples 2, 5, and 28. Optionally, optically pure materials can be
5 obtained chemically to provide the desired enantiomer as illustrated in Examples 29-34.

Depending on substituents, the compounds of this invention may exist in geometric, optical and other isomeric forms and this invention embraces any of these isomers or enantiomers.

10 Particularly preferred compounds of this invention are as follows:

- 1a) N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 1b) (3S)-N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 15 1c) N-Hydroxy- α -methyl-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 1d) α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 1e) (3S)- α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-
20 methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 1f) α -[2-(1,3-Dihydro-1,3-dioxo-2H-naphthoisoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 1g) N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(4,5,6,7-tetrafluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-pyrrolidineacetamide,
- 25 1h) α -[2-(5,6-Dichloro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 1i) α -[2-(5-Amino-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 1j) N-Hydroxy-3-(2-methylpropyl)- α -[2-(4-nitro-1,3-dihydro-1,3-dioxo-2H-
30 isoindol-2-yl)ethyl]-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 1k) N-Hydroxy-3-(2-methylpropyl)- α -[2-(5-nitro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 1l) α -[2-(4-Fluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 35 1m) α -[2-(4,7-Difluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,

- 1n) α -[2-(5-Fluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 1o) α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 5 1p) α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 1q) N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(2-thienylthio)ethyl]-3-pyrrolidineacetamide,
- 1r) N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(2-thienylthio)propyl]-3-pyrrolidineacetamide,
- 10 1s) N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(2-thienylthio)methyl]-3-pyrrolidineacetamide,
- 1t) N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 15 1u) N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 1v) N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)-3-pyrrolidineacetamide,
- 1w) α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)-3-pyrrolidineacetamide,
- 20 1x) N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)- α -[2-(4,5,6,7-tetrafluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-pyrrolidineacetamide,
- 1y) 1-(3-Fluorophenyl)methyl)- α -[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetamide,
- 25 1z) α ³-[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N³-hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 2a) N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α ³-[2-(4,5,6,7-tetrafluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-1,3-pyrrolidinediacetamide,
- 2b) [S-(R*, R*)]-N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 30 2c) [S,R-(R*, R*)]- α ³-[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N³-hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 2d) [S-(R*, R*)]-N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 35 2e) [S-(R*, R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo-N¹-(2-phenethyl)- α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,

- (phenylmethyl)-1,3-pyrrolidinediacetamide,
 2f) [S-(R*, R*)]-N³-Hydroxy-N¹-methyl- α ¹,3-bis (2-methylpropyl)-2-oxo-
 1,3-pyrrolidinediacetamide,
 2g) [S-(R*, R*)]- α ¹-(Cyclohexylmethyl)-N³-hydroxy-N¹-methyl-3-(2-
 5 methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
 2h) [S-(R*, R*)]-N³-Hydroxy-N¹-methyl-3-(3-methylbutyl)-2-oxo- α ¹-
 (phenylmethyl)-1,3-pyrrolidinediacetamide,
 2i) N-Hydroxy-3-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-3-
 pyrrolidineacetamide,
 10 2j) N-Hydroxy-3-methyl-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-4-
 imidazolidineacetamide,
 2k) N-Hydroxy-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-4-
 imidazolidineacetamide,
 2l) N-Hydroxyl-4-(2-methylpropyl)-5-oxo-1-(2-phenylethyl)-4-
 15 pyrazolidineacetamide monohydrochloride,
 2m) [S-(R*, R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo-N¹-phenyl- α ¹-
 (phenylmethyl)-1,3-pyrrolidinediacetamide,
 2n) [S-(R*, R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-
 N¹-(2-pyridinylmethyl)-1,3-pyrrolidinediacetamide,
 20 2o) [S-(R*, R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-
 N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
 2p) [S-(R*, R*)]-N¹-(4-Fluorophenyl)-N³-hydroxy-3-(2-methylpropyl)-2-oxo-
 α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
 2q) [S-(R*, R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-
 25 N¹-[1-(phenylmethyl)-4-piperdinyl]-1,3-pyrrolidinediacetamide,
 2r) [S-(R*, R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-
 N¹-(4-piperdinyl)-1,3-pyrrolidinediacetamide,
 2s) [S-(R*, R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-
 N¹-(4-pyridinylmethyl)-1,3-pyrrolidinediacetamide,
 30 2t) [S-(R*, R*)]-N¹-(4-Fluorophenylmethyl)-N³-hydroxy-3-(2-methylpropyl)-
 2-oxo- α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
 2u) [S-(R*, R*)]-N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α ¹-(2-
 phenylethyl)-1,3-pyrrolidinediacetamide,
 2v) [S-(R*, R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo- α ¹-(2-phenylethyl)-
 35 N¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
 2w) [S-(R*, R*)]-N³-Hydroxy- α ¹,3-bis(2-methylpropyl)-2-oxo-N¹-2-pyridinyl-

- 1,3-pyrrolidinediacetamide,
 2x) [S-(R*,R*)]- α^1 -Cyclohexyl-*N*³-hydroxy-*N*¹-methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
 2y) [S-(R*,R*)]- α^1 -Cyclohexyl-*N*³-hydroxy-3-(2-methylpropyl)-2-oxo-*N*¹-2-pyridinyl-1,3-pyrrolidinediacetamide,
 2z) [S-(R*,R*)]-3-(Cyclopentylmethyl)-*N*³-hydroxy-*N*¹-methyl-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide,
 3a) [S-(R*,R*)]-3-(Cyclopentylmethyl)-*N*³-hydroxy-*N*¹-methyl-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide,
 3b) [3S-{1(R*),3R*(R*)}]- α^3 -[2-(Benzoylamino)ethyl]-*N*³-hydroxy-*N*¹-methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide,
 3c) [S-(R*,R*)]-*N*³-Hydroxy-3-(2-methylpropyl)-*N*¹-[2-(4-morpholinyl)ethyl]-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide,
 3d) [S-(R*,R*)]-*N*-Hydroxy-3-(2-methylpropyl)-1-[2-(4-morpholinyl)-2-oxo-1-(phenylmethyl)ethyl]-2-oxo-3-pyrrolidineacetamide,
 3e) [1(1S)-[1(R*(R*)), 3 α ,5 α]]-1-[2-(3,5-Dimethyl-1-piperazinyl)-2-oxo-1-(phenylmethyl)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetamide,
 3f) [S-(R*,R*)]-*N*³-Hydroxy-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-*N*¹-2-pyridinyl-1,3-pyrrolidinediacetamide,
 3g) [3S-{1(R*),3R*(R*)}]- α^3 -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-*N*³-hydroxy-*N*¹-methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide,
 3h) [S-(R*,R*)]- α^1 -Cyclohexyl-*N*¹-cyclopropylmethyl-*N*³-hydroxy-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
 3i) [S-(R*,R*)]- α^1 -Cyclohexyl-*N*¹-(4-fluorophenyl)-*N*³-hydroxy-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
 3j) [S-(R*,R*)]- α^1 -*tert*-Butyl-*N*³-hydroxy-*N*¹-methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
 3k) *N*-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(5-propyloxy-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-pyrrolidineacetamide,
 3l) [R-(R*,S*)]-5-Fluoro-1,3-dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1,3-dioxo-2H-isoindole-2-butanamide,
 3m) α -[2-(5,6-Difluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
 3n) *N*-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(5-

- trifluoromethyl-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-pyrrolidineacetamide,
- 3o) α -[2-(1,3,4,5,6,7-Hexahydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 3p) α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(3-phenylpropyl)-3-pyrrolidineacetamide,
- 5 3q) 1-[2-(4-Fluorophenyl)ethyl]- α -[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetamide,
- 3r) α -[2-(o-benzoic sulfimide)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 10 3s) Ethyl Phenylmethyl [4-(hydroxyamino)-3-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-4-oxobutyl]imidodicarbonate,
- 3t) *S*-(*R*^{*},*R*^{*})-1,3-Dihydro-N-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1,3-dioxo-2H-isoindole-2-butanamide,
- 3u) 1,3-Dihydro-N-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-[2-(4-fluorophenyl)ethyl]-3-pyrrolidinyl]-1,3-dioxo-2H-isoindole-2-butanamide,
- 15 3v) α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 3w) [*R*-(*R*^{*},*S*^{*})- α -[2-[(3-Fluorobenzoyl)amino]ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 20 3x) α -[2-[(4-Fluorobenzoyl)amino]ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 3y) N-Hydroxy-3-(2-methylpropyl)- α -[2-[(3-nitrobenzoyl)amino]ethyl]-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 3z) α -[2-[(3-Fluorobenzoyl)amino]ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 25 4a) α -[2-[(3-Fluorobenzoyl)amino]ethyl]-1-[2-(4-fluorophenyl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetamide,
- 4b) α -[2-[(4-Biphenylcarbonyl)amino]ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 30 4c) N-Hydroxy- α -[2-[(4-methylphenyl)sulfonyl]amino]ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 4d) α -[2-[(4-Fluorophenyl)sulfonyl]amino]ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 4e) N-Hydroxy- α -[2-[(4-methoxyphenyl)sulfonyl]amino]ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 35

- 4f) *N*-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-
[(phenylsulfonyl)amino]ethyl]-3-pyrrolidineacetamide,
- 4g) $[R-(R^*,S^*)]$ - α -[2-[(4-Fluorophenyl)sulfonyl]amino]ethyl]-*N*-hydroxy-3-
(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 5 4h) 5,6-Difluoro-1,3-dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-(2-
phenylethyl)-3-pyrrolidinyl]-1-oxo-2*H*-isoindole-2-butanamide,
- 4i) 1,3-Dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-
pyrrolidinyl]-1-oxo-2*H*-isoindole-2-butanamide,
- 4j) $[R-(R^*,S^*)]$ -6-Fluoro-1,3-dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-
10 oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1-oxo-2*H*-isoindole-2-butanamide,
- 4k) $[R-(R^*,S^*)]$ -5-Fluoro-1,3-dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-
oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1-oxo-2*H*-isoindole-2-butanamide,
- 4l) $[R-(R^*,S^*)]$ -5,6-Difluoro-1,3-dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-
oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1-oxo-2*H*-isoindole-2-butanamide,
- 15 4m) *N*-Hydroxy- α -{[(4-methoxyphenyl)sulfonyl]amino}-methyl-3-(2-
methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (α R-diastereomer),
- 4n) *N*-Hydroxy- α -{[(4-methoxyphenyl)sulfonyl]amino}-methyl-3-(2-
methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (α S-diastereomer),
- 4o) α -{[(4-Fluorophenyl)sulfonyl]amino}-*N*-hydroxy-3-(2-methylpropyl)-2-
20 oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (R-diastereomer),
- 4p) α -{[(4-Fluorophenyl)sulfonyl]amino}-*N*-hydroxy-3-(2-methylpropyl)-2-
oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (α S-diastereomer),
- 4q) α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(3-hydroxypropyl)-
2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 25 4r) α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(2-hydroxyethyl)-
2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 4s) $[R-(R^*,S^*)]$ - α -[2-[(3-Fluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(3-
hydroxypropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 4t) $S-(R^*,R^*)$ -*N*³-hydroxy-*N*¹-methyl- α ¹-(1-methylethyl)-3-(2-
30 methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 4u) $[S-(R^*,R^*)]$ -*N*¹-cyclopropyl-*N*³-hydroxy- α ¹-(1-methylethyl)-3-(2-
methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide.,
- 4v) $[S-(R^*,R^*)]$ -*N*³-hydroxy- α ¹-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-
*N*¹-phenyl-1,3-pyrrolidinediacetamide,
- 35 4w) $[S-(R^*,R^*)]$ -*N*¹-(4-fluorophenyl)-*N*³-hydroxy- α ¹-(1-methylethyl)-3-(2-
methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,

- 4x) [S-(R*,R*)]-N³-hydroxy-α¹-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 4y) [S-(R*,R*)]-α¹-*tert*-butyl-N¹-cyclopropyl-N³-hydroxy-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 5 4z) [S-(R*,R*)]-α¹-*tert*-butyl-N³-hydroxy-3-(2-methylpropyl)-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 5a) [S-(R*,R*)]-α¹-*tert*-butyl-N¹-(4-fluorophenyl)-N³-hydroxy-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 5b) [S-(R*,R*)]-α¹-*tert*-butyl-N³-hydroxy-3-(2-methylpropyl)-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 10 5c) [S-(R*,R*)]-α¹-cyclohexyl-N³-hydroxy-3-(2-methylpropyl)-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 5d) [S-(R*,R*)]-α¹-cyclohexyl-N³-hydroxy-3-(2-methylpropyl)-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 15 5e) [S-(R*,R*)]-3-(cyclopentylmethyl)-N³-hydroxy-N¹-methyl-α¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 5f) [S-(R*,R*)]-3-(cyclopentylmethyl)-N¹-cyclopropyl-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 5g) [S-(R*,R*)]-3-(cyclopentylmethyl)-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 20 5h) [S-(R*,R*)]-3-(cyclopentylmethyl)-N¹-(4-fluorophenyl)-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 5i) [S-(R*,R*)]-3-(cyclopentylmethyl)-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 25 5j) [S-(R*,R*)]-α¹-*tert*-butyl-3-(cyclopentylmethyl)-N³-hydroxy-N¹-methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 5k) [S-(R*,R*)]-α¹-*tert*-butyl-3-(cyclopentylmethyl)-N¹-cyclopropyl-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 5l) [S-(R*,R*)]-α¹-*tert*-butyl-3-(cyclopentylmethyl)-N³-hydroxy-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 30 5m) [S-(R*,R*)]-α¹-*tert*-butyl-3-(cyclopentylmethyl)-N¹-(4-fluorophenyl)-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 5n) [S-(R*,R*)]-α¹-*tert*-butyl-3-(cyclopentylmethyl)-N³-hydroxy-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 35 5o) [S-(R*,R*)]-α¹-cyclohexyl-3-(cyclopentylmethyl)-N³-hydroxy-N¹-methyl-2-oxo-1,3-pyrrolidinediacetamide,

- 5p) [S-(R*,R*)]- α^1 -cyclohexyl-3-(cyclopentylmethyl)-N¹-cyclopropyl-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 5q) [S-(R*,R*)]- α^1 -cyclohexyl-3-(cyclopentylmethyl)-N³-hydroxy-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 5 5r) [S-(R*,R*)]- α^1 -cyclohexyl-3-(cyclopentylmethyl)-N¹-(4-fluorophenyl)-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 5s) [S-(R*,R*)]- α^1 -cyclohexyl-3-(cyclopentylmethyl)-N³-hydroxy-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 5t) [S-(R*,R*)]-N³-hydroxy-N¹-methyl- α^1 -(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 10 5u) [S-(R*,R*)]-N¹-cyclopropyl-N³-hydroxy- α^1 -(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 5v) [S-(R*,R*)]-N³-hydroxy- α^1 -(1-methylethyl)-2-oxo-N¹-phenyl-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 15 5w) [S-(R*,R*)]-N¹-(4-fluorophenyl)-N³-hydroxy- α^1 -(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 5x) [S-(R*,R*)]-N³-hydroxy- α^1 -(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 5y) [S-(R*,R*)]- α^1 -tert-butyl-N³-hydroxy-N¹-methyl-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 20 5z) [S-(R*,R*)]- α^1 -tert-butyl-N¹-cyclopropyl-N³-hydroxy-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 6a) [S-(R*,R*)]- α^1 -tert-butyl-N³-hydroxy-2-oxo-N¹-phenyl-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 25 6b) [S-(R*,R*)]- α^1 -tert-butyl-N¹-(4-fluorophenyl)-N³-hydroxy-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 6c) [S-(R*,R*)]- α^1 -tert-butyl-N³-hydroxy-2-oxo-3-(3-phenylpropyl)-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamid,
- 6d) [S-(R*,R*)]- α^1 -cyclohexyl-N³-hydroxy-N¹-methyl-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 30 6e) [S-(R*,R*)]- α^1 -cyclohexyl-N¹-cyclopropyl-N³-hydroxy-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 6f) [S-(R*,R*)]- α^1 -cyclohexyl-N³-hydroxy-2-oxo-N¹-phenyl-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 35 6g) [S-(R*,R*)]- α^1 -cyclohexyl-N¹-(4-fluorophenyl)-N³-hydroxy-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,

- 6h) $[S-(R^*, R^*)]-\alpha^1$ -cyclohexyl- N^3 -hydroxy-2-oxo-3-(3-phenylpropyl)- N^1 -(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 6i) $[S-(R^*, R^*)]-3$ -[3-(4-fluorophenyl)propyl]- N^3 -hydroxy- N^1 -methyl- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 5 6j) $[S-(R^*, R^*)]-N^1$ -cyclopropyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 6k) $[S-(R^*, R^*)]-3$ -[3-(4-fluorophenyl)propyl]- N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo- N^1 -phenyl-1,3-pyrrolidinediacetamide,
- 6l) $[S-(R^*, R^*)]-N^1$ -(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 10 6m) $[S-(R^*, R^*)]-3$ -[3-(4-fluorophenyl)propyl]- N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo- N^1 -(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 6n) $[S-(R^*, R^*)]-\alpha^1$ -*tert*-butyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy- N^1 -methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 15 6o) $[S-(R^*, R^*)]-\alpha^1$ -*tert*-butyl- N^1 -cyclopropyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 6p) $[S-(R^*, R^*)]-\alpha^1$ -*tert*-butyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo- N^1 -phenyl-1,3-pyrrolidinediacetamide,
- 6q) $[S-(R^*, R^*)]-\alpha^1$ -*tert*-butyl- N^1 -(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 20 6r) $[S-(R^*, R^*)]-\alpha^1$ -*tert*-butyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo- N^1 -(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 6s) $[S-(R^*, R^*)]-\alpha^1$ -cyclohexyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy- N^1 -methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 25 6t) $[S-(R^*, R^*)]-\alpha^1$ -cyclohexyl- N^1 -cyclopropyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 6u) $[S-(R^*, R^*)]-\alpha^1$ -cyclohexyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo- N^1 -phenyl-1,3-pyrrolidinediacetamide,
- 6v) $[S-(R^*, R^*)]-\alpha^1$ -cyclohexyl- N^1 -(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 30 6w) $[S-(R^*, R^*)]-\alpha^1$ -cyclohexyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo- N^1 -(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 6x) $[S-(R^*, R^*)]-3$ -[3-(biphen-4-yl)propyl]- N^3 -hydroxy- N^1 -methyl- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 35 6y) $[S-(R^*, R^*)]-3$ -[3-(biphen-4-yl)propyl]- N^1 -cyclopropyl- N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,

- 6z) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 7a) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-N¹-(4-fluorophenyl)-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 5 7b) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 7c) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-tert-butyl-N³-hydroxy-N¹-methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 7d) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-tert-butyl-N¹-cyclopropyl-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 10 7e) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-tert-butyl-N³-hydroxy-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 7f) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-tert-butyl-N¹-(4-fluorophenyl)-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 15 7g) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-tert-butyl-N³-hydroxy-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 7h) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-cyclohexyl-N³-hydroxy-N¹-methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 7i) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-cyclohexyl-N¹-cyclopropyl-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 20 7j) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-cyclohexyl-N³-hydroxy-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 7k) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-cyclohexyl-N¹-(4-fluorophenyl)-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 25 7l) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-cyclohexyl-N³-hydroxy-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 7m) [S-(R*,R*)]-3-[3-(4'-fluorobiphen-4-yl)propyl]-N³-hydroxy-N¹-methyl-α¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 7n) [S-(R*,R*)]-3-[3-(4'-fluorobiphen-4-yl)propyl]-N¹-cyclopropyl-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 30 7o) [S-(R*,R*)]-3-[3-(4'-fluorobiphen-4-yl)propyl]-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 7p) [S-(R*,R*)]-3-[3-(4'-fluorobiphen-4-yl)propyl]-N¹-(4-fluorophenyl)-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 35 7q) [S-(R*,R*)]-3-[3-(4'-fluorobiphen-4-yl)propyl]-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,

- 7r) [S-(R*,R*)]- α^1 -*tert*-butyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-N³-hydroxy-N¹-methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 7s) [S-(R*,R*)]- α^1 -*tert*-butyl-N¹-cyclopropyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 5 7t) [S-(R*,R*)]- α^1 -*tert*-butyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-N³-hydroxy-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 7u) [S-(R*,R*)]- α^1 -*tert*-butyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-N¹-(4-fluorophenyl)-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 7v) [S-(R*,R*)]- α^1 -*tert*-butyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-N³-hydroxy-10 2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 7w) [S-(R*,R*)]- α^1 -cyclohexyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-N³-hydroxy-N¹-methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 7x) [S-(R*,R*)]- α^1 -cyclohexyl-N¹-cyclopropyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 15 7y) [S-(R*,R*)]- α^1 -cyclohexyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-N³-hydroxy-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 7z) [S-(R*,R*)]- α^1 -cyclohexyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-N¹-(4-fluorophenyl)-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 8a) [S-(R*,R*)]- α^1 -cyclohexyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-N³-hydroxy-20 2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 8b) Preparation of [S-(R*,R*)]-3-heptyl-N³-hydroxy-N¹-methyl- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 8c) Preparation of [S-(R*,R*)]-N¹-cyclopropyl-3-heptyl-N³-hydroxy- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 25 8d) Preparation of [S-(R*,R*)]-3-heptyl-N³-hydroxy- α^1 -(1-methylethyl)-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 8e) Preparation of [S-(R*,R*)]-3-heptyl-N¹-(4-fluorophenyl)-N³-hydroxy- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 8f) Preparation of [S-(R*,R*)]-3-heptyl-N³-hydroxy- α^1 -(1-methylethyl)-2-30 oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 8g) Preparation of [S-(R*,R*)]- α^1 -*tert*-butyl-3-heptyl-N³-hydroxy-N¹-methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 8h) Preparation of [S-(R*,R*)]- α^1 -*tert*-butyl-N¹-cyclopropyl-3-heptyl-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 35 8i) Preparation of [S-(R*,R*)]- α^1 -*tert*-butyl-3-heptyl-N³-hydroxy-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,

- 8j) Preparation of $[S-(R^*,R^*)]-\alpha^1$ -*tert*-butyl- N^1 -(4-fluorophenyl)-3-heptyl- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 8k) Preparation of $[S-(R^*,R^*)]-\alpha^1$ -*tert*-butyl-3-heptyl- N^3 -hydroxy-2-oxo- N^1 -(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 5 8l) Preparation of $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl-3-heptyl- N^3 -hydroxy- N^1 -methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 8m) Preparation of $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl- N^1 -cyclopropyl-3-heptyl- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 8n) Preparation of $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl-3-heptyl- N^3 -hydroxy-2-oxo- N^1 -phenyl-1,3-pyrrolidinediacetamide,
- 10 8o) Preparation of $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl-3-heptyl- N^1 -(4-fluorophenyl)- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide, and
- 8p) Preparation of $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl-3-heptyl- N^3 -hydroxy-2-oxo- N^1 -(4-pyridinyl)-1,3-pyrrolidinediacetamide.

15

The compounds represented by the general formula I can be prepared by the methods of reaction in Schemes A-D.

- As shown in Scheme A-1, structure 2 is readily prepared from structure 1 (commercially available) according to the procedures described in J. Am. Chem. Soc. Vol. 75, 3679 (1953). Alkylation of structure 2 requires an alkyl group (R_1) attached to an appropriate leaving group. The alkylation occurs in the presence of a suitable base such as lithium diisopropylamide (LDA) at a suitable temperature in the range -78 °C to 5 °C to provide structure 3. The ester side chain of structure 4 is introduced by alkylation of 3 with an alkyl ($R' = C_{1-6}$ alkyl) bromoacetate in the presence of a suitable base such as LDA in a suitable solvent such as tetrahydrofuran (THF), at a suitable temperature in the range -78 °C to 0 °C. Hydrolysis of structure 4 by the procedures well known to one of ordinary skill in the art affords structure 5, which is then converted to the hydroxamate 6 by reaction of structure 5 with hydroxylamine hydrochloride and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) as an acid activating agent at a suitable temperature in the range -20 °C to 20 °C. The reaction occurs in the presence of a catalyst such as 1-hydroxybenzotriazole hydrate (HOBT) and an appropriate acid scavenger such as N-methylmorpholine in a suitable solvent such as DMF, CH_2Cl_2 or a mixture thereof. Alternatively, alkylation of structure 4 with a halide compound $I-R_2$ (I is halogen, R_2 is defined as above) by procedures well known to one of ordinary skill in the art affords structure 7. For example,
- 20
- 25
- 30
- 35

alkylation of 4 with allyl bromide introduces an allyl group on the α -position of side chain using a suitable base such as LDA in a suitable solvent such as THF at a suitable temperature in the range -78°C to 25°C . The resultant allyl intermediate is then converted to the corresponding alcohol by ozonolysis and reduction NaBH_4 or
5 by hydroboration with 9-BBN. In many cases the alcohols are converted to a phthalimide via the Mitsunobu protocol. Alternatively, the alcohol can be converted to a leaving group (such as Ms, Ts) which is subsequently displaced with the desired nucleophile such as SR, NR_2 , OR, etc. The remaining synthetic steps which leads structure 7 to structure 9 is similar to that described above.

10 A slightly different approach is employed to prepare 16 as shown in Scheme A-2, which incorporates a terminal amide R_4 (R_4 is as defined above, except R_4 is not hydrogen). Alkylation of commercially available 10 affords lactam 11 according to the procedures described in Fisher, M. J. and Overman, L. E., J. Org. Chem., Vol. 55, pp 1447-1459 (1990). Lactam 11 is reacted with allyl bromide to provide 12.
15 The yields for this reaction are generally quite high. Alkylation of 12 with ethyl bromoacetate provides ester 13. Structure 13 is then converted to the corresponding amide 14, which followed by oxidation with ruthenium tetroxide in a solvent mixture such as carbontetrachloride, water, and acetonitrile at room temperature affords pyrrolidineacetic acid 15. The step which leads from structure 15 to
20 structure 16 is similar to that described above in Scheme A-1.

Scheme A-3 illustrates another method for preparing the compounds of formula I. As shown in Scheme A-3, reaction of structure 10 with di-tert-butyl dicarbonate in the presence of DMAP provided protected lactam 17. Alkylation of 17 with alkyl or alkenyl halides in the presence of HMPA provides lactam 18. The
25 ester side chain of structure 19 is introduced by alkylation of 18 with alkyl bromoacetate as described in Scheme A-1. Structure 19 can then be deprotected using magnesium methoxide in a suitable solvent according the procedure described in Tetrahedron Lett. Vol. 35, p 847 (1994) to provide structure 20. Alternatively, alkylation of 19 with a halide compound I-R_2 by procedures well known to one of
30 ordinary skill in the art affords structure 21. Deprotection of structure 21 affords structure 22. The R substituent can be introduced directly by N-alkylation of 20 or 22 with a desired halide compound using a suitable base such as sodium hydride in a suitable solvent such as THF or DMF to provide structures 4 or 7, respectively.

If desired, lactam 20 and 22 can be resolved using chiral HPLC or chemical
35 methods to provide the corresponding enantiomers as illustrated in Examples 2 and

28. Each antipode can be converted to the appropriate chiral analogs 20a and 22a as shown in Scheme A-4. Lactam 20 and 22, either as the racemate or a single enantiomer, are used in the alkylation steps as described in Schemes A-3 and A-4. As shown in scheme A-4, the alkylation of lactam 20a or 22a with the triflate 23 affords 24 and 28, respectively. For simplicity, only a single antipode of 20a or 22a and triflate 23 are presented. This chemistry can be carried out for both the racemate or a single enantiomer. Triflate 23 can be prepared following the procedure described in J. Org. Chem. Vol. 58, pp 2725-2737 (1993). A preferred approach to provide 24 involves deprotonation of 20a with a suitable base such as sodium hydride in a suitable solvent such as THF at a temperature in the range -20°C to 15 °C, followed by the addition of triflate 25. Warming to ambient temperature affords desired structure 24. If racemate 20 is utilized the diastereomers can be separated at this stage by silica gel chromatography or HPLC. Hydrolysis of the methyl ester 24 with aqueous NaOH provide 25, which following the formation of an amide by the procedure outlined in Scheme A-3, affords 26. The remaining synthetic steps which lead from structure 26 to structure 27 are similar to that described in Scheme A-1. In a similar fashion, the compounds represented by structure 31 are prepared.

Alternatively, an enantiospecific method can be employed to prepare a single antipode as shown in Scheme A-5. Alkylation of commercially available compound 32 requires an alkyl or allyl (R_1) attached to a leaving group in the presence of a suitable base such as lithium diisopropylamide (LDA) provides structure 33 as a mixture of diastereoisomers at the C-3 position of the ring. The mixture is alkylated with allyl bromide to provide 34 in optically pure form as shown in A-5. The trityl group is removed with TFA to provide 35, which is converted to lactol 36 following the protocol described in J. Chem. Soc. C.C. pp 1119-1122 (1989). The key cyclization step is effected quite simply by reaction of the lactol 36 with an amine 37 in the presence of sodium cyanoborohydride followed by heating the crude uncyclized intermediate at reflux in toluene to provide 38 as a single isomer. Amine 37 can be prepared through the conversion of a commercial available L-, or D-amino acid to the corresponding amine by procedures well known to one of ordinary skill in the art. Following the chemistry outlined in Schemes A-2, the olefin is oxidized with ruthenium tetroxide to provide 39, which is coupled with O-benzylhydroxylamine hydrochloride (CDI, THF) and then deprotected by hydrogenation with palladium on carbon to provide 41.

A series of other ring system are synthesized as shown in Schemes B-E. Scheme B illustrates a method for preparing 2,5-dioxo pyrrolidines. Exhaustive ruthenium tetroxide oxydation of 4 in the presence of sodium periodate in the suitable solvent such as water/acetonitrile/carbontetrachloride at an ambient
5 temperature provides 42. In a similar fashion as described in Scheme A-1, hydroxamate 43 is prepared.

Two different synthetic routes are developed for the synthesis of the hydantoin analogs as shown in Schemes C-1 and C-2. In Scheme C-1, N-alkylation of 1-methylhydantoin 44 with 2-bromoethylbenzene occurs in the presence of a
10 suitable base such as sodium hydride, in a suitable solvent such as DMF, at the temperature in the range -20°C to 15 °C. Following C-alkylation with a halide compound in the presence of a suitable base such as LDA at the temperature in the range -78°C to 15 °C affords 46. Formation of the quaternary center through C-alkylation with an alkyl bromoacetate in the presence of a suitable base such as
15 LDA at the temperature in the range -78°C to 15 °C affords 47. Conversion of 47 to the hydroxamate 48 is conducted following the previously outlined procedures. An alternative approach is developed for the synthesis of the unsubstituted (1-H) hydantoin analog of 48. Amino acid 49 can be prepared according to the procedures described in Dellaria, J. F., J. ORG. Chem. Vol. 53, p 5607 (1988). Following the
20 general procedure of Van der Veen, J.M. at el. J. C. S. Perkin II pp 653-658 (1979), amino acid 49 is reacted with an appropriate substituted isocyanate followed by cyclization under acidic conditions to provide hydantoin 50. The remaining synthetic steps which lead to structure 52 are similar to that described previously.

Scheme D illustrates an approach into a pyrazolidinone ring system.
25 Protection of pyrrazolidinone 53 by the procedures described in Perri, S. T. at el., J. Org. Chem., Vol. 55, pp 6037-6047 (1990) provides 54. Following N-alkylation and C-alkylations as outlined previously, lead to structure 57. An atmosphere of hydrogen is placed over a mixture of 57 and Pearlman's catalyst in a suitable solvent such as MeOH at ambient temperature to afford the desired compound 58.

30 The pharmaceutical compositions of this invention may be prepared by combining the compounds of formula I of this invention with a solid or liquid pharmaceutically acceptable carrier, and optionally, with pharmaceutically acceptable adjuvants and excipients employing standard and conventional techniques. Solid form compositions include powders, tablets, dispersible granules,
35 capsules and suppositories. A solid carrier can be at least one substance which may

also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent. Inert solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, cellulosic materials, low melting wax, cocoa butter, and the like. Liquid form compositions include solutions, suspensions and emulsions. For example, there may be provided solutions of the compounds of this invention dissolved in water, water-propylene glycol, and water-polyethylene glycol systems, optionally containing conventional coloring agents, flavoring agents, stabilizers and thickening agents.

10 The pharmaceutical composition is provided by employing conventional techniques. Preferably the composition is in unit dosage form containing an effective amount of the active component, that is, the compounds of formula I according to this invention.

15 The quantity of active component, that is the compounds of formula I according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application method, the potency of the particular compound and the desired concentration. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.

20 In therapeutic use for treating a patient, suffering from or susceptible to a diseases involving connective tissue degradation, or inhibiting various enzymes from the matrix metalloproteinase family, including collagenase, stromelysin, and gelatinase, the compounds or pharmaceutical compositions thereof will be administered orally, parenterally and/or topically at a dosage to obtain and maintain a concentration, that is, an amount, or blood-level of active component in the patient undergoing treatment which will be effective to inhibit such enzymes. Generally, an effective amount of the active compound will be in the range of about 0.1 to about 100 mg/kg. It is to be understood that the dosages may vary depending upon the requirements of the patient, the severity of connective tissue degradation being treated, and the particular compounds being used. Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired blood-level or the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administration, e.g., two to four times per day.

The compounds of the present invention inhibit various enzymes from the matrix metalloproteinase family, including collagenase, stromelysin, and gelatinase, and hence are useful for the treatment of matrix metallo endoproteinase diseases such as osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as
5 osteoporosis, tumor metastasis (invasion and growth), periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, and other diseases related to connective tissue degradation. Such diseases and conditions are well known and readily diagnosed by physician of ordinary skill.

These compounds may also inhibit the release of cytokines including tumor
10 necrosis factor (TNF α) and hence may also be useful in inflammation, fever, acute infections and shock. In general, the preferred form of administration is orally.

Pharmaceutical compositions for parenteral administration will generally contain a pharmaceutically acceptable amount of the compounds according to formula I as a soluble salt (acid addition salt or base salt) dissolved in a
15 pharmaceutically acceptable liquid carrier such as, for example, water-for-injection and a suitably buffered isotonic solution having a pH of about 3.5-6. Suitable buffering agents include, for example, trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine and L(+)-arginine, to name a few. The compounds according to formula I generally will be dissolved in
20 the carrier in an amount sufficient to provide a pharmaceutically acceptable injectable concentration in the range of about 1 mg/ml to about 400 mg/ml. The resulting liquid pharmaceutical composition will be administered so as to obtain the above-mentioned inhibitory effective amount of dosage. The compounds of formula I according to this invention are advantageously administered orally in solid and
25 liquid dosage forms.

Inhibitory activity is evaluated in one or more of the MMP enzymes (stromelysin, gelatinase, and collagenase) in vitro using a particle concentration fluorescence techniques. An inhibitor binds to MMP enzymes prevents the degradation of a substrate of stromelysin, gelatinase, or collagenase. The substrate
30 is attached with a fluorescein and a biotin. The intact substrate then binds to an avidin-coated particle via the biotin moiety. Once the particle is washed and dried, a fluorescent signal is generated since the fluorescent group is attached to the particle. Without an inhibitor present, the substrate is degraded by MMP enzymes and the fluorescein group is removed, therefore, no fluorescent signal can be
35 detected. Testing compounds are dissolved in DMSO to the desired concentration, then the solutions are diluted to 1:5 with MMP buffer (50 mM Tris-HCl, pH 7.5; 150

mM NaCl; 0.02% NaN₃). Serial two-fold dilutions of each compound are prepared. A concentrated, activated enzyme solution is transferred into each plate of the testing compounds, and the mixture is incubated at room temperature for 15 minutes. Thawed MMP substrate is then added into all plates, and the plates are incubated in the dark for 1-3 hours at room temperature. At this point, the substrate mixture is reacted with 0.1% avidin-coated polystyrene particles. After 15 minutes, the inhibitory activities are evaluated by Ki assay. Inhibitory data for the compounds of this invention are shown in TABLE 1. Compounds with lower Ki value are expected to be more effective as MMP inhibitors. It is expected that a compound with a Ki less than 15 μ M against any one of the MMP's will display therapeutic effects in connective tissue disorders.

TABLE 1
MMP Inhibition Constants (K_i, μ M) for Hydroxamic Acid Derivatives

Example No.	Stromelysin	Gelatinase	Collagenase
	K _i (μ M)	K _i (μ M)	K _i (μ M)
Example 1	27.2	3.55	2.3
Example 2	20.2	3.29	1.04
Example 3	10.86	11.68	4.23
Example 4	0.275	0.204	5.7
Example 5	0.041	0.115	4.37
Example 6	0.491	0.082	-
Example 7	1.27	1.42	-
Example 8	1.14	0.734	-
Example 9	0.903	0.78	14.3
Example 10	6.04	-	-

Example No.	Stromelysin	Gelatinase	Collagenase
	K _i (μM)	K _i (μM)	K _i (μM)
Example 11	1.02	0.498	0.073
Example 12	0.12	0.312	-
Example 13	0.334	0.28	-
Example 14	0.046	0.097	0.533
Example 15	0.188	0.782	21.3
Example 16	0.0924	2.87	14.2
Example 17	2.22	4.09	-
Example 18	1.47	3.04	-
Example 19	2.77	2.47	-
Example 20	16.6	3.103	0.579
Example 21	2.08	0.049	0.022
Example 22	1.96	1.3	2.07
Example 23	4.19	1.56	0.453
Example 24	7	-	-
Example 25	0.649	1.28	1.9
Example 26	0.713	0.998	-
Example 27	11	16.5	-
Example 29	0.57	0.981	0.484
Example 30	1.05	0.024	0.016

5

10

15

Example No.	Stromelysin	Gelatinase	Collagenase
	K _i (μM)	K _i (μM)	K _i (μM)
Example 31	0.517	0.0193	0.096
Example 32	0.73	0.05	0.036
Example 33	-	-	0.031
Example 34	4.14	0.031	0.022
Example 35	3.12	-	-
Example 36	2.4	44	-
Example 37	4.74	-	-
Example 38	31.2	14.5	13.3
Example 39	0.101	0.0759	0.00581
Example 40	1.99	0.0105	0.037
Example 41	0.014	0.0023	0.0028
Example 42	0.0255	0.0054	0.00244
Example 43	1.8	0.0023	0.00236
Example 44	4	0.011	0.0202
Example 45	1.01	0.017	0.0235
Example 46	2.1	0.04	0.035
Example 47	0.868	0.0853	0.0815
Example 48	0.385	0.16	0.072
Example 49	0.138	0.061	0.085

Example No.	Stromelysin	Gelatinase	Collagenase
	K _i (μM)	K _i (μM)	K _i (μM)
Example 50	0.283	0.017	0.00606
Example 51	0.084	0.023	0.0422
Example 52	0.187	0.0011	0.0013
Example 53	0.0105	0.00106	0.00069
Example 54	0.7	0.07	0.076
Example 55	1.9	0.211	0.75
Example 56	2.3	0.34	0.925
Example 57	0.075	0.0095	0.012
Example 58	0.023	0.0029	-
Example 59	0.23	0.011	0.0033
Example 60	0.019	0.0123	0.018
Example 62	0.369	0.31	55
Example 63	0.058	0.032	1.5
Example 64	0.107	0.049	0.735
Example 65	1.05	0.227	0.51
Example 66	0.39	0.75	4.7
Example 67	0.216	0.036	5
Example 68	0.35	0.16	1.46
Example 69	0.214	0.498	1.2

5

10

15


Example No.	Stromelysin	Gelatinase	Collagenase
	K _i (μM)	K _i (μM)	K _i (μM)
Example 70	0.194	0.0522	1.2
Example 71	-	-	0.098
Example 72	0.64	0.083	0.039
Example 74	0.052	0.021	0.026
Example 75	0.295	0.264	0.074
Example 76	10.8	3.3	0.298
Example 77	0.146	0.0319	0.0685
Example 78	0.696	0.278	0.018
Example 79	0.038	0.00177	0.339
Example 81	0.273	1.4	5.6
Example 82	0.379	0.878	2.4
Example 83	0.107	0.58	17
Example 84	1.73	3	0.385
Example 85	0.116	0.031	0.084
Example 86	0.102	0.046	0.647
Example 87	0.091	0.00488	0.23
Example 88	0.288	0.062	0.326
Example 89	0.318	0.146	2.5
Example 90	1.77	0.624	0.052

Example No.	Stromelysin	Gelatinase	Collagenase
	K _i (μM)	K _i (μM)	K _i (μM)
Example 92	0.309	0.273	0.37
Example 93	2.08	1.1	0.098
Example 94	0.016	0.0012	0.0134
Example 95	0.119	0.013	0.025
Example 96	0.0087	0.00098	0.0127

5

In order to more fully illustrate the nature of the invention and the manner of practicing the same, the following experimental examples are presented, but they should not be taken as limiting.

Example 1 Preparation of N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



Step 1. Preparation of 1-(2-Phenylethyl)-2-pyrrolidinone.

Following the procedure of Boekelheide and Godfrey (J. Am. Chem. Soc. 1953, 75, 3679), γ -butyrolactone (50.0 mL, 650 mmol) and phenethylamine (85.0 mL, 677 mmol) are heated in a sealed reaction vessel from room temperature to 200 °C over 2.5 hours, at 280-300 °C for 2 hours, and is allowed to cool to room temperature. The reaction mixture is distilled (1.5 mm, 130-144 °C) to yield 107 g of the title compound which solidified upon standing (mp 50.5-52.5 °C).

IR (mineral oil) 3334, 3079, 3022, 1671, 1634, 1498, 1493, 1433, 1425, 1328, 1280, 1248, 1156, 759, 707 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.10-7.35, 3.53, 3.25, 2.84, 2.35, 1.8-2.0;

MS (EI) m/z 189, 104, 98, 70.

Step 2. Preparation of 3-(2-Methylpropyl)-1-(2-phenylethyl)-2-pyrrolidinone.

A solution of 1-(2-phenylethyl)-2-pyrrolidinone (500 mg, 2.64 mmol) and THF (6 mL) is cooled to -78 °C. Some precipitation occurred and 2 mL of THF is added. A solution of lithium diisopropylamide (LDA, 1.4 mL, 2.8 mmol, 2.0 M in heptane/THF/ethylbenzene) is added and the mixture stirred at -78° C for 40 minutes, giving a dark brown solution. To this solution is added 1-iodo-2-methylpropane (0.37 mL, 3.2 mmol). The solution is allowed to warm from -78 °C to 5 °C over 2.5 hours. After quenching with saturated aqueous ammonium chloride, aqueous workup (EtOAc , MgSO_4) and purification by column chromatography (20% EtOAc /hexane) to give 642 mg (99%) of the title compound as a white solid (mp 69-71 °C).

IR (mineral oil) 3032, 3002, 1665, 1632, 1499, 1441, 1425, 1303, 1271, 1168, 772, 745, 704, 619 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.15-7.40, 3.40-3.65, 3.10-3.20, 2.84, 2.35-2.45,

2.05-2.2, 1.45-1.80, 1.10-1.25, 0.93, 0.89;

MS (EI) m/z 245, 189, 154, 126, 98, 54.

Step 3. Preparation of *tert*-Butyl 3-(2-Methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate.

5 LDA (2.0 M, 11.5 mL, 23.0 mmol) is added to a solution of 3-(2-methylpropyl)-1-(2-phenylethyl)-2-pyrrolidinone (4.70 g, 19.2 mmol) and THF (80 mL) at -78 °C. The solution is stirred at -78 °C for 45 minutes, and *tert*-butyl bromoacetate (3.4 mL, 23 mmol) is added. The solution is allowed to warm to 0 °C over 2 hours and is allowed to stir overnight at room temperature. After quenching with saturated
10 aqueous ammonium chloride, aqueous workup (EtOAc, $MgSO_4$) and purification by column chromatography (10% EtOAc/5% CH_2Cl_2 /hexane) to give 4.67 g (68%) of the title compound as a colorless oil. An analytical sample is crystallized from hexane (mp 50 °C).

IR (liq.) 2957, 2930, 2870, 1728, 1688, 1497, 1455, 1444, 1429, 1367, 1347,
15 1278, 1258, 1156, 701 cm^{-1} ;

1H NMR (300 MHz, $CDCl_3$) δ 7.15-7.35, 3.6-3.75, 3.35-3.5, 3.15-3.25, 2.85, 2.43, 2.05-2.2, 1.9-2.0, 1.55-1.7, 1.35-1.5, 1.42, 0.88, 0.86;

MS (EI) m/z 359, 303, 286, 268, 247, 212, 184, 166, 156, 138, 105.

Step 4. Preparation of 3-(2-Methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetic Acid.
20

A solution of *tert*-butyl 3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (659 mg, 1.83 mmol), trifluoroacetic acid (6.5 mL) and CH_2Cl_2 (6.5 mL) is stirred at room temperature for 1 hour. The solution is concentrated from CH_2Cl_2 (3 x 50 mL), dissolved in 1 N NaOH (10 mL), and the basic layer is
25 extracted with Et_2O (2 x 25 mL). The pH of the basic layer is adjusted to pH 1 with 6 N HCl. The acidic layer is extracted with CH_2Cl_2 (2 x 25 mL), the combined CH_2Cl_2 layers dried ($MgSO_4$), filtered and concentrated to give 511 mg (92%) of the title compound as a colorless oil.

IR (mineral oil) 3065, 3029, 1738, 1647, 1497, 1440, 1304, 1213, 1183, 1171,
30 1152, 1112, 756, 733, 701 cm^{-1} ;

1H NMR (300 MHz, $CDCl_3$) δ 7.10-7.35, 3.50-3.70, 3.15-3.35, 2.89, 2.55, 2.05-2.15, 1.60-1.85, 1.57, 1.36, 0.91, 0.87;

MS (EI) m/z 303, 247, 213, 212, 184, 166, 156, 138, 105, 104.

Step 5. Preparation of N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.
35

Solid 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC, 451


mg, 2.35 mmol) is added to a solution of 3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetic acid (595 mg, 1.96 mmol), 1-hydroxybenzotriazole hydrate (HOBT, 281 mg, 2.08 mmol) and 4-methylmorpholine (0.26 mL, 2.4 mmol) in CH_2Cl_2 (19 mL) and DMF (4 mL) at 0 °C. The solution is stirred at 0 °C for 1 hour, and then a near solution of hydroxylamine hydrochloride (204 mg, 2.94 mmol) and 4-methylmorpholine (0.32 mL, 2.9 mmol) in DMF (2.7 mL) is added. After stirring at room temperature overnight, the mixture is concentrated under high vacuum, and purified by column chromatography (3% MeOH/ CH_2Cl_2). Crystallization from Et_2O /hexane provided 193 mg (31%) of the title compound as a white solid (mp 123-124 °C).

IR (mineral oil) 3205, 3071, 3026, 1664, 1638, 1496, 1353, 1316, 1296, 1283, 1271, 1078, 982, 751, 705 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.15-7.35, 3.55, 3.10-3.30, 2.84, 2.39, 1.85-2.20, 1.55-1.75, 1.50, 1.32, 0.88, 0.85;

MS (EI) m/z 318, 227, 211, 193, 182, 166, 154, 138, 110, 105.

EXAMPLE 2 Preparation of (3S)-N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.




Resolution of *tert*-butyl 3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate. A solution of 50 mg/mL of racemic *tert*-butyl 3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (EXAMPLE 1, step 3) is made in the mobile phase that consisted of 10% isopropanol in hexane (V/V). Aliquots of 3.5 mL (175 mg) are injected onto a 2.1x25 cm Chiralpak AD column (Chiral technologies, Inc.). The column is eluted at 10 mL/min and monitored at 220 nm. The two enantiomers are collected using a peak recognition program and fractions are pooled appropriately. Each enantiomer is obtained at >99% ee. Enantiomeric excess is determined on a 0.46x25 cm Chiralpak AD column (Chiral Technologies, Inc.), developed with the same solvent at 0.5 mL/min and the monitor set at 220 nm. The

retention times here are 12.2 and 23.0 minutes ($\alpha = 2.61$).

Following the general procedure outlined in EXAMPLE 1 (steps 4-5), and making non-critical variations but starting with (S)-*tert*-butyl 3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (the faster eluting enantiomer described above), the title compound is obtained.

^1H NMR (300 MHz, CDCl_3) δ 7.10-7.35, 3.40-3.70, 3.10-3.30, 2.75-2.95, 2.38, 1.15-2.20, 0.75-1.00.

EXAMPLE 3 Preparation of N-Hydroxy- α -methyl-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



Step 1. Preparation of *tert*-Butyl α -Methyl-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate.

LDA (1.5 mL, 3.0 mmol, 2.0 M in heptane/THF/ethylbenzene) is added to a solution of *tert*-butyl 3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (967 mg, 2.69 mmol) and THF (11.0 mL) at -78°C . The solution is stirred at -78°C for 30 minutes and then iodomethane (0.19 mL, 3.1 mmol) is added. The solution is stirred at -78°C for 2 hours and then allowed to slowly warm to room temperature overnight. Aqueous workup (EtOAc , MgSO_4) and purification by flash chromatography (1:1 hexane: EtOAc) gives 791 mg (79%) of the title compound as an oil.

IR (liq.) 2975, 2956, 2931, 2869, 1724, 1686, 1497, 1455, 1429, 1367, 1279, 1257, 1153, 1114, 700, cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.15-7.35, 3.60-3.75, 3.30-3.45, 3.25, 2.82, 2.65, 2.25-2.40, 1.50-1.80, 1.35-1.50, 1.40, 1.12, 0.86, 0.84;

MS (EI) m/z 373, 317, 300, 282, 261, 227, 226, 152, 105, 104, 57.

Step 2. Preparation of α -Methyl-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetic Acid.

TFA (10.0 mL) is added to a solution of *tert*-butyl α -methyl-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (780 mg, 2.09 mmol) and

CH₂Cl₂ (10 mL) at 0 °C. The solution is stirred for 2.5 hours at 0 °C and 1.5 hours at room temperature. After concentration, the residue is partitioned between EtOAc and water. The organic layer is extracted several times with 10% NaOH, the combined basic layers acidified (4 N HCl), and the acidic layers extracted several times with CH₂Cl₂. The CH₂Cl₂ layers are dried (MgSO₄), filtered, and concentrated to provide 79 mg (12%) of the title compound as a white solid (mp 94-95 °C).

IR (mineral oil) 2400, 1731, 1616, 1505, 1497, 1488, 1443, 1354, 1326, 1289, 1266, 745, 736, 702, 607, cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.15-7.35, 3.65-3.85, 3.45-3.60, 3.20-3.40, 2.90, 2.59, 1.50-2.10, 1.06, 0.89, 0.85;

MS (EI) *m/z* 317, 261, 227, 226, 216, 180, 152, 105, 104, 55.

Step 3. Preparation of N-Benzyloxy-α-methyl-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.

CDI (39.7 mg, 0.245 mmol) is added to a solution of α-methyl-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetic acid (74.0 mg, 0.233 mmol) and CH₂Cl₂ (2.0 mL). The solution is stirred for 1 hour at room temperature. To this is added O-benzylhydroxylamine-HCl (63.2 mg, 0.396 mmol) and N-methylmorpholine (44 μL, 0.40 mmol). The resultant solution is stirred for 16 hours at room temperature. Aqueous workup (CH₂Cl₂, MgSO₄) and purification by flash chromatography (2:1 EtOAc:hexane) gives 88.1 mg (89%) of the title compound as an oil.

IR (liq.) 3230, 3063, 3029, 2956, 2936, 2869, 1664, 1497, 1454, 1367, 1310, 1282, 1029, 748, 699 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 10.16, 7.10-7.45, 4.87, 3.35-3.60, 3.10-3.30, 2.81, 2.42, 2.10-2.30, 1.75-1.90, 1.35-1.70, 1.05, 0.85, 0.79;

MS (EI) *m/z* 422, 300, 225, 196, 152, 105, 104, 91, 77, 69, 55.

Step 4. Preparation of N-Hydroxy-α-methyl-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.


An atmosphere of hydrogen is placed over a mixture of N-benzyloxy-α-methyl-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (80.0 mg, 0.189 mmol), MeOH (4.5 mL) and Pearlman's catalyst (15 mg). The mixture is stirred at room temperature for 4 hours. The mixture is filtered, the solids rinsed with MeOH (4 X 5 mL), and the filtrate concentrated to give 55.9 mg of an oil. Crystallization from hexane provided 46.9 mg (75%) of the title compound as a white

solid (mp 107-108 °C).

IR (mineral oil) 3227, 3044, 3026, 1658, 1641, 1498, 1436, 1294, 1262, 1031, 774, 735, 713, 695, 611 cm^{-1} ;

MS (FAB) m/z 333, 332, 301, 300, 272, 105, 69, 55, 41.

- 5 **EXAMPLE 4** Preparation of α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



- 10
15
20 **Step 1.** Preparation of *tert*-Butyl 3-(2-Methylpropyl)-2-oxo-1-(2-phenylethyl)- α -(propen-2-yl)-3-pyrrolidineacetate.

LDA (2.0 M, 7.7 mL, 16 mmol) is added to a solution of *tert*-butyl 3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (**EXAMPLE 1**, step 3; 4.62 g, 12.9 mmol) and THF (45 mL) at -78 °C. The solution is stirred at -78 °C for 45 minutes and allyl bromide (1.3 mL, 16 mmol) is added. The solution is allowed to
25 warm to 0 °C over 2 hours, and is allowed to stir overnight at room temperature. After quenching with saturated aqueous ammonium chloride, aqueous workup (EtOAc, MgSO_4) and purification by column chromatography (2:1:17 v/v EtOAc: CH_2Cl_2 :hexane) gives 4.43 g (86%) of the title compound as yellow oil which solidified upon standing (mp 54.5-56 °C).

30 IR (mineral oil) 1712, 1686, 1641, 1497, 1432, 1298, 1281, 1270, 1250, 1237, 1205, 1155, 912, 752, 702, cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.15-7.35, 5.65-5.8, 4.95-5.1, 3.55-3.7, 3.3-3.45, 3.15-3.25, 2.82, 2.53, 2.2-2.5, 1.7-1.85, 1.5-1.65, 1.35-1.45, 1.40, 0.87, 0.83;

MS (EI) m/z 399, 343, 326, 308, 253, 252, 234, 202, 105, 57.

- 35 **Step 2.** Preparation of *tert*-Butyl α -(2-Hydroxyethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate.

Ozone is bubbled through a solution of *tert*-butyl 3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -(propen-2-yl)-3-pyrrolidineacetate (555 mg, 1.39 mmol) and EtOH (12 mL) at -78 °C for 5 minutes. Nitrogen is then bubbled through the solution for 5 minutes. Sodium borohydride (79 mg, 2.1 mmol) is added and the mixture is
5 allowed to warm slowly and to stir at room temperature overnight. The mixture is concentrated to near dryness, and aqueous workup (EtOAc, MgSO₄) to give 511 mg (91%) of the title compound as a colorless oil.

IR (liq.) 2957, 2931, 2870, 1720, 1672, 1671, 1497, 1455, 1392, 1367, 1282, 1257, 1152, 1055, 701 cm⁻¹;

10 ¹H NMR (300 MHz, CDCl₃) δ 7.15-7.35, 3.55-3.75, 3.35-3.45, 3.15-3.25, 2.82, 2.61, 2.3-2.45, 1.85-2.0, 1.65-1.8, 1.35-1.60, 1.43, 0.87, 0.83;

MS (EI) *m/z* 403, 347, 330, 291, 270, 256, 238, 227, 202, 181, 105, 104.

Step 3. Preparation of *tert*-Butyl α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate.
15

Diethyl azodicarboxylate (182 μ L, 1.16 mmol) is added to a mixture of *tert*-butyl α -(2-hydroxyethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (468 mg, 1.16 mmol), triphenylphosphine (304 mg, 1.16 mmol), phthalimide (171 mg, 1.16 mmol) and THF (10 mL) at room temperature. The
20 mixture is allowed to stir overnight and is concentrated. Purification by column chromatography (2 columns, 5% acetone/CH₂Cl₂ and 10% EtOAc/hexane) provided 327 mg (51%) of the title compound as a colorless oil.

IR (liq.) 2956, 2932, 1773, 1716, 1685, 1467, 1454, 1438, 1397, 1368, 1299, 1255, 1152, 720, 701 cm⁻¹;

25 ¹H NMR (300 MHz, CDCl₃) δ 7.8-7.9, 7.65-7.75, 7.15-7.35, 3.55-3.8, 3.3-3.4, 3.15-3.25, 2.80, 2.51, 2.3-2.4, 2.0-2.15, 1.8-1.95, 1.6-1.8, 1.35-1.6, 1.46, 0.85, 0.82;

MS (EI) *m/z* 532, 476, 459, 441, 420, 385, 339, 311, 245, 202, 160, 105.

Step 4. Preparation of α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetic Acid.

30 Trifluoroacetic acid (2.0 mL) is added to a solution of *tert*-butyl α -[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (282 mg, 0.507 mmol) in CH₂Cl₂ (4.0 mL) at 0 °C. The solution is stirred for 1 hour at 0 °C. A second portion of trifluoroacetic acid (2.0 mL) is added, and the solution is stirred for 30 minutes at 0 °C and for 30 minutes at room
35 temperature. Concentration and aqueous workup (CH₂Cl₂, MgSO₄) to give 217 mg (90%) of the title compound as a colorless oil.

IR (mineral oil) 1711, 1606, 1509, 1498, 1485, 1445, 1403, 1359, 1295, 1262, 1244, 1111, 704 cm^{-1} ,

^1H NMR (300 MHz, CDCl_3) δ 7.85-7.9, 7.7-7.8, 7.15, 6.9-7.0, 3.7-3.9, 3.55-3.65, 3.35-3.5, 3.25-3.35, 2.75-2.95, 2.49, 2.0-2.1, 1.80-1.95, 1.65-1.75, 1.5-1.65, 1.2-1.45, 0.91, 0.84;

MS (EI) m/z 476, 420, 385, 339, 311, 272, 258, 202, 160, 105.

Step 5. Preparation of N-Benzoyloxy- α -[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.

CDI (82 mg, 0.51 mmol) is added to a solution of α -[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetic acid (202 mg, 0.424 mmol) and CH_2Cl_2 (3.2 mL) at room temperature, and the solution is stirred for 1 hour at room temperature. O-Benzylhydroxylamine hydrochloride (98 mg, 0.614 mmol) and 4-methylmorpholine (84 μL , 0.76 mmol) are added in succession, and the solution is allowed to stir overnight at room temperature. Aqueous workup (CH_2Cl_2 , MgSO_4) and purification by column chromatography (2% acetone/ CH_2Cl_2) gives 120 mg (49%) of the title compound as a colorless oil.

IR (mineral oil) 1773, 1715, 1683, 1663, 1662, 1497, 1398, 1340, 1301, 1270, 1038, 1030, 748, 699 cm^{-1} ,

^1H NMR (300 MHz, CDCl_3) δ 7.8-7.9, 7.7-7.8, 7.05-7.55, 4.93, 3.55-3.8, 3.48, 3.1-3.2, 2.77, 2.15-2.3, 1.7-1.9, 1.35-1.65, 0.80, 0.73;

MS (FAB) m/z 582, 459, 431, 160, 105, 91.

Step 6. Preparation of α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.


A mixture of N-benzoyloxy- α -[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (58 mg, 0.10 mmol) and 5% Pd/C (20 mg) is stirred for 1.5 hours at room temperature under an atmosphere of hydrogen. Palladium hydroxide on carbon (10 mg) is added and the mixture is stirred under hydrogen at room temperature for 6 hours. The mixture is filtered and the filtrate is concentrated. Purification by column chromatography (5% MeOH/EtOAc) gives 39 mg of an oil which is crystallized from EtOAc/hexane to give 29 mg (59%) of the title compound as a white solid (mp 158-159 $^{\circ}\text{C}$).

IR (mineral oil) 3212, 3101, 3087, 3005, 1773, 1711, 1659, 1495, 1444, 1401, 1310, 1292, 1040, 706 cm^{-1} ,

^1H NMR (300 MHz, CDCl_3) δ 10.19, 7.8-7.9, 7.7-7.8, 7.05-7.35, 6.9-7.0, 3.3-3.8, 3.19, 2.79, 2.39, 2.1-2.3, 1.75-2.0, 1.35-1.7, 0.83, 0.76;

MS (EI) m/z 491, 459, 435, 419, 400, 375, 355, 327, 262, 261, 245, 202, 160, 105.

- 5 **EXAMPLE 5** Preparation of (3S)- α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



15

Following the general procedure outlined in **EXAMPLE 4**, and making non-critical variations but starting with (S)-*tert*-butyl 3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (**EXAMPLE 2**, faster eluting enantiomer), the title compound is obtained (mp 102-105 °C).


IR (mineral oil) 3546, 3172, 3087, 3064, 3024, 1770, 1717, 1665, 1497, 1434, 1407, 1303, 746, 725, 703 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.80-7.90, 7.65-7.80, 7.05-7.35, 6.80, 3.25-3.80, 3.10-3.25, 2.79, 2.35-2.45, 2.10-2.30, 1.75-2.00, 1.30-1.75, 0.83, 0.76;

25 MS (EI) m/z 491, 459, 435, 431, 327, 262, 261, 244, 160, 105.

EXAMPLE 6 Preparation of α -[2-(1,3-Dihydro-1,3-dioxo-2H-naphthoisoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.

30




Following the general procedure of EXAMPLE 4 and making non-critical variations but starting with *tert*-butyl α-(2-hydroxyethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate and 2,3-naphthalenedicarboximide, the title compound is obtained (mp 203-205 °C).

IR (mineral oil) 3216, 3061, 3028, 1767, 1703, 1662, 1515, 1497, 1437, 1394, 1343, 1131, 769, 765, 616 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 8.31, 7.95-8.10, 7.60-7.75, 6.90-7.35, 3.30-3.90, 3.18, 2.78, 2.35-2.50, 2.15-2.35, 1.75-2.10, 1.35-1.75, 0.82, 0.75;

MS (EI) m/z 541, 485, 262, 261, 245, 210, 202, 180, 154, 105, 56.

EXAMPLE 7 Preparation of N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-α-[2-(4,5,6,7-tetrafluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-pyrrolidineacetamide.



Following the general procedure of EXAMPLE 4 and making non-critical variations but starting with *tert*-butyl α-(2-hydroxyethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate and tetrafluorophthalimide, the title compound is obtained (mp 172.5-173.5 °C).

IR (mineral oil) 3216, 1724, 1712, 1664, 1639, 1514, 1503, 1418, 1341, 1301, 1156, 1038, 948, 940, 754 cm^{-1} ;


^1H NMR (300 MHz, CDCl_3) δ 8.89, 7.47, 6.95-7.35, 3.35-3.80, 3.10-3.35, 2.79, 2.38, 1.30-2.30, 0.85, 0.80;

5 MS (EI) m/z 563, 507, 454, 261, 245, 202, 154, 110, 105, 104, 55.

EXAMPLE 8 Preparation of α -[2-(5,6-Dichloro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.

10

15



Following the general procedure of EXAMPLE 4 and making non-critical variations but starting with *tert*-butyl α -(2-hydroxyethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate and 4,5-dichlorophthalimide, the title compound is obtained (mp 207-208 $^{\circ}\text{C}$).


IR (mineral oil) 3173, 3070, 1775, 1709, 1667, 1630, 1441, 1434, 1401, 1330, 1278, 1033, 749, 706, 601 cm^{-1} ;

25 ^1H NMR (300 MHz, CDCl_3) δ 10.18, 8.91, 7.89, 7.42, 7.00-7.40, 3.35-3.80, 3.05-3.35, 2.78, 2.38, 2.05-2.30, 1.30-2.05, 0.83, 0.78;

MS (EI) m/z 559, 505, 503, 262, 261, 245, 244, 230, 228, 202, 105.

EXAMPLE 9 Preparation of α -[2-(5-Amino-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.


30



Following the general procedure of EXAMPLE 4 and making non-critical variations but starting with *tert*-butyl α-(2-hydroxyethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate and 4-aminophthalimide, the title compound is obtained (mp 187-188 °C).

¹H NMR (300 MHz, CDCl₃) δ 7.56, 7.10-7.35, 7.01, 6.83, 3.30-3.70, 3.15-3.30, 2.80, 2.35-2.50, 2.15-2.30, 1.70-1.95, 1.20-1.60, 0.83, 0.75.

EXAMPLE 10 Preparation of N-Hydroxy-3-(2-methylpropyl)-α-[2-(4-nitro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



Following the general procedure of EXAMPLE 4 and making non-critical variations but starting with *tert*-butyl α-(2-hydroxyethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate and 3-nitrophthalimide, the title compound is obtained (mp 136-138 °C):


IR (mineral oil) 3189, 3096, 3069, 1720, 1695, 1655, 1545, 1496, 1429, 1400, 1347, 1306, 1043, 749, 707 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 8.05-8.15, 7.85-7.95, 7.05-7.35, 3.35-3.85, 3.10-

3.25, 2.79, 2.35-2.50, 2.10-2.25, 1.75-2.05, 1.35-1.70, 0.85, 0.79;

MS (FAB) m/z 537, 536, 523, 521, 505, 504, 476, 105, 104.

EXAMPLE 11 Preparation of N-Hydroxy-3-(2-methylpropyl)- α -[2-(5-nitro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.




Following the general procedure of EXAMPLE 4 and making non-critical variations but starting with *tert*-butyl α -(2-hydroxyethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate and 4-nitrophthalimide, the title compound is obtained (mp 161-162 °C).

IR (mineral oil) 3158, 3106, 3060, 3027, 1707, 1664, 1543, 1496, 1434, 1411, 1344, 1132, 725, 719, 700 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 8.65, 8.59, 8.04, 7.05-7.35, 3.35-3.90, 3.10-3.25, 2.79, 2.35-2.50, 2.10-2.30, 1.75-2.05, 1.35-1.75, 0.84, 0.79;

MS (FAB) m/z 537, 523, 522, 504, 476, 202, 105.

EXAMPLE 12 Preparation of α -[2-(4-Fluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.




Following the general procedure of EXAMPLE 4 and making non-critical variations but starting with *tert*-butyl α -(2-hydroxyethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate and 3-fluorophthalimide, the title compound is obtained (mp 145-146 °C).

5 IR (mineral oil) 3205, 3065, 3028, 1776, 1717, 1657, 1611, 1497, 1483, 1399, 1349, 1303, 1255, 746, 701 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.55-7.80, 7.36, 6.80-7.35, 3.35-3.85, 3.05-3.30, 2.79, 2.30-2.55, 2.05-2.30, 1.70-2.00, 1.35-1.70, 0.83, 0.78;

MS (EI) m/z 509, 477, 453, 449, 345, 262, 261, 178, 105, 104.

10 **EXAMPLE 13** Preparation of α -[2-(4,7-Difluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.




15 Following the general procedure of EXAMPLE 4 and making non-critical variations but starting with *tert*-butyl α -(2-hydroxyethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate and 3,6-difluorophthalimide, the title compound is obtained (mp 131-132 °C).

IR (mineral oil) 3196, 3029, 1779, 1721, 1657, 1495, 1421, 1395, 1359, 1263, 1256, 911, 908, 753, 697 cm^{-1} ;

20 ^1H NMR (300 MHz, CDCl_3) δ 7.10-7.45, 6.94, 3.35-3.80, 3.15-3.30, 2.79, 2.30-2.50, 2.00-2.30, 1.75-2.00, 1.35-1.75, 0.85, 0.79;

MS (EI) m/z 527, 495, 471, 467, 363, 262, 261, 202, 196, 105, 104.

25 **EXAMPLE 14** Preparation of α -[2-(5-Fluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



5


10 Following the general procedure of EXAMPLE 4 and making non-critical variations but starting with *tert*-butyl α -(2-hydroxyethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate and 4-fluorophthalimide, the title compound is obtained (mp 143-144 °C).

15 IR (mineral oil) 3218, 3072, 3006, 1775, 1713, 1660, 1612, 1495, 1483, 1400, 1293, 1264, 1040, 747, 707 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.83, 7.50, 6.85-7.45, 3.35-3.80, 3.05-3.25, 2.79, 2.30-2.50, 2.05-2.30, 1.75-2.00, 1.30-1.70, 0.83, 0.77;

MS (EI) m/z 509, 477, 453, 449, 345, 262, 261, 178, 105, 104.

20 **EXAMPLE 15** Preparation of α -(2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl)-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



25

30

Following the general procedure of EXAMPLE 4 and making non-critical variations but starting with *tert*-butyl α -(3-hydroxypropyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (prepared similarly to that described in

35 **EXAMPLE 4**, step 2) and phthalimide, the title compound is obtained (mp 113-114 °C).

IR (mineral oil) 3241, 3087, 3058, 3026, 1773, 1715, 1663, 1498, 1399, 1352, 1320, 1298, 1067, 718, 604 cm^{-1} ;


^1H NMR (300 MHz, CDCl_3) δ 10.66, 7.75-7.85, 7.60-7.55, 6.95-7.45, 3.35-3.80, 3.10-3.25, 2.80, 2.44, 2.10-2.30, 1.85-2.00, 1.30-1.85, 0.85, 0.79;

5 MS (EI) m/z 505, 473, 445, 261, 245, 244, 202, 160, 105, 104.

EXAMPLE 16 Preparation of α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.

10

15



Step 1. Preparation of *tert*-Butyl α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate.

20

LDA (1.50 mL, 3.0 mmol, 2.0 M in heptane/THF/ethylbenzene) is added to a solution of *tert*-butyl 3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (EXAMPLE 1, step 3; 1.02 g, 2.84 mmol), HMPA (0.51 mL, 2.9 mmol), and THF (10 mL) at -78°C . The solution is stirred at -78°C for 30 minutes and then a solution of *N*-(bromomethyl)phthalimide (0.887 g, 3.69 mmol) and THF (4.0 mL) is added. The solution is stirred at -78°C for 1 hour and then allowed to warm slowly to room temperature overnight. Aqueous workup (EtOAc , MgSO_4) and purification by flash chromatography (3:1 hexane: EtOAc) gives 374 mg (25%) of the title compound as a white solid (mp $96-98^\circ\text{C}$).

30

IR (mineral oil) 1772, 1753, 1724, 1713, 1668, 1435, 1403, 1309, 1234, 1143, 1094, 737, 725, 714, 697 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.70-7.90, 7.15-7.35, 4.07, 3.86, 3.55-3.70, 3.35-3.50, 3.25-3.35, 3.11, 2.84, 2.50-2.65, 1.75-1.90, 1.60-1.75, 1.20, 0.85-0.95;

35

MS (FAB) m/z 519, 464, 463, 445, 159, 105, 57, 41, 29.

Step 2. Preparation of α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-3-

(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetic Acid.

TFA (5.0 mL) is added to a solution of *tert*-butyl α -[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (374 mg, 0.721 mmol) and CH_2Cl_2 (5.0 mL) at 0 °C. The solution is stirred for 2 hours at 0 °C and 2 hours at room temperature. The solution is concentrated and reconstituted twice more from CH_2Cl_2 (2 X 30 mL). Aqueous workup (CH_2Cl_2 , MgSO_4) provides 291 mg (87%) of the title compound as an oil which is carried on crude.

^1H NMR (300 MHz, CDCl_3) δ 7.65-7.95, 7.05-7.35, 3.90-4.05, 3.64, 3.35-3.55, 3.12, 2.80-3.05, 2.83, 2.10-2.40, 1.50-1.80, 0.90, 0.86.

Step 3. Preparation of α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.

EDC (129 mg, 0.672 mmol) is added to a solution of α -[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetic acid (270 mg, 0.584 mmol), CH_2Cl_2 (5.7 mL), DMF (1.4 mL), HOBT (78.9 mg, 0.584 mmol), and N-methylmorpholine (74 μL , 0.67 mmol) at 0 °C. The solution is stirred for 5 minutes at 0 °C and for 1 hour at room temperature. Hydroxylamine hydrochloride (80.9 mg, 1.16 mmol) and N-methylmorpholine (0.13 mL, 1.2 mmol) are added and the mixture stirred overnight at room temperature. Aqueous workup (CH_2Cl_2 , MgSO_4) and purification by flash chromatography (EtOAc) provides 160 mg of the hydroxamate as a white foam which is crystallized from ether/hexane to give 129 mg (46%) of the title compound as a white crystalline material which is a 4.25:1 mixture of diastereomers (mp 170-171 °C).


IR (mineral oil) 3194, 3105, 3050, 3028, 1773, 1709, 1665, 1644, 1496, 1434, 1409, 1393, 1309, 721, 701 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 10.97, 7.65-7.90, 7.10-7.35, 3.65-3.90, 3.20-3.55, 2.75-2.95, 2.35-2.50, 2.00-2.15, 1.50-1.85, 0.87;

MS (FAB) m/z 478 477, 445, 261, 202, 160, 105, 43.

EXAMPLE 17 Preparation of N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(2-thienylthio)ethyl]-3-pyrrolidineacetamide.

5



- 10 Step 1. Preparation of *tert*-Butyl α -[2-(Methanesulfonyloxy)ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate.

Methanesulfonyl chloride (0.29 mL, 3.7 mmol) is added to a solution of *tert*-butyl α -(2-hydroxyethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (EXAMPLE 4, step 2; 1.36 g, 3.37 mmol), triethylamine (0.52 mL,
15 3.7 mmol) and CH_2Cl_2 (8 mL) at 0 °C. The mixture is stirred for 2 hours, washed with saturated NaHCO_3 (2 x 10 mL), water (10 mL), dried (MgSO_4), filtered, and concentrated to give 1.22 g (75%) of the title compound as a light yellow oil.

^1H NMR (300 MHz, CDCl_3) δ 7.15-7.35, 4.10-4.30, 3.55-3.70, 3.35-3.50, 3.20-3.30, 3.01, 2.82, 2.55, 2.10-2.35, 1.85-2.05, 1.70-2.05, 1.40-1.65, 1.44, 0.87, 0.83.

- 20 Step 2. Preparation of *tert*-Butyl 3-(2-Methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(2-thienylthio)ethyl]-3-pyrrolidineacetate.

Sodium hydride (60%, 41 mg, 1.0 mmol) is added to a solution of thiophenethiol (118 mg, 1.02 mmol), THF (25 mL) and DMF (25 mL) at 0 °C. The mixture is stirred for 30 minutes at 0 °C and a solution of *tert*-butyl α -[2-(methanesulfonyloxy)ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (490 mg, 1.02 mmol) in THF (15 mL) is added. The solution is
25 allowed to warm slowly and is stirred at room temperature overnight.

Concentration, aqueous workup (EtOAc , MgSO_4), and purification by flash chromatography (25% EtOAc /hexane) gives 361 mg (71%) of title compound as a
30 colorless oil.

IR (liq.) 2956, 2930, 2868, 1720, 1685, 1497, 1454, 1428, 1367, 1276, 1258, 1217, 1147, 847, 700 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.15-7.40, 7.10-7.15, 6.90-7.00, 3.55-3.65, 3.30-3.45, 3.15-3.25, 2.75-2.90, 2.60-2.75, 2.58, 2.25-2.40, 1.80-2.00, 1.65-1.80, 1.35-1.65,
35 1.39, 0.84, 0.80;

MS (EI) m/z 501, 428, 386, 331, 330, 303, 247, 246, 212, 105, 57.

Step 3. Preparation of 3-(2-Methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(2-thienylthio)ethyl]-3-pyrrolidineacetic Acid.

A solution of *tert*-butyl 3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(2-thienylthio)ethyl]-3-pyrrolidineacetate (338 mg, 0.674 mmol), trifluoroacetic acid (3 mL), and CH₂Cl₂ (3 mL) is stirred at 0 °C for 15 minutes and at room temperature for 1.5 hour. Concentration and aqueous workup (CH₂Cl₂, MgSO₄) gives 287 mg (96%) of the title compound as a colorless oil.

IR (liq.) 2958, 2931, 2870, 1736, 1683, 1620, 1498, 1480, 1465, 1454, 1444, 1263, 1216, 746, 700 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 13.75, 7.35-7.40, 7.05-7.35, 6.95-7.05, 3.70-3.85, 3.35-3.50, 3.15-3.35, 2.80-2.95, 2.55-2.80, 2.00-2.15, 1.35-1.90, 0.91, 0.84;

MS (EI) *m/z* 445, 331, 330, 258, 247, 246, 228, 212, 156, 105, 55.

Step 4. Preparation of N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(2-thienylthio)ethyl]-3-pyrrolidineacetamide.

A solution of HOBT (83 mg, 0.62 mmol) in DMF (1.3 mL) is added to a solution of 3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(2-thienylthio)ethyl]-3-pyrrolidineacetic acid (259 mg, 0.581 mmol) in CH₂Cl₂ (6 mL) at room temperature.


The solution is cooled to 0 °C. To this is added 4-methylmorpholine (77 μ L, 0.70 mmol) and EDC (134 mg, 0.697 mmol). The solution is stirred at 0 °C for 1 hour and then a mixture of hydroxylamine hydrochloride (57 mg, 0.87 mmol), 4-methylmorpholine (96 μ L, 7.4 mmol), and DMF (0.8 mL) is added. The mixture is stirred overnight at room temperature and concentrated. Purification of the residue by flash chromatography (50% EtOAc/hexane) and crystallization (ether/hexane) gives 95 mg (36%) of the title compound as a white solid (mp 109-110 °C).

IR (mineral oil) 3202, 3096, 3081, 3023, 1652, 1496, 1441, 1432, 1314, 1294, 1280, 1222, 751, 717, 702 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 10.55, 7.05-7.40, 6.90-7.00, 3.50-3.65, 3.05-3.25, 2.70-2.95, 2.50-2.70, 1.95-2.25, 1.35-1.95, 0.85, 0.80;

MS (EI) *m/z* 460 345, 284, 262, 261, 228, 105, 81, 79, 55.

EXAMPLE 18 Preparation of N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(2-thienylthio)propyl]-3-pyrrolidineacetamide.



10


Following the general procedure of EXAMPLE 17 and making non-critical variations but starting with *tert*-butyl α -(3-hydroxypropyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate, the title compound is obtained (mp 104-105 °C).

15 IR (mineral oil) 3211, 3101, 3069, 3028, 1667, 1653, 1497, 1428, 1399, 1310, 1298, 1293, 1249, 760, 710 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 6.70-7.75, 3.05-3.95, 2.50-3.05, 1.15-2.50, 0.87, 0.82;

MS (EI) m/z 474, 442, 386, 359, 326, 298, 244, 202, 105, 55.

20 **EXAMPLE 19** Preparation of N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(2-thienylthio)methyl]-3-pyrrolidineacetamide.



25

30 Following the general procedure of EXAMPLE 17 and making non-critical variations but starting with *tert*-butyl α -(1-hydroxymethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate, the title compound is obtained (mp 145-146 °C).


35 IR (mineral oil) 3177, 3085, 3027, 1664, 1641, 1496, 1408, 1297, 1274, 1218, 1029, 1000, 845, 746, 702 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.68, 7.15-7.40, 6.90-7.15, 3.35-3.70, 2.55-3.30,

2.05-2.25, 1.65-1.70, 1.25-1.60, Major diastereomer peaks. 0.80, 0.71, Minor diastereomer peaks. 0.75, 0.61;

MS (EI) m/z 446, 246, 245, 203, 202, 154, 105.

EXAMPLE 20 Preparation of N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide.



Step 1. Preparation of 1-Trimethylsilyl-2-pyrrolidinone.

Chlorotrimethylsilane (TMSCl, 56.0 mL, 441 mmol) is added dropwise to a solution of 2-pyrrolidinone (30.4 mL, 400 mmol), triethylamine (70.0 mL, 502 mmol) and toluene (400 mL) at room temperature. After stirring at room temperature with a mechanical stirrer for 20 minutes, the mixture is heated at 50 °C for 4 hours. After cooling, the mixture is diluted with hexane (300 mL) and stirred for 30 minutes at room temperature. The mixture is filtered and the filtrate concentrated. Distillation of the residue (1 mm, 68-74 °C) gives 50.0 g (94%) of the title compound as an oil.

¹H NMR (300 MHz, *d*₅-pyridine) δ 3.17, 2.26, 1.70-1.85, 0.32.

Step 2. Preparation of 3-(2-methylpropyl)-2-pyrrolidinone.

A solution of LDA (2.0 M, 111 mL, 222 mmol) and THF (300 mL) is cooled to -78 °C and a solution of 1-trimethylsilyl-2-pyrrolidinone (29.4 g, 221 mmol) in THF (145 mL) is added. After stirring for 45 minutes at -78 °C, the enolate solution is added via cannula over 1 hour to a solution of 1-iodo-2-methylpropane (42.7 g, 232 mmol) in THF (200 mL) at -78 °C. The solution is allowed to warm slowly and stirred at room temperature overnight. The reaction is quenched by the addition of 50 mL of acetic acid. Aqueous workup (EtOAc, MgSO₄) and purification by column chromatography (30→100% EtOAc/hexane) gives 12.8 g of the title compound as an oil.

¹H NMR (300 MHz, CDCl₃) δ 6.30, 3.10-3.30, 2.05-2.35, 1.45-1.80, 1.00-1.20, 0.81, 0.76.

Step 3. Preparation of 3-(2-methylpropyl)-1-trimethylsilyl-2-pyrrolidinone.

TMSCl (2.2 mL, 18 mmol) is added dropwise to a solution of 3-(2-methylpropyl)-2-pyrrolidinone (2.25 g, 15.9 mmol), triethylamine (2.7 mL, 19 mmol), and toluene (16 mL) at room temperature. The mixture is heated at 40 °C for 3 hours and diluted with hexane (50 mL). After stirring for 10 minutes at 0 °C, the mixture is filtered and the filtrate concentrated. Distillation (1 mm, 62-68 °C) of the residue gives 2.40 g (71%) of the title compound as an oil.

^1H NMR (300 MHz, CDCl_3) δ 3.05-3.30, 2.20-2.35, 2.05-2.20, 1.45-1.70, 1.05-1.15, 0.82, 0.78, 0.15.

Step 4. Preparation of 3-(2-Methylpropyl)-3-(propen-2-yl)-2-pyrrolidinone.

A solution of 3-(2-methylpropyl)-1-trimethylsilyl-2-pyrrolidinone (10.2 g, 47.8 mmol) and THF (153 mL) is cooled to -78 °C, and LDA (2.0 M, 26.3 mL, 52.6 mmol) is added. The solution is stirred at -78 °C for 30 minutes and then allyl bromide (5.0 mL, 57 mmol) is added. The solution is allowed to warm to 5 °C over 2.5 hours, and is then stirred at 5 °C for 1 hour. After quenching with saturated aqueous ammonium chloride (25 mL), aqueous workup (EtOAc , MgSO_4) and purification by column chromatography (1:9:10 v/v CH_2Cl_2 : EtOAc :hexane) provides 7.76 g (90%) of the title compound as an oil.

IR (liq.) 3241, 3077, 2957, 2929, 2902, 2873, 1708, 1693, 1640, 1440, 1284, 1277, 1264, 1251, 842 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 6.43, 5.65-5.85, 5.00-5.15, 3.15-3.35, 2.00-2.40, 1.65-1.85, 1.40-1.60, 0.92;

MS (EI) m/z 138, 125, 124, 98, 73, 60, 55, 45, 43, 41.

Step 5. Preparation of Ethyl 3-(2-methylpropyl)-2-oxo-3-(propen-2-yl)-1-pyrrolidineacetate.

A solution of potassium bis(trimethylsilyl)amide (0.5 M in toluene, 16.4 mL, 8.19 mmol) is cooled to 0 °C, and a solution of 3-(2-methylpropyl)-3-(propen-2-yl)-2-pyrrolidinone (1.24 g, 6.82 mmol) in THF (10 mL) is added dropwise over 2 minutes. After stirring at 0 °C for 40 minutes, ethyl bromoacetate (0.91 mL, 8.2 mmol) is added. The reaction is stirred at 0 °C for 3 hours and for 1 hour at room temperature. After quenching with saturated aqueous ammonium chloride (10 mL), aqueous workup (EtOAc , MgSO_4) and purification by column chromatography (1:9:10 v/v CH_2Cl_2 : EtOAc :hexane) provided 1.66 g (91%) of the title compound as an oil.

IR (liq.) 2957, 2930, 2906, 2872, 1750, 1692, 1462, 1440, 1375, 1296, 1281, 1252, 1196, 1028, 916 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 5.50-5.75, 4.90-5.05, 4.00-4.15, 3.93, 3.15-3.30,

2.15-2.30, 2.00-2.15, 1.80-2.00, 1.55-1.75, 1.30-1.50, 1.16, 0.82, 0.77;

MS (EI) m/z 212, 211, 210, 194, 152, 138, 137, 110.

Step 6. Preparation of N-Methyl-3-(2-methylpropyl)-2-oxo-3-(propen-2-yl)-1-pyrrolidineacetamide.

5 Ethyl 3-(2-methylpropyl)-2-oxo-3-(propen-2-yl)-1-pyrrolidineacetate (500 mg, 1.87 mmol) is stirred in a saturated solution of methylamine in EtOH (50 mL) at room temperature overnight. The solution is concentrated and purified by column chromatography (1:12:8 v/v CH_2Cl_2 :EtOAc:hexane) to give 401 mg (85%) of the title compound as an oil.

10 IR (liq.) 3308, 2955, 2928, 2872, 1662, 1560, 1495, 1464, 1443, 1413, 1279, 1263, 1252, 915, 842 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 6.32, 5.50-5.75, 4.90-5.10, 3.79, 3.28, 2.67, 2.17, 1.85-2.10, 1.55-1.75, 1.30-1.55, 0.84, 0.77;

MS (EI) m/z 252, 221, 210, 209, 196, 194, 166, 165, 152, 138, 124, 110, 95,

15 73.

Step 7. Preparation of 1-(N-Methylacetamide)-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetic Acid.

Ruthenium(IV) oxide hydrate (15 mg, 0.11 mmol) is added at room temperature to a mixture of sodium periodate (944 mg, 4.41 mmol) in acetonitrile
20 (1.9 mL), carbon tetrachloride (0.9 mL) and water (2.0 mL). After stirring for 10 minutes, sodium bicarbonate (2.32 g, 27.6 mmol) is added, followed by a solution of N-methyl-3-(2-methylpropyl)-2-oxo-3-(propen-2-yl)-1-pyrrolidineacetamide (139 mg, 0.552 mmol) in acetonitrile (2.0 mL). Sodium periodate (approximately 150 mg) is added until the black mixture turns light green. After 5 minutes the mixture is
25 poured into 100 mL of water. The pH of the mixture is adjusted to pH 2 (pH paper) with concentrated HCl. The acidic solution is extracted with CH_2Cl_2 and EtOAc. The combined organic layers are dried (MgSO_4), filtered, and concentrated to provide 157 mg (100%) of the title compound as an oil.

^1H NMR (300 MHz, CDCl_3) δ 7.09, 4.30-4.45, 3.20-3.50, 2.67, 2.63, 1.95-2.25,
30 1.55-1.70, 1.30-1.45, 0.84, 0.78.

Step 8. Preparation of N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide.

EDC (1.14 g, 5.95 mmol) is added to a solution of 1-(N-methylacetamide)-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetic acid (1.34 g, 4.96 mmol), HOBT (710 mg,
35 5.26 mmol) and 4-methylmorpholine (0.65 mL, 5.9 mmol) in CH_2Cl_2 (51 mL) and DMF (10 mL) at 0 °C. The solution is stirred at 0 °C for 1 hour, and then a mixture


of hydroxylamine hydrochloride (517 mg, 7.44 mmol) in DMF (7 mL) is added followed by 4-methylmorpholine (0.82 mL, 7.4 mmol). After stirring for 7 days at room temperature, the mixture is concentrated under high vacuum and purified by column chromatography (3% MeOH/CH₂Cl₂). Crystallization from Et₂O/hexane provides 211 mg (15%) of the title compound as a white solid (mp 145-147 °C).

IR (mineral oil) 3259, 3199, 3097, 3017, 1662, 1564, 1522, 1501, 1412, 1405, 1313, 1297, 1275, 750, 724 cm⁻¹;

¹H NMR (300 MHz, CDCl₃/CD₃OD) δ 4.25-4.45, 3.05-3.50, 2.74, 2.32, 1.90-2.20, 1.55-1.75, 1.30-1.50, 0.87, 0.79;

MS (EI) *m/z* 285, 254, 229, 226, 194, 180, 169, 166, 152, 138, 124, 110, 55.

EXAMPLE 21 Preparation of N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo-α¹-(phenylmethyl)-1,3-pyrrolidinediacetamide.



Step 1. Preparation of Ethyl 3-(2-methylpropyl)-2-oxo-α-(phenylmethyl)-3-(propen-2-yl)-1-pyrrolidineacetate.

A solution of ethyl 3-(2-methylpropyl)-2-oxo-3-(propen-2-yl)-1-pyrrolidineacetate (Example 20, step 5; 1.63 g, 6.10 mmol) and THF (15 mL) is cooled to -78 °C and LDA (2.0 M, 3.2 mL, 6.4 mmol) is added. The solution is stirred at -78 °C for 30 minutes and then benzyl bromide (0.80 mL, 6.7 mmol) is added. The solution is allowed to warm to 0 °C over 2 hours, and then stirred at 0 °C for 1 hour. After quenching with saturated aqueous ammonium chloride (10 mL), aqueous workup (EtOAc, MgSO₄) and purification by column chromatography (10% EtOAc/hexane) provided 1.94 g (89%) of the title compound as an oil in a 1:1 mixture of diastereomers.

IR (liq.) 2975, 2956, 2930, 2906, 1739, 1689, 1499, 1455, 1425, 1266, 1207, 1192, 1032, 915, 698 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.05-7.30, 5.55-5.75, 4.85-5.20, 4.65-4.85, 4.00-

4.20, 3.00-3.40, 2.80-2.95, 2.12, 1.50-1.95, 1.30-1.45, 1.15-1.30, 1.00-1.15, 0.83, 0.79, 0.66, 0.54;

MS (EI) m/z 357, 301, 238, 228, 284, 282, 267, 266, 210, 200, 176, 164, 125, 102, 91.

- 5 Step 2. Preparation of N-Methyl-3-(2-methylpropyl)-2-oxo- α -(phenylmethyl)-3-(propen-2-yl)-1-pyrrolidineacetamide.

Methylamine gas is bubbled through a solution of ethyl 3-(2-methylpropyl)-2-oxo- α -(phenylmethyl)-3-(propen-2-yl)-1-pyrrolidineacetate (3.40 g, 9.51 mmol) in EtOH (120 mL) for 30 minutes at room temperature, and the solution is stirred at
10 room temperature overnight. The solution is concentrated and purified by flash chromatography (1:6:11 \rightarrow 1:10:9 v/v CH_2Cl_2 :EtOAc:hexane) to give 3.01 g (92%) of the title compound as a solid (mp 91-92 °C) which is a ca. 1:1 mixture of diastereomers.

IR (mineral oil) 3315, 1684, 1654, 1584, 1562, 1499, 1442, 1414, 1296, 1278, 1264, 1225, 913, 744, 708 cm^{-1} ;

15 ^1H NMR (300 MHz, CDCl_3) δ 7.10-7.30, 6.15-6.40, 5.50-5.70, 5.10-5.30, 4.95-5.10, 4.75-4.95, 3.15-3.35, 2.90-3.10, 2.72, 2.71, 1.95-2.20, 1.50-1.95, 1.15-1.50, 0.86, 0.78, 0.74, 0.64;

MS (EI) m/z 342, 300, 284, 267, 251, 242, 200, 162, 132, 105, 91, 81, 73, 67.

- 20 Step 3. Preparation of N¹-Methylacetamide-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-3-pyrrolidineacetic Acid.

Ruthenium(IV) oxide hydrate (29 mg, 0.22 mmol) is added to a mixture of sodium periodate (1.85 g, 8.65 mmol) in acetonitrile (3.8 mL), carbon tetrachloride (1.8 mL), and water (3.9 mL) at room temperature. After stirring for 10 minutes, sodium bicarbonate (4.55 g, 54.2 mmol) is added, followed by a solution of N-methyl-
25 3-(2-methylpropyl)-2-oxo- α -(phenylmethyl)-3-(propen-2-yl)-1-pyrrolidineacetamide (371 mg, 1.08 mmol) in acetonitrile (4.0 mL). Sodium periodate (approximately 300 mg) is added until the black mixture turns light green. After 5 minutes, the mixture is poured into 100 mL of water. The mixture is extracted with EtOAc (2 x 50 mL). The pH of the aqueous mixture is adjusted to pH 2 (pH paper) with
30 concentrated HCl. The acidic mixture is extracted with CH_2Cl_2 and EtOAc, and these layers are combined with the original EtOAc extracts, dried (MgSO_4), filtered, and concentrated to give 300 mg of the crude acid as a dark brown oil. This material is dissolved in 15% NaOH (10 mL) and extracted with Et_2O (3 x 20 mL). These Et_2O layers are discarded. The pH of the aqueous layer is adjusted to pH 2
35 (pH paper) with concentrated HCl. The acidic layer is extracted with EtOAc (3 x 30 mL), the combined EtOAc layers dried (MgSO_4), filtered, and concentrated to give

230 mg (59%) of the title compound as an oil as a 1:1 mixture of diastereomers.

IR (mineral oil) 3358, 3087, 3064, 3029, 1721, 1649, 1550, 1498, 1441, 1413, 1297, 1272, 1233, 1192, 700 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.05-7.40, 6.55-6.70, 5.10, 4.56, 3.64, 3.20-3.55, 2.70-3.05, 2.30-2.70, 1.75-2.20, 1.55-1.75, 1.49, 1.05-1.40, 0.80-1.00, 0.90, 0.83, 0.69, 0.66;

MS (EI) m/z 360, 336, 303, 302, 284, 269, 256, 246, 228, 200, 162, 161, 132, 105, 91.

Step 4. Preparation of N^3 -Hydroxy- N^1 -methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide.


EDC (1.08 g, 5.66 mmol) is added to a solution of N^1 -methylacetamide-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-3-pyrrolidineacetic acid (1.70 g, 4.72 mmol), HOBT (676 mg, 5.00 mmol) and 4-methylmorpholine (0.52 mL, 4.7 mmol) in CH_2Cl_2 (49 mL) and DMF (10 mL) at 0 $^\circ\text{C}$. The solution is stirred at 0 $^\circ\text{C}$ for 1 hour and then a mixture of hydroxylamine hydrochloride (491 mg, 7.08 mmol) in DMF (7 mL) is added, followed by 4-methylmorpholine (0.79 mL, 7.1 mmol). The mixture is stirred at room temperature overnight and concentrated under high vacuum. The residue is dissolved in 15% NaOH (13 mL) and extracted with EtOAc (3 x 20 mL). These EtOAc layers are discarded. The pH of the aqueous layer is adjusted to pH 2 (pH paper) with 6 N HCl. The acidic layer is extracted with CH_2Cl_2 (3 x 30 mL), the combined CH_2Cl_2 layers dried (MgSO_4), filtered, and concentrated. Purification by column chromatography (5 % MeOH/ CH_2Cl_2) and crystallization from Et_2O /hexane provided 255 mg (14%) of the title compound as a white solid (mp 166-168 $^\circ\text{C}$) as a mixture of diastereomers.

IR (mineral oil) 3373, 3199, 3087, 3064, 3027, 1686, 1667, 1634, 1546, 1498, 1404, 1356, 1303, 742, 697 cm^{-1} ;

^1H NMR (300 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$) major diastereomer, key peaks: δ 4.48, 2.76, 0.89, 0.81. Minor diastereomer, key peaks: δ 5.05, 2.82, 0.69, 0.62;

MS (EI) m/z 375, 344, 317, 316, 285, 284, 256, 132, 91.

EXAMPLE 22 Preparation of α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)-3-pyrrolidineacetamide.



5

10

Step 1. Preparation of *N*-*tert*-Butyloxycarbonyl-2-pyrrolidinone.

A solution of di-*tert*-butyl dicarbonate (28.2 g, 129 mmol) in dry CH_2Cl_2 (80 mL) is added to a stirred solution of 2-pyrrolidinone (10.0 g, 117 mmol) and DMAP (200 mg, catalytic amount) in dry CH_2Cl_2 (230 mL) over 10 minutes. After 16 hours, the solution is diluted with H_2O (150 mL) and extracted with EtOAc (4 x 100 mL). The organic layers are combined, dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure to give a red oil. The oil is purified by silica gel chromatography (200 g SG, 40% EtOAc/hexane) to yield 20.1 g (93%) of the title compound as a gold oil.

IR (liq.) 2980, 1786, 1752, 1714, 1459, 1394, 1368, 1315, 1256, 1228, 1154, 1045, 1018, 858, 778 cm^{-1} ;
 ^1H NMR (300 MHz, CDCl_3) δ 3.74, 2.50, 1.90-2.05, 1.52; MS (FAB) m/z 186, 131, 130, 112, 86, 57, 41.

Step 2. Preparation of *N*-*tert*-Butyloxycarbonyl-3-(2-methylpropen-2-yl)-2-pyrrolidinone.

A solution of *N*-*tert*-butyloxycarbonyl-2-pyrrolidinone (10.0 g, 54.0 mmol) and HMPA (9.40 mL, 54.0 mmol) in dry THF (200 mL) is cooled to -78°C and treated drop-wise over 6.5 minutes with lithium diisopropylamide (LDA, 29.7 mL, 59.4 mmol, 2 M in heptane/THF/ethylbenzene). After 30 minutes at -78°C , 3-bromo-2-methylpropene (6.53 mL, 64.8 mmol) is added. The solution is maintained at -78°C under N_2 for 6 hours, and is then quenched with saturated NH_4Cl (100 mL). The solution is warmed to 0°C and diluted with H_2O (300 mL). The crude olefin is extracted into EtOAc (3 x 200 mL), dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure to give an oil. The oil is purified by silica gel chromatography (350 g gel; 20% EtOAc/hexane) to yield 7.75 g (60%) of the title compound as a golden oil.

IR (liq.) 2980, 2934, 2909, 1785, 1749, 1716, 1457, 1394, 1368, 1322, 1295, 1251, 1227, 1155, 779 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 4.79, 4.71, 3.70-3.80, 3.50-3.65, 2.60-2.75, 1.95-2.20, 1.72, 1.55-1.75, 1.52;

5 MS (EI) m/z 239, 183, 166, 165, 139, 57.

Step 3. Preparation of *tert*-Butyl *N-tert*-Butyloxycarbonyl-3-(2-methylpropen-2-yl)-2-oxo-3-pyrrolidineacetate.

A solution of *N-tert*-butyloxycarbonyl-3-(2-methylpropen-2-yl)-2-pyrrolidinone (7.39 g, 30.8 mmol) in dry THF (125 mL) is cooled to -78°C and treated drop-wise
10 with LDA (17.0 mL, 33.9 mmol). After 30 minutes at -78°C , *tert*-butyl bromoacetate (5.46 mL, 37.0 mmol) is added. The solution is maintained at -78°C for 6 hours and then quenched with saturated NH_4Cl (50 mL). The solution is warmed to 0°C and diluted with H_2O (50 mL). The crude ester is extracted into EtOAc (3 x 100 mL), dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure to
15 give an orange oil. The material is purified by silica gel chromatography (2 columns: 250 g, 100 g SG, 10% EtOAc/hexane) to yield 7.69 g (71%) of the title compound as a golden oil.

IR (liq.) 2980, 2934, 2918, 1786, 1748, 1718, 1457, 1394, 1369, 1315, 1258, 1208, 1155, 965, 853 cm^{-1} ;

20 ^1H NMR (300 MHz, CDCl_3) δ 4.90, 4.78, 3.50-3.75, 2.53, 2.30, 2.05-2.20, 1.72, 1.51, 1.42;

MS (EI) m/z 353, 297, 280, 241, 224, 223, 196, 180, 57.

Step 4. Preparation of *tert*-Butyl *N-tert*-Butyloxycarbonyl-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetate.

25 A solution of *tert*-butyl *N-tert*-butyloxycarbonyl-3-(2-methylpropen-2-yl)-2-oxo-3-pyrrolidineacetate (7.90 g, 22.4 mmol) in EtOH (150 mL) is treated with 10% palladium on carbon (1.98 g, 25% by weight) and hydrogenated in a Parr flask at 45 psi for 16 hours at room temperature. The mixture is filtered through celite; the residual cake is washed with EtOH (2 x 100 mL), MeOH (2 x 100 mL), and CH_2Cl_2
30 (100 mL). The filtrate is concentrated under reduced pressure to yield 7.86 g (99%) of the title compound as a thick, cloudy oil.

IR (liq.) 2978, 2934, 1786, 1749, 1717, 1476, 1458, 1393, 1369, 1317, 1258, 1207, 1155, 1117, 969 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 3.55-3.80, 2.53, 2.05-2.20, 1.90-2.05, 1.60-1.80,
35 1.40-1.60, 1.52, 1.42, 0.91, 0.90;

MS (FAB) m/z 356, 300, 244, 226, 200, 182, 154, 57.

Step 5. Preparation of *tert*-Butyl *N-tert*-Butyloxycarbonyl-3-(2-methylpropyl)-2-oxo- α -(propen-2-yl)-3-pyrrolidineacetate.

A solution of *tert*-butyl *N-tert*-butyloxycarbonyl-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetate (3.65 g, 10.3 mmol) in dry THF (45 mL) is cooled to -78 °C and
5 treated drop-wise with LDA (5.70 mL, 11.3 mmol). After 30 minutes at -78 °C, allyl bromide (1.10 mL, 12.4 mmol) is added. The solution is maintained at -78 °C for 3 hours, and is then allowed to slowly warm to room temperature under N₂. After 12 hours, the solution is quenched with saturated NH₄Cl (10 mL) and diluted with H₂O (50 mL). The crude lactam is extracted into EtOAc (3 x 100 mL). The organic
10 extracts are combined, washed with brine (50 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give 4.72 g of gold oil. The oil is purified by silica gel chromatography (300 g SG, 5% EtOAc/hexane) to yield 2.98 g (73%) of the title compound as a clear, pale gold oil as a mixture of diastereomers.

IR (liq.) 2979, 2961, 2934, 1785, 1748, 1719, 1457, 1393, 1369, 1315, 1257,
15 1207, 1156, 1125, 851 cm⁻¹;

¹H NMR (300 MHz, CDCl₃, key peaks of the major diastereomer): δ 5.60-5.85, 4.95-5.15, 3.55-3.75, 2.64, 2.20-2.50, 1.35-1.90, 1.52, 1.42, 0.91, 0.88;

MS (FAB) *m/z* 396, 340, 285, 284, 266, 222, 57, 41, 29.

Step 6. Preparation of *tert*-Butyl 3-(2-Methylpropyl)-2-oxo- α -(propen-2-yl)-3-pyrrolidineacetate.
20

A solution of *tert*-butyl *N-tert*-butyloxycarbonyl-3-(2-methylpropyl)-2-oxo- α -(propen-2-yl)-3-pyrrolidineacetate (5.40 g, 13.7 mmol) in MeOH (70 mL) is treated with magnesium methoxide (74.7 mL, 68.5 mmol, 10.3 wt % in MeOH). The resultant solution is stirred under N₂ at room temperature for 16 hours. The
25 solution is quenched with 1:1 glacial AcOH/H₂O (100 mL). The solution is reduced to a minimal volume under reduced pressure, and the unprotected lactam is extracted into CH₂Cl₂ (3 x 100 mL). The organic layers are combined, washed with saturated NH₄Cl (100 mL), brine (100 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give 4.75 g of a gold oil. The oil is
30 purified by silica gel chromatography (100 g SG, 25% EtOAc/hexane) to yield 3.85 g (96%) of the title compound as an off-white, low-melting solid.

IR (mineral oil) 3206, 3105, 1720, 1701, 1352, 1299, 1268, 1255, 1231, 1162, 1153, 1125, 923 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 6.28, 5.65-5.85, 4.90-5.15, 3.20-3.40, 2.60, 2.20-2.60, 1.85-2.00, 1.65-1.80, 1.35-1.65, 1.41, 0.93, 0.91;

MS (FAB) *m/z* 296, 240, 222, 194, 57.

Step 7. Preparation of *tert*-Butyl 3-(2-Methylpropyl)-2-oxo-1-(phenylmethyl)- α -(propen-2-yl)-3-pyrrolidineacetate.

A cold (0 °C) solution of *tert*-butyl 3-(2-methylpropyl)-2-oxo- α -(propen-2-yl)-3-pyrrolidineacetate (1.11 g, 3.76 mmol) in dry THF (25 mL) is treated with NaH (60% dispersion in mineral oil, 226 mg, 5.64 mmol) in one portion. After 30 minutes, benzyl bromide (537 μ L, 4.51 mmol) is added. The solution is allowed to slowly warm to room temperature, stirring under N₂ overnight. The mixture is quenched with H₂O (25 mL) and extracted with EtOAc (3 x 25 mL). The organic extracts are combined, washed with brine (25 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to yield 1.70 g of yellow oil. The oil is purified by silica gel chromatography (30 g SG, 10% EtOAc/hexane) to give 1.37 g (94%) of the title compound as a clear, colorless oil.

IR (liq.) 2977, 2957, 2930, 2870, 1721, 1687, 1496, 1454, 1440, 1367, 1287, 1260, 1238, 1153, 701 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.20-7.35, 5.65-5.85, 4.95-5.15, 4.41, 3.05-3.30, 2.62, 2.20-2.55, 1.50-1.85, 1.41, 0.89, 0.87;

MS (EI) *m/z* 385, 329, 312, 232, 231, 188, 91, 57.

Step 8. Preparation of *tert*-Butyl α -(2-Hydroxyethyl)-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)-3-pyrrolidineacetate.

Ozone is bubbled through a cold (-78 °C) solution of *tert*-butyl 3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)- α -(propen-2-yl)-3-pyrrolidineacetate (1.32 g, 3.42 mmol) in EtOH (30 mL). After purging the solution with N₂, sodium borohydride (195 mg, 5.14 mmol) is added in one portion (at -78 °C). The solution is allowed to slowly warm to room temperature under N₂ overnight. The reaction mixture is concentrated to a white solid, diluted with H₂O (10 mL) and extracted with EtOAc (3 x 25 mL). The organic extracts are combined, washed with brine (25 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to yield 1.37 g of a clear, colorless oil. The oil is purified by silica gel chromatography (50 g SG, 20% EtOAc/hexane) to give 850 mg (64%) of the title compound as a clear, colorless oil, which is a single diastereomer.

IR (liq.) 2956, 2930, 2870, 1771, 1720, 1684, 1497, 1464, 1454, 1441, 1367, 1286, 1261, 1154, 701 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.20-7.40 4.42, 3.55-3.80, 3.10-3.30, 2.70, 2.35-2.50, 1.90-2.05, 1.50-1.90, 1.44, 0.88, 0.87;

MS (EI) *m/z* 389, 333, 287, 259, 258, 232, 230, 140, 119, 91.

Step 9. Preparation of *tert*-Butyl α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)-3-pyrrolidineacetate.

A solution of *tert*-butyl α -(2-hydroxyethyl)-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)-3-pyrrolidineacetate (435 mg, 1.12 mmol) in dry THF (10 mL) is treated with triphenylphosphine (323 mg, 1.23 mmol), diethylazodicarboxylate (194 μ L, 1.23 mmol), and phthalimide (181 mg, 1.23 mmol). The solution is allowed to stir overnight at room temperature under N_2 . The reaction mixture is concentrated and purified by silica gel chromatography (25 g SG, 20% EtOAc/hexane) to give 518 mg (89%) of the title compound as an off-white, amorphous solid.

IR (mineral oil) 1773, 1754, 1744, 1722, 1713, 1671, 1433, 1398, 1309, 1264, 1164, 1116, 706 cm^{-1} ;

1H NMR (300 MHz, $CDCl_3$) δ 7.80-7.90, 7.65-7.80, 7.20-7.35, 4.41, 3.60-3.85, 3.05-3.25, 2.59, 2.30-2.50, 2.00-2.20, 1.75-1.95, 1.40-1.75, 1.48, 0.87;

MS (FAB) m/z 519, 464, 463, 445, 417, 230, 91, 57.

Step 10. Preparation of α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)-3-pyrrolidineacetamide.

A cold (0 $^{\circ}C$) solution of *tert*-butyl α -[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)-3-pyrrolidineacetate (500 mg, 0.964 mmol) in CH_2Cl_2 (2 mL) is treated with TFA (2 mL) and maintained at 0 $^{\circ}C$ for 1 hour, and then at room temperature for 1 hour. The solvent is removed *in vacuo* to give a quantitative yield of α -[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)-3-pyrrolidineacetic acid as a gelatinous solid.

IR (liq.) 2962, 1775, 1755, 1716, 1617, 1469, 1455, 1441, 1402, 1377, 1309, 721, 702 cm^{-1} ;

1H NMR (300 MHz, $CDCl_3$) δ 7.80-7.90, 7.70-7.80, 7.10-7.30, 4.44, 3.60-3.90, 3.32, 2.68, 1.80-2.25, 1.55-1.75, 0.91, 0.84;

MS (EI) m/z 462, 406, 302, 244, 232, 230, 188, 160, 91.

A cold (0 $^{\circ}C$) solution of α -[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)-3-pyrrolidineacetic acid (559 mg) in CH_2Cl_2 /DMF (8 mL/2 mL) is treated with 1-hydroxybenzotriazole (158 mg, 1.17 mmol), 4-methylmorpholine (129 μ L, 1.17 mmol), and EDC (224 mg, 1.17 mmol).

After 1 hour, additional 4-methylmorpholine (159 μ L, 1.45 mmol) and hydroxylamine


HCl (101 mg, 1.45 mmol) are added. The solution is allowed to slowly warm to room temperature, stirring under N₂ overnight. The reaction mixture is diluted with H₂O (25 mL) and extracted into CH₂Cl₂ (3 x 50 mL). The organic extracts are dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure, and reconstituted in EtOAc (50 mL). The EtOAc layer is washed with more H₂O (3 x 25 mL) and brine (25 mL). The organic layer is dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give 416 mg of white foam. The foam is purified by silica gel chromatography (50 g SG, 2% MeOH/CHCl₃) to yield 220 mg of white foam which is triturated with Et₂O to give 181 mg (39%) of the title compound as a white solid (mp 162-164 °C).

IR (mineral oil) 3167, 3059, 3033, 3022, 1776, 1710, 1666, 1653, 1498, 1396, 1265, 706, 696 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.80-7.90, 7.65-7.80, 7.05-7.40, 4.20-4.60, 3.60-4.00, 3.05-3.35, 1.40-2.75, 0.75-0.95;

MS (EI) *m/z* 477, 445, 421, 417, 248, 247, 188, 160, 91.

EXAMPLE 23 Preparation of N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)-3-pyrrolidineacetamide.




Following the general procedure in EXAMPLE 22 and making non-critical variations but starting with *tert*-butyl *N-tert*-butoxycarbonyl-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetate (EXAMPLE 22, step 4), the title compound is obtained (mp 119-120 °C).

IR (mineral oil) 3265, 3164, 3065, 3029, 3016, 1658, 1519, 1494, 1305, 1291, 1260, 1063, 701, 651, 617 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 10.13, 7.60-8.30, 7.10-7.40, 4.44, 3.10-3.30, 2.48, 2.15-2.30, 1.95-2.10, 1.35-1.85, 0.88, 0.87;

MS (EI) m/z 304, 272, 248, 215, 188, 187, 186, 92, 91, 65.

EXAMPLE 24 Preparation of N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)- α -[2-(4,5,6,7-tetrafluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-pyrrolidineacetamide.




Following the general procedure in **EXAMPLE 22** and making non-critical variations but starting with *tert*-butyl α -(2-hydroxyethyl)-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)-3-pyrrolidineacetate (**EXAMPLE 22**, step 8), the title compound is obtained (mp 183-185 °C).

IR (mineral oil) 3221, 1724, 1713, 1694, 1672, 1629, 1513, 1503, 1418, 1262, 1155, 1033, 954, 941, 754 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.10-7.40, 4.25-4.55, 3.60-4.00, 3.10-3.35, 2.40-2.55, 1.40-1.35, 1.80-1.95;

MS (FAB) m/z 550, 534, 517, 489, 230, 91.

EXAMPLE 25 Preparation of 1-(3-Fluorophenyl)methyl)- α -[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetamide.



10


Following the general procedure in EXAMPLE 22 and making non-critical variations but starting with *tert*-butyl 3-(2-methylpropyl)-2-oxo- α -(propen-2-yl)-3-pyrrolidineacetate (EXAMPLE 22, step 6), the title compound is obtained (mp 162-163 °C).

15 IR (mineral oil) 3169, 3058, 3048, 1776, 1709, 1667, 1653, 1614, 1590, 1487, 1397, 1292, 1267 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.75-7.90, 7.65-7.75, 7.15-7.35, 6.80-7.00, 4.40, 3.60-3.85, 3.10-3.30, 2.30-2.65, 1.40-2.25, 0.85, 0.79;

MS (EI) m/z 495, 463, 435, 379, 322, 288, 248, 206, 160, 138, 109.

20 **EXAMPLE 26** Preparation of α^3 -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]- N^3 -hydroxy- N^1 -methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide.



25

30

Following the general procedure in EXAMPLE 22 and making non-critical variations but starting with *tert*-butyl 3-(2-methylpropyl)-2-oxo- α -(propen-2-yl)-3-pyrrolidineacetate (EXAMPLE 22, step 6), the title compound is obtained (mp 120 °C, dec).

IR (mineral oil) 3296, 3100, 3060, 1773, 1714, 1668, 1547, 1496, 1400, 1340, 1299, 1272, 1171, 1038 cm^{-1} ;


^1H NMR (300 MHz, CDCl_3) δ 7.80-7.90, 7.65-7.80, 6.85, 4.33, 3.60-3.95, 3.25-3.55, 2.81, 2.65-2.85, 2.20-2.40, 1.70-2.20, 1.15-1.70, 0.75-0.95, 0.81, 0.68;

5 MS (EI) m/z 458, 402, 340, 339, 229, 212, 185, 169, 160, 138.

EXAMPLE 27 Preparation of N^3 -Hydroxy- N^1 -methyl-3-(2-methylpropyl)-2-oxo- α^3 -[2-(4,5,6,7-tetrafluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-1,3-pyrrolidinediacetamide.

10

15



20

Following the general procedure in EXAMPLE 22 and making non-critical variations but starting with *tert*-butyl 3-(2-methylpropyl)-2-oxo- α -(propen-2-yl)-3-pyrrolidineacetate (EXAMPLE 22, step 6), the title compound is obtained (mp 130 $^{\circ}\text{C}$, dec).


25 IR (mineral oil) 3293, 1785, 1723, 1668, 1550, 1514, 1500, 1410, 1314, 1273, 1158, 1035, 944, 754 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 6.55, 4.30, 3.60-4.00, 3.20-3.55, 2.55-2.90, 1.30-1.40, 1.10-1.30, 0.89, 0.78;

MS (EI) m/z 530, 498, 474, 411, 232, 212, 180, 169, 154, 152, 138.

30 EXAMPLE 28 Preparation of [S-(R^* , R^*)]- N^3 -Hydroxy- N^1 -methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide.

5



10 Step 1. Resolution of *tert*-Butyl *N*-*tert*-Butyloxycarbonyl-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetate.

A 20 mg/mL solution of racemic *tert*-butyl *N*-*tert*-butyloxycarbonyl-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetate (EXAMPLE 22, step 4) is made in the mobile phase, 2% isopropanol in hexane (V/V). Aliquots of 53 mL (1.06 g) are
 15 injected onto a 5.1x50 cm Chiralcel OD column (Chiral Technologies, Inc., Exton, PA 19341) using a SepTech 140 HPLC (EM Separations, Inc., Wakefield, RI 02880) instrument in the automated peak shaving and recycling mode. The flow rate is 60 mL/min and the monitor is set at 213 nm. After four passes through the column with appropriate peak shaving, both peaks are obtained in nearly 100% yield at
 20 >99% ee for the earlier eluting enantiomer (enantiomer 1) and 96.4% ee for the later eluting enantiomer (enantiomer 2). Enantiomeric excess is determined on a 0.46 x 25 cm Chiralcel OD-H column (Chiral Technologies, Inc.) using 5% isopropanol in hexane (V/V) at 0.5 mL/min with the monitor set at 210 nm. Enantiomer 1 eluted at 8.8 minutes and enantiomer 2 eluted at 10.2 minutes ($\alpha = 1.42$).

25 Step 2. Preparation of (S) *tert*-Butyl 3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetate.

A solution of (S)-*tert*-butyl *N*-*tert*-butyloxycarbonyl-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetate (193 mg, 0.543 mmol), magnesium methoxide (3.0 mL, 6-10 wt. % in MeOH), and MeOH (2.7 mL) is stirred at room temperature for 16 hours. The
 30 solution is poured into water (15 mL) and the mixture acidified with acetic acid. The mixture is extracted several times with CH₂Cl₂, the combined filtrates dried (MgSO₄), filtered, and concentrated to give 124 mg (89%) of the title compound as an oil.

IR (mineral oil) 3209, 3100, 3001, 1728, 1691, 1496, 1318, 1302, 1281, 1261,
 35 1208, 1163, 1132, 1079, 969 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 5.77, 3.25-3.40, 2.49, 2.20-2.40, 2.05-2.20, 1.65-

1.85, 1.35-1.60, 1.44, 1.42, 0.85-1.00;

MS (FAB) m/z 256, 201, 200, 182, 154, 57, 41.

Step 3. Preparation of Methyl D-Phenyllactate.

A mixture of D-phenyllactic acid (4.79 g, 28.8 mmol), iodomethane (1.80 mL, 28.9 mmol), K_2CO_3 (4.07 g, mmol), and DMF (80 mL) is stirred for 16 hours at room temperature. The solution is diluted with 500 mL of ether. The mixture washed with water (3 X 150 mL) and brine (150 mL). The organic layer is dried ($MgSO_4$), filtered, and concentrated to give 3.89 g (75%) of the title compound as a white solid.

1H NMR (300 MHz, $CDCl_3$) δ 7.15-7.40, 4.40-4.55, 3.78, 3.13, 2.97, 2.68.

Step 4. Preparation of the Triflate of Methyl D-Phenyllactate.

Trifluoromethylsulfonic anhydride (1.37 mL, 8.14 mmol) is added to a solution of methyl D-phenyllactate (1.20 g, 6.66 mmol), CCl_4 (8.6 mL), and pyridine (0.70 mL, 8.7 mmol) at 0 °C. The mixture is stirred for 1 hour at 0 °C and then diluted with pentane (35 mL). The mixture is allowed to warm to room temperature and is filtered. The solids are washed with pentane (35 mL) and the combined filtrates concentrated. Purification by flash chromatography (4:1 hexane:EtOAc) to give 1.39 g (55%) of the title compound as an oil.

1H NMR (300 MHz, $CDCl_3$) δ 7.15-7.40, 5.25, 3.84, 3.35, 3.21.

Step 5. Preparation of [S-(R*, R*)]N³-*tert*-Butyl-N¹-methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetate.

Sodium hydride (21.4 mg, 0.535 mmol, 60% mineral oil dispersion) is added to a solution of (S) *tert*-butyl 3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetate (124 mg, 0.486 mmol) and THF (1.65 mL) at 0 °C. The solution is stirred for 15 minutes at 0 °C and then a solution of the triflate (166 mg, 0.532 mmol) in 0.5 mL of pentane is added. The solution is stirred for 2 hours at 0 °C and 1 hour at room temperature. Aqueous workup ($EtOAc$, $MgSO_4$) and purification (4:1 hexane:EtOAc) provides 88.3 mg (44%) of the title compound as an oil.

IR (liq.) 2956, 2933, 1744, 1731, 1693, 1455, 1435, 1393, 1368, 1352, 1269, 1209, 1156, 1155, 700 cm^{-1} ;

1H NMR (300 MHz, $CDCl_3$) δ 7.15-7.35, 5.14, 3.70, 3.20-3.45, 3.00, 1.95-2.10, 2.08, 1.60-1.80, 1.45-1.55, 1.35-1.45, 1.40, 0.89, 0.86;

MS (EI) m/z 417, 361, 344, 305, 302, 271, 270, 214, 162, 132, 57.

Step 6. Preparation of [S-(R*, R*)] 3-(*tert*-Butylacetoxy)-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1-pyrrolidineacetic Acid.

A mixture of [S-(R*, R*)]-N³-*tert*-butyl-N¹-methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetate (254 mg, 0.608 mmol), MeOH (12 mL),

water (3.0 mL), and sodium hydroxide (98.4 mg, 2.46 mmol) is stirred at room temperature for 16 hours and then concentrated. The residue is diluted with water, acidified (10% HCl) and the aqueous layer extracted several times with CH₂Cl₂. The organic layers are dried (MgSO₄), filtered, and concentrated to give 233 mg
5 (95%) of the title compound as an oil.

IR (liq.) 2958, 2933, 2872, 1730, 1693, 1651, 1456, 1443, 1393, 1368, 1273, 1258, 1207, 1155, 699 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.20-7.35, 4.67, 3.40, 3.20-3.35, 3.00-3.10, 2.29, 1.95-2.10, 1.80-1.95, 1.60-1.75, 1.52, 1.41, 1.31, 0.91, 0.87;

10 MS (EI) *m/z* 403, 347, 330, 303, 302, 291, 256, 200, 132, 57, 55.

Step 7. [S-(R*, R*)] *tert*-Butyl N¹-Methylacetamide-3-(2-methylpropyl)-2-oxo-
α¹-(phenylmethyl)-3-pyrrolidineacetate.

CDI (94.3 mg, 0.582 mmol) is added to a solution of [S-(R*, R*)] 3-(*tert*-butylacetoxyl)-3-(2-methylpropyl)-2-oxo-α¹-(phenylmethyl)-1-pyrrolidineacetic acid
15 (224 mg, 0.555 mmol) and THF (2.5 mL). The solution is stirred for 1 hour at room temperature and then 0.27 mL of 40% aq methylamine is added. The solution is stirred at room temperature for 16 hours. Aqueous workup (EtOAc, 3% HCl, 10% NaOH and brine washes, MgSO₄) gives 259 mg of crude product which is purified by flash chromatography (1:1 hexane:EtOAc) to give 198 mg (86%) of the title
20 compound as an oil.

IR (mineral oil) 3395, 1719, 1682, 1656, 1545, 1442, 1351, 1306, 1274, 1248, 1210, 1150, 1117, 747, 703 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.15-7.30, 6.90-7.05, 4.25, 3.41, 3.20-3.35, 2.95-3.10, 2.82, 2.43, 1.95-2.10, 1.75-1.90, 1.50-1.70, 1.43, 1.08, 0.88, 0.81;

25 MS (EI) *m/z* 416 (M⁺) 360, 358, 343, 303, 302, 284, 269, 161, 132, 57.

Step 8. Preparation of [S-(R*, R*)] N¹-Methylacetamide-3-(2-methylpropyl)-2-oxo-α¹-(phenylmethyl)-3-pyrrolidineacetic Acid.

TFA (3.0 mL) is added to a solution of [S-(R*, R*)] *tert*-butyl N¹-methylacetamide-3-(2-methylpropyl)-2-oxo-α¹-(phenylmethyl)-3-pyrrolidineacetate
30 (192 mg, 0.461 mmol) and CH₂Cl₂ (3.0 mL) at 0 °C. The solution is stirred for 1 hour at 0 °C and for 3 hours at room temperature. The solution is concentrated which is repeated twice more from CH₂Cl₂ (2 X 30 mL). Aqueous workup (CH₂Cl₂, MgSO₄) provides 158 mg (95%) of the title compound as an oil.

¹H NMR (300 MHz, CDCl₃) δ 7.15-7.35, 6.10-6.25, 4.66, 3.25-3.50, 3.17, 2.76,
35 2.38, 2.00-2.10, 1.60-1.85, 1.53, 1.25-1.40, 0.90, 0.84;

MS (EI) *m/z* 360, 303, 302, 284, 269, 161, 149, 132, 69, 57, 55.


Step 9. Preparation of [S-(R*, R*)]-N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide.

EDC (92.2 mg, 0.481 mmol) is added to a solution of [S-(R*, R*)] N¹-methylacetamide-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-3-pyrrolidineacetic acid (151 mg, 0.419 mmol), CH₂Cl₂ (4.1 mL), DMF (1.0 mL), HOBT (56.4 mg, 0.417 mmol), and N-methylmorpholine (50 μ L, 0.46 mmol) at 0 °C. The solution is stirred for 5 minutes at 0 °C and 1 hour at room temperature. Hydroxylamine hydrochloride (57.8 mg, 0.832 mmol) and N-methylmorpholine (90 μ L, 0.82 mmol) are added and the mixture stirred overnight at room temperature. Aqueous workup (CH₂Cl₂, MgSO₄) and purification by flash chromatography (20:1 CH₂Cl₂:MeOH) provided 74 mg of the hydroxamate as an oil which is crystallized from ether/EtOAc/hexane to give 50 mg (32%) of the title compound as a white crystalline material (mp 159-164 °C): $[\alpha]_D^{25}$ -84° (c 0.49, CHCl₃).

IR (mineral oil) 3372, 3196, 3028, 1687, 1669, 1635, 1605, 1543, 1441, 1404, 1355, 1302, 1287, 747, 703 cm⁻¹;

MS (EI) *m/z* 375, 317, 316, 302, 299, 284, 200, 132, 91, 58, 55.

EXAMPLE 29 Preparation of [R,R-(R*, R*)]- α^3 -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N³-hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide.



Step 1. Preparation of (R) *tert*-Butylmethyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)- α^3 -(propen-2-yl)-1,3-pyrrolidinediacetate.

Sodium hydride (129 mg, 3.23 mmol, 60% mineral oil dispersion) is added to a solution of *tert*-butyl 3-(2-methylpropyl)-2-oxo- α -(propen-2-yl)-3-pyrrolidineacetate
 5 (EXAMPLE 22, step 6; 862 mg, 2.92 mmol) and THF (10 mL) at 0 °C. The solution is stirred for 20 minutes at 0 °C and then a solution of the triflate (EXAMPLE 28, step 4; 1.01 g, 3.23 mmol) in 2.0 mL of pentane is added. The solution is stirred for 2 hours at 0 °C and 1.5 hours at room temperature. Aqueous workup (EtOAc, MgSO₄) and purification (4:1 hexane:EtOAc) provided 922 mg (69%) of the title
 10 compound as an oil which is a mixture of diastereomers.

IR (liq.) 2975, 2956, 2934, 1745, 1724, 1690, 1455, 1435, 1425, 1368, 1288, 1267, 1237, 1210, 1153, cm⁻¹;

¹H NMR (300 MHz, CDCl₃) major peaks only δ 3.71, 3.70, 1.40, 1.38, 0.89, 0.83, 0.69, 0.56;

15 MS (EI) *m/z* 457, 401, 342, 310, 304, 303, 260, 200, 162, 91, 57.

Step 2. Preparation of (R) 3-(*tert*-Butylacetoxy)-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)- α^3 -(propen-2-yl)-1-pyrrolidineacetic Acid.

A mixture of (R) *tert*-butylmethyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)- α^3 -(propen-2-yl)-1,3-pyrrolidinediacetate (913 mg, 2.00 mmol), MeOH (32 mL), water
 20 (8.0 mL), and sodium hydroxide (362 mg, 9.05 mmol) is stirred at room temperature for 16 hours and then concentrated. The residue is diluted with water, acidified (10% HCl), and the aqueous layer extracted several times with CH₂Cl₂. The organic layers are dried (MgSO₄), filtered, and concentrated to give 829 mg (93%) of the title compound as an oil.

25 IR (liq.) 3003, 2974, 2959, 2932, 1725, 1692, 1652, 1643, 1455, 1368, 1284, 1272, 1255, 1206, 1153 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) major peaks only δ 3.57, 2.99, 2.69, 1.40, 1.38, 0.89, 0.85, 0.61, 0.59;

MS (EI) *m/z* 443, 387, 342, 296, 290, 289, 252, 246, 200, 91, 57.

30 Step 3. Preparation of [R,R-(R*, R*)] and [S,R-(S*, S*)] *tert*-Butyl N¹-Methylacetamide-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)- α^3 -(propen-2-yl)-3-pyrrolidineacetate.

CDI (314 mg, 1.94 mmol) is added to a solution of (R) 3-(*tert*-butylacetoxy)-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)- α^3 -(propen-2-yl)-1-pyrrolidineacetic acid
 35 (821 mg, 1.85 mmol) and THF (8.0 mL). The solution is stirred for 1 hour at room temperature and then 1.1 mL of 40% aq methylamine is added. The solution is

stirred at room temperature for 16 hours. Aqueous workup (EtOAc, 3% HCl, 10% NaOH and brine washes, MgSO₄) gives 921 mg of crude product which is purified by flash chromatography (1:1 hexane:EtOAc) to give 126 mg of diastereomer A.

Further elution provided diastereomer B contaminated by diastereomer A and two minor diastereomers. Repurification of the mixture by flash chromatography (two collums; 1:1 hexane EtOAc) provides an additional 174 mg of diastereomer A (total 300 mg, 36%) as an oil.

IR (mineral oil) 3376, 1702, 1685, 1667, 1538, 1501, 1443, 1433, 1277, 1267, 1249, 1232, 1156, 742, 697 cm⁻¹;

MS (EI) *m/z* 456, 400, 399, 398, 343, 342, 324, 309, 200, 132, 57.

Further elution provided 209 mg (25%) of impure diastereomer B:

IR (liq.) 3328, 2975, 2957, 2934, 1724, 1663, 1554, 1498, 1455, 1438, 1368, 1292, 1266, 1152, 699 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.10-7.30, 6.25-6.35, 5.50-5.70, 4.90-5.10, 4.64, 3.30-3.45, 3.08, 2.80, 2.71, 2.10-2.40, 1.70-1.90, 1.30-1.65, 0.86, 0.79;

MS (EI) *m/z* 456, 400, 398, 343, 342, 324, 309, 259, 200, 132, 57.

Step 4. Preparation of [R,R-(R*, R*)]-*tert*-Butyl α³-(2-Hydroxyethyl)-N¹-methylacetamide-3-(2-methylpropyl)-2-oxo-α¹-1-(phenylmethyl)-3-pyrrolidineacetate.

Ozone is passed through a solution of [R,R-(R*, R*)]-*tert*-butyl N¹-methylacetamide-3-(2-methylpropyl)-2-oxo-α¹-1-(phenylmethyl)-α³-(propen-2-yl)-3-pyrrolidineacetate (EXAMPLE 29, step 3, diastereomer B; 203 mg, 0.445 mmol) and EtOH (4.4 mL) at -78 °C for 4 minutes. After purging with oxygen, sodium borohydride (27 mg, 0.71 mmol) is added. The mixture is stirred at -78 °C for 1 hour and then allowed to slowly warm to room temperature over 1 hour. After 1 hour at room temperature, sodium borohydride (14 mg, 0.37 mmol) is added and the mixture stirred an additional 2 hours at room temperature. Concentration and aqueous workup (EtOAc, MgSO₄) provided 198 mg (97%) of the title compound as an oil which is carried on crude.

IR (liq.) 3320, 2957, 2934, 1722, 1659, 1455, 1437, 1414, 1392, 1368, 1260, 1152, 1057, 734, 699 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.10-7.35, 6.15-6.25, 4.64, 2.70, 1.44, 0.86, 0.79;

MS (EI) *m/z* 460, 346, 328, 132, 105, 91, 81, 69, 58, 57, 55.

Step 5. Preparation of [R,R-(R*, R*)]-*tert*-Butyl α^3 -[2-(1,3-Dihydro-1,3-dioxo-2H-isindol-2-yl)ethyl]-N¹-methylacetamide-3-(2-methylpropyl)-2-oxo- α^1 -1-(phenylmethyl)-3-pyrrolidineacetate.

DEAD (73.4 μ L, 0.446 mmol) is added to a solution of [R,R-(R*, R*)]-*tert*-butyl α^3 -(2-hydroxyethyl)-N¹-methylacetamide-3-(2-methylpropyl)-2-oxo- α^1 -1-(phenylmethyl)-3-pyrrolidineacetate (195 mg, 0.423 mmol), triphenylphosphine (122 mg, 0.465 mmol), phthalimide (68.1 mg, 0.463 mmol) and THF (5.0 mL). The solution is stirred for 16 hours at room temperature. Concentration and purification by flash chromatography (two columns; 1:1 hexane:EtOAc) give 144 mg (58%) of the title compound as an oil.

¹H NMR (300 MHz, CDCl₃) major peaks δ 7.78-7.90, 7.65-7.75, 7.10-7.35, 6.30-6.40, 4.59, 2.71, 1.49, 0.83, 0.78.

Step 6. Preparation of [R,R-(R*, R*)]- α^3 -[2-(1,3-Dihydro-1,3-dioxo-2H-isindol-2-yl)ethyl]-N³-hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α^1 -1-(phenylmethyl)-1,3-pyrrolidinediacetamide.

TFA (2.0 mL) is added to a solution of [R,R-(R*, R*)]-*tert*-butyl α^3 -[2-(1,3-dihydro-1,3-dioxo-2H-isindol-2-yl)ethyl]-N¹-methylacetamide-3-(2-methylpropyl)-2-oxo- α^1 -1-(phenylmethyl)-3-pyrrolidineacetate (144 mg, 0.244 mmol) and CH₂Cl₂ (2.0 mL) at 0 °C. The solution is stirred for 0.5 hours at 0 °C and for 1.5 hours at room temperature. The solution is concentrated which is repeated twice more from CH₂Cl₂ (2 X 40 mL). Aqueous workup (CH₂Cl₂, MgSO₄) provides 127 mg (97%) of the acid intermediate as an oil.

EDC (52.7 mg, 0.275 mmol) is added to a solution of the crude acid (127 mg, 0.238 mmol), CH₂Cl₂ (2.4 mL), DMF (0.6 mL), HOBT (32.2 mg, 0.238 mmol), and N-methylmorpholine (28.5 μ L, 0.259 mmol) at 0 °C. The solution is stirred for 5 minutes at 0 °C and 1 hour at room temperature. Hydroxylamine hydrochloride (33.2 mg, 0.478 mmol) and N-methylmorpholine (51 μ L, 0.46 mmol) are added and the mixture stirred overnight at room temperature. Aqueous workup (CH₂Cl₂, MgSO₄) and purification by flash chromatography (40:1 EtOAc:MeOH) provides 65.9 mg of the title compound as an oil which is crystallized from ether/hexane to give 45 mg (34%) of the product as a white powder material (mp 176-180°C).

IR (mineral oil) 1714, 1672, 1634, 1401 cm⁻¹;


¹H NMR (300 MHz, CDCl₃) δ 7.70-7.90, 7.05-7.35, 6.85-7.00, 6.10-6.20, 4.68, 3.35-3.75, 3.41, 3.23, 2.90-3.10, 2.70, 2.32, 2.10-2.35, 1.30-1.95, 0.82, 0.73;

MS (EI) *m/z* 548, 430, 429, 302, 259, 244, 200, 185, 160, 130, 56.

EXAMPLE 30 Preparation of [S-(R*, R*)]-N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide.

5

10



15 **Step 1.** Preparation of (γ S)- α -(2-Methylpropen-2-yl)- γ -trityloxymethyl- γ -butyrolactone.

Lithium diisopropylamide (10.6 mL, 21.2 mmol, 2.0 M, heptane/THF/ethylbenzene) is added to a solution of S-(+)- γ -trityloxymethyl- γ -butyrolactone (6.36 g, 17.6 mmol), THF (51 mL), and HMPA (3.8 mL) at -78 °C. After stirring for 30 minutes at -78 °C, a solution of 3-bromo-2-methylpropene (1.96 mL, 19.4 mmol) and THF (10.0 mL) is added. The solution is allowed to stir for 4 hours at -78 °C and is then quenched with aqueous ammonium chloride (50 mL). After warming to room temperature, aqueous workup (EtOAc, MgSO₄) provides an oil which is crystallized from hexane/EtOAc (4:1) to give 3.89 g of the title compound as a white solid (mp 134-135.5°C). The filtrate is concentrated and purified by flash chromatography (4:1 hexane:EtOAc) to give additional title compound (6.11 g total, 84%):

IR (mineral oil) 1764, 1489, 1216, 1179, 1151, 1102, 1041, 1029, 962, 902, 771, 749, 707, 694, 636 cm⁻¹;
 30 ¹H NMR (300 MHz, CDCl₃) δ 7.15-7.50, 4.81, 4.72, 4.50-4.65, 3.45, 3.13, 2.95-3.15, 2.60-2.70, 1.85-2.25, 1.73;

MS (EI) *m/z* 412, 335, 259, 258, 244, 243, 165, 105, 93, 77, 55.

Step 2. Preparation of (γ S)- α -(2-Methylpropyl)- γ -trityloxymethyl- γ -butyrolactone.

35 A mixture of (γ S)- α -(2-methylpropen-2-yl)- γ -trityloxymethyl- γ -butyrolactone (6.10 g, 14.8 mmol), 10% Pd/C (800 mg) and EtOAc (250 mL) is hydrogenated (42

psi) in a Parr flask at room temperature for 18 hours. The mixture is filtered and the residue washed with EtOAc, CH_2Cl_2 , and EtOAc. The filtrate is dried (MgSO_4), filtered, and concentrated to give 5.67 g (92%) of the title compound as an oil which is a mixture of diastereomers.

- 5 IR (liq.) 2956, 2930, 2871, 1773, 1490, 1449, 1227, 1172, 1093, 1033, 974, 767, 747, 706, 633 cm^{-1} ;
 ^1H NMR (300 MHz, CDCl_3) δ 7.15-7.50, 4.50-4.65, 3.44, 3.12, 2.80-2.95, 2.15-2.30, 1.85-2.00, 1.60-1.85, 1.20-1.40, 0.95, 0.91;
 MS (EI) m/z 414, 337, 259, 258, 244, 243, 165, 109, 105, 77, 69.

- 10 Step 3. Preparation of [S-(R*, R*)]- α -(2-Methylpropyl)- α -(propen-2-yl)- γ -trityloxymethyl- γ -butyrolactone.

Lithium diisopropylamide (8.3 mL, 16.6 mmol, 2.0 M, heptane/THF/ethylbenzene) is added to a solution of (γ S)- α -(2-methylpropyl)- γ -trityloxymethyl- γ -butyrolactone (5.67 g, 13.7 mmol), THF (50 mL), and HMPA (2.9 mL) at -78 °C. After stirring for 30 minutes at -78 °C, a solution of allyl bromide (1.46 mL, 16.9 mmol) and THF (8.0 mL) is added. The solution is allowed to stir for 4 hours at -78 °C and is then quenched with aqueous ammonium chloride (50 mL). After warming to room temperature, aqueous workup (EtOAc, MgSO_4) and purification by flash chromatography (6:1 hexane:EtOAc) to give 5.12 g of the title compound (82%) as a white powder (mp 84-85 °C).

- 20 IR (mineral oil) 1770, 1489, 1184, 1119, 1089, 1070, 1034, 1027, 1002, 991, 775, 754, 704, 632 cm^{-1} ;
 ^1H NMR (300 MHz, CDCl_3) δ 7.15-7.50, 5.65-5.85, 5.10-5.20, 4.40-4.55, 3.15-3.35, 2.20-2.40, 1.90-2.15, 1.45-1.80, 0.92, 0.85;
 25 MS (EI) m/z 454, 377, 259, 258, 244, 243, 165, 109, 105, 77, 55.

- Step 4. Preparation of [S-(R*, R*)]- α -(2-Methylpropyl)- α -(propen-2-yl)- γ -hydroxymethyl- γ -butyrolactone.

TFA (15.0 mL) is added to a solution of [S-(R*, R*)]- α -(2-methylpropyl)- α -(propen-2-yl)- γ -trityloxymethyl- γ -butyrolactone (2.09 g, 4.60 mmol) and CH_2Cl_2 (30.0 mL) at 0 °C. The solution is stirred for 75 minutes at 0 °C and is concentrated. Aqueous workup (CH_2Cl_2 , MgSO_4) and purification by flash chromatography (1:1 hexane:EtOAc) provides 684 mg (70%) of the title compound as an oil.

- 35 IR (liq.) 3434, 2958, 2932, 2872, 1767, 1368, 1191, 1140, 1101, 1075, 1058, 1034, 998, 923, 622 cm^{-1} ;
 ^1H NMR (300 MHz, CDCl_3) δ 5.70-5.90, 5.10-5.25, 4.45-4.55, 3.89, 3.60, 2.00-

2.50, 1.60-1.90, 1.52, 0.96, 0.89;

MS (EI) m/z 212, 156, 111, 109, 93, 81, 69, 67, 55, 43, 41.

Step 5. Preparation of [R*,R*] α -(2-Methylpropyl)- α -(propen-2-yl)- γ -hydroxy- γ -butyrolactone.

5 A mixture of [S-(R*, R*)]- α -(2-methylpropyl)- α -(propen-2-yl)- γ -hydroxymethyl- γ -butyrolactone (682 mg, 3.21 mmol), NaOH (350 mg, 8.75 mmol), THF (40 mL), and H₂O (10 mL) is stirred for 19 hours at room temperature. Additional NaOH (114 mg, 2.85 mmol) is added after 16 hours. The mixture is concentrated and the residue taken up into MeOH (43 mL). A solution of sodium periodate (862 mg, 4.03
10 mmol) and H₂O (4.3 mL) is added and the mixture stirred at room temperature for 3 hours. After concentration, the aqueous residue is acidified (HCl) and extracted with CH₂Cl₂ (3 X 40 mL). The organic layers are dried (MgSO₄), filtered, and concentrated to provide 625 mg (98%) of the title compound as a semi-solid.

IR (liq.) 3389, 2959, 2933, 2873, 1769, 1747, 1746, 1369, 1186, 1170, 1129,
15 988, 963, 944, 926 cm⁻¹;
¹H NMR (300 MHz, CDCl₃) δ 5.60-5.90, 5.10-5.25, 3.30-3.50, 1.45-2.55, 0.85-1.00;

MS (EI) m/z 142, 113, 97, 95, 67, 57, 55, 43, 41, 39.

Step 6. Preparation of L-Phenylalanine Methyl Amide.

20 CDI (545 mg, 3.36 mmol) is added to a solution of CBZ-L-phenylalanine (1.00 g, 3.34 mmol) and THF (12.5 mL). The solution is stirred for 1 hour at room temperature and then 40% aqueous methylamine (1.5 mL) is added. The solution is stirred for 16 hours at room temperature. The solution is diluted with EtOAc and is washed with NaHCO₃, 10% HCl, NaHCO₃, and brine. The organic layer is dried
25 (MgSO₄), filtered, and concentrated to give 983 mg (94%) of the carbamate intermediate as a white solid.

¹H NMR (300 MHz, CDCl₃) δ 7.10-7.40, 5.50-5.65, 5.25-5.40, 5.07, 4.33, 2.95-3.20, 2.70.

Ammonium formate (644 mg, 10.2 mmol) is added to a mixture of the
30 carbamate (980 mg, 3.14 mmol), MeOH (21 mL), and 10% Pd/C (104 mg). The mixture is stirred for 1 hour at room temperature and is filtered. The residue is washed with MeOH, CH₂Cl₂, and is concentrated. The residue is diluted with 30:1 CH₂Cl₂:MeOH (30 mL), dried (MgSO₄), filtered, and concentrated to provide 504 mg (90%) of the title compound as a foam which is carried on crude.

35 ¹H NMR (300 MHz, CDCl₃) δ 8.12, 7.15-7.40, 4.07, 3.72, 3.26, 2.65-2.85, 2.78.

Step 7. Preparation of [S-(R*, R*)] Methyl-3-(2-methylpropyl)-2-oxo- α -(phenylmethyl)-3-(propen-2-yl)-1-pyrrolidineacetamide.

A solution of L-phenylalanine methyl amide (EXAMPLE 30, step 6; 210 mg, 1.18 mmol) and MeOH (8.5 mL) is added to [R*,R*] α -(2-methylpropyl)- α -(propen-2-yl)- γ -hydroxy- γ -butyrolactone (EXAMPLE 30, step 5; 200 mg, 1.01 mmol). Sodium cyanoborohydride (85.0 mg, 1.35 mmol) is added and the solution stirred for 16 hours at room temperature. Concentration and aqueous workup (20:1 CHCl₃:MeOH, MgSO₄) provided 397 mg of the uncyclized intermediate as an oil. A mixture of the crude residue, toluene (24 mL), MeOH (8.0 mL), and silica gel (800 mg) is slowly heated to reflux allowing the MeOH to boil off. The mixture is then maintained at reflux for 3 hours and is allowed to cool to room temperature. The mixture is filtered, the solids washed with 20:1 CH₂Cl₂:MeOH (3 X 40 mL), and the filtrate concentrated. Purification by flash chromatography (EtOAc) provided 218 mg (63%) of the title compound as an oil.

IR (liq.) 3314, 2955, 2929, 2871, 1661, 1660, 1558, 1498, 1455, 1439, 1413, 1296, 1267, 741, 698 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.15-7.35, 6.15-6.30, 5.10-5.35, 4.75-5.00, 3.15-3.40, 3.07, 2.74, 2.00-2.15, 1.55-2.00, 1.35-1.55, 0.90, 0.81;

MS (EI) m/z 342, 311, 299, 285, 284, 162, 132, 105, 91, 81, 67, 58, 55.

Step 8. Preparation of [S-(R*, R*)] N¹-Methylacetamide-3-(2-methylpropyl)-2-oxo- α -(phenylmethyl)-3-(propen-2-yl)-1-pyrrolidineacetic Acid.

Ruthenium(IV) oxide hydrate (17.3 mg, 0.130 mmol) is added to a mixture of sodium periodate (1.07 g, 5.00 mmol), H₂O (14.0 mL), CH₃CN (14.0 mL), and CCl₄ (14.0 mL). The mixture is stirred for 20 minutes at room temperature and then NaHCO₃ (1.32 g, 15.7 mmol) and H₂O (7.0 mL) are added. After stirring an additional 5 minutes, a solution of [S-(R*, R*)]-methyl-3-(2-methylpropyl)-2-oxo- α -(phenylmethyl)-3-(propen-2-yl)-1-pyrrolidineacetamide (215 mg, 0.628 mmol) and CH₃CN (6.0 mL) is added. After stirring for 8 minutes at room temperature, the residue is poured into a mixture of H₂O (40 mL) and EtOAc (100 mL). The aqueous layer is removed and the organic layer extracted with 10% NaOH (2 X 15 mL). The combined basic layers are acidified (4 N HCl) and extracted with CH₂Cl₂ (3 X 50 mL). The CH₂Cl₂ layers are dried (MgSO₄), filtered, and concentrated to provide 109 mg (48%) of the title compound as an oil.

IR (liq.) 3347, 3029, 2957, 2872, 1724, 1657, 1552, 1498, 1455, 1440, 1413, 1296, 1271, 1193, 700 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.10-7.40, 6.81, 4.54, 3.15-3.50, 2.73, 2.45, 1.80-

2.05, 1.55-1.75, 1.40-1.55, 1.24, 0.89, 0.82;

MS (EI) m/z 360, 303, 302, 284, 269, 244, 200, 161, 132, 91, 55.

Step 9. Preparation of [S-(R*, R*)]-N³-Benzyloxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide.

5 CDI (59.0 mg, 0.364 mmol) is added to a solution of [S-(R*, R*)]-N¹-methylacetamide-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-3-pyrrolidineacetic acid (109 mg, 0.302 mmol) and CH₂Cl₂ (2.3 mL). The solution is stirred for 1 hour at room temperature and then O-benzylhydroxylamine hydrochloride (70.0 mg, 0.439 mmol) and N-methylmorpholine (0.06 mL, 5.5 mmol) are added. The solution is
10 stirred for 16 hours at room temperature. Aqueous workup (CH₂Cl₂, MgSO₄) and purification by flash chromatography (EtOAc) provides 82.4 mg (59%) of the title compound as an oil.

IR (liq.) 3213, 3031, 2957, 2872, 1662, 1545, 1498, 1455, 1441, 1412, 1368, 1295, 1280, 750, 699 cm⁻¹;

15 ¹H NMR (300 MHz, CDCl₃) δ 8.85-9.00, 7.10-7.50, 6.40-6.55, 4.75-5.00, 4.40-4.55, 3.10-3.45, 2.75, 2.15-2.30, 1.80-2.15, 1.40-1.65, 1.10-1.30, 0.87, 0.79;

MS (EI) m/z 465, 407, 284, 132, 105, 92, 91, 77, 69, 58, 55.

Step 10. Preparation of [S-(R*, R*)]-N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide.

20 An atmosphere of hydrogen is placed over a mixture of [S-(R*, R*)]-N³-benzyloxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide (79.2 mg, 0.170 mmol), MeOH (4.0 mL) and 10% Pd/C (15 mg). After stirring for 4 hours at room temperature, the mixture is filtered, the solids washed with MeOH (4 X 5 mL) and CH₂Cl₂ (5 mL), and the combined filtrate
25 concentrated to provide 41 mg of the desired product as an oil. Trituration (ether/hexane) provides 39.4 mg (62%) of the title compound as a white powder (mp 162-165°C): [α]_D²⁵ -96° (c 0.26, CHCl₃).


IR (mineral oil) 3372, 3195, 3028, 1687, 1669, 1636, 1605, 1542, 1441, 1405, 1355, 1302, 1287, 747, 704 cm⁻¹;

30 ¹H NMR (300 MHz, CDCl₃) δ 7.15-7.40, 6.50-6.65, 4.50-4.65, 3.10-3.50, 2.78, 2.32, 1.90-2.15, 1.45-1.80, 1.20-1.35, 0.90, 0.83;

MS (EI) m/z 375, 317, 302, 301, 299, 284, 244, 200, 132, 91, 55.

EXAMPLE 31 Preparation of [S-(R*, R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo-N¹-(2-phenethyl)- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide.
35

5



10 Following the general procedure of EXAMPLE 30 and making non-critical variations but starting with [R*,R*] α -(2-methylpropyl)- α -(propen-2-yl)- γ -hydroxy- γ -butyrolactone (EXAMPLE 30, Step 5) and L-phenylalanine phenethyl amide (prepared similarly to that described in EXAMPLE 30, Step 6), the title compound is obtained (mp 158-159°C).

15 $[\alpha]_D^{25}$ -83° (c 0.35, CHCl₃);


IR (mineral oil) 3219, 3087, 3063, 3029, 1668, 1644, 1558, 1498, 1354, 1311, 1297, 1283, 749, 743, 701 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 9.63, 7.00-7.40, 6.31, 4.59, 3.30-3.60, 3.00-3.20, 2.65-2.85, 2.14, 1.85-2.10, 1.40-1.75, 1.25, 0.87, 0.80;

20 MS (EI) *m/z* 465, 318, 317, 316, 284, 200, 132, 105, 91, 55.

EXAMPLE 32 Preparation of [S-(R*, R*)]-N³-Hydroxy-N¹-methyl- α ¹,3-bis (2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide.

25



30

Following the general procedure of EXAMPLE 30 and making non-critical
35 variations but starting with [R*,R*] α -(2-methylpropyl)- α -(propen-2-yl)- γ -hydroxy- γ -

butyrolactone (EXAMPLE 30, Step 5) and L-leucine methyl amide (prepared similarly to that described in EXAMPLE 30, Step 6), the title compound is obtained (mp 138-139°C).


$[\alpha]_D^{25} +117^\circ$ (c 0.28, CHCl_3);

5 IR (mineral oil) 3376, 3198, 3023, 1689, 1676, 1639, 1543, 1493, 1406, 1355, 1304, 1281, 1195, 1166 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 9.91, 6.31, 4.35-4.50, 3.30-3.55, 2.76, 2.44, 2.20-2.40, 2.00-2.15, 1.35-1.90, 0.75-1.00;

MS (EI) m/z 341, 310, 284, 283, 282, 251, 250, 222, 98, 86, 55.

10 **EXAMPLE 33** Preparation of [S-(R*, R*)]- α^1 -(Cyclohexylmethyl)-N³-hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide.




15 Following the general procedure of EXAMPLE 30 and making non-critical variations but starting with [R*, R*] α -(2-methylpropyl)- α -(propen-2-yl)- γ -hydroxy- γ -butyrolactone (EXAMPLE 30, Step 5) and β -cyclohexyl-L-alanine methyl amide (prepared similarly to that described in EXAMPLE 30 Step 6), the title compound is obtained (mp 150-152 °C).

25 IR (mineral oil) 3253, 3194, 3058, 1678, 1643, 1544, 1502, 1409, 1285, 1268, 1259, 1228, 1048, 738, 647 cm^{-1} ;

30 ^1H NMR (300 MHz, CDCl_3) δ 6.52, 4.42, 3.30-3.55, 2.77, 2.44, 2.20-2.35, 1.95-2.15, 1.98, 1.35-1.90, 0.75-1.35, 0.92, 0.86;

MS (EI) m/z 381, 324, 323, 322, 290, 208, 86, 67.

EXAMPLE 34 Preparation of [S-(R*, R*)]-N³-Hydroxy-N¹-methyl-3-(3-methylbutyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide.



Following the general procedure of EXAMPLE 30 and making non-critical variations but starting with [R*,R*] α -(3-methylbutyl)- α -(propen-2-yl)- γ -hydroxy- γ -butyrolactone (prepared similarly to that described in EXAMPLE 30, Steps 1-5) and L-phenylalanine methyl amide (EXAMPLE 30, step 6), the title compound is obtained (mp 167-168°C).


$[\alpha]_{25}^D$ -104° (c 0.43, CHCl₃);

IR (mineral oil) 3372, 3195, 3064, 3029, 1687, 1670, 1635, 1545, 1497, 1443, 1405, 1297, 1287, 745, 701 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 9.50-9.80, 7.10-7.40, 6.92, 4.40-4.50, 3.10-3.45, 2.79, 2.23, 1.90-2.20, 1.70-1.90, 1.05-1.55, 0.75-1.00;

MS (FAB) m/z 390, 389, 374, 357, 331, 298, 132.

EXAMPLE 35 Preparation of N-Hydroxy-3-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



Step 1. Preparation of Ethyl 3-(2-Methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-3-pyrrolidineacetate.

Ruthenium(IV) oxide hydrate (27 mg, 0.20 mmol) is added to a mixture of ethyl 3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (prepared
5 similarly to that described in EXAMPLE 1, steps 1-3; 900 mg, 2.71 mmol), sodium periodate (2.71 g, 12.7 mmol), water (27 mL), and CCl₄ (27 mL) at room temperature. After stirring overnight at room temperature, aqueous workup (CH₂Cl₂, MgSO₄) and purification by column chromatography (20% EtOAc/hexane) gives 611 mg of the title compound (65%) as a colorless oil.

10 IR (liq.) 2959, 1775, 1733, 1704, 1455, 1438, 1403, 1368, 1346, 1255, 1218, 1193, 1165, 1030, 699 cm⁻¹;
¹H NMR (300 MHz, CDCl₃) δ 7.15-7.35, 4.09, 3.65-3.85, 2.50-3.00, 1.35-1.80, 1.22, 0.91, 0.85;
MS (EI) *m/z* 345, 300, 289, 259, 203, 105, 104.

15 Step 2. Preparation of 3-(2-Methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-3-pyrrolidineacetic Acid.

Sodium hydroxide (283 mg, 7.08 mmol) is added to a mixture of ethyl 3-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-3-pyrrolidineacetate (611 mg, 1.77 mmol), methanol (10 mL), and water (5 mL), and the mixture is allowed to stir overnight at
20 room temperature. The mixture is partitioned with 10 ml of water and 10 mL of Et₂O. The layers are separated and the pH of the aqueous layer was adjusted to pH 2 (pH meter) with 1.2 N HCl. The aqueous layer is extracted with EtOAc (2 x 10 mL) and CH₂Cl₂ (2 x 10 mL), and the combined organic layers are dried (MgSO₄), filtered and concentrated to give 500 mg (89%) of the title compound as a white
25 foam which is carried on crude.

¹H NMR (300 MHz, CDCl₃) δ 7.10-7.40, 3.30-3.85, 2.50-2.95, 1.10-1.85, 0.75-1.00.

Step 3. Preparation of N-Benzoyloxy-3-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.

30 CDI (153 mg, 0.945 mmol) is added to a mixture of 3-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-3-pyrrolidineacetic acid (300 mg, 0.945 mmol) and CH₂Cl₂ (7.5 mL) at room temperature. After stirring at room temperature for 1 hour, O-benzylhydroxylamine hydrochloride (181 mg, 1.13 mmol) and 4-methylmorpholine (124 μL, 1.13 mmol) are added to the solution. The mixture is allowed to stir
35 overnight at room temperature. Basic workup (CH₂Cl₂, NaHCO₃, MgSO₄) and

purification by column chromatography (1.5% MeOH/CHCl₃) affords 70 mg (18%) of the title compound as a white solid (mp 115-117 °C).

IR (mineral oil) 3195, 1705, 1677, 1659, 1409, 1357, 1182, 1169, 1018, 773, 752, 707, 700, 693, 627 cm⁻¹;

5 ¹H NMR (300 MHz, CDCl₃) δ 8.53, 8.10-8.30, 7.10-7.45, 4.70-4.90, 3.60-3.80, 2.65-2.95, 2.10-2.65, 1.25-1.60, 0.86, 0.79;

MS (EI) m/z 422, 389, 366, 300, 260, 229, 194, 179, 125, 105, 104, 91.

Step 4. Preparation of N-Hydroxy-3-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.


10 A mixture of N-benzyloxy-3-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (80 mg, 0.19 mmol), Pd/C (10%, 5 mg), ammonium formate (59 mg, 0.95 mmol) and EtOH (2.5 mL) is stirred at room temperature. After 2 hours, a second portion of ammonium formate (35 mg, 0.56 mmol) is added and the mixture is allowed to stir overnight at room temperature. The mixture is filtered, and the
15 filter cake washed with MeOH (3 x 15 mL) and CHCl₃ (3 x 15 mL). The filtrate is concentrated, reconstituted in 100 mL of 5%MeOH/CHCl₃, dried (MgSO₄), filtered and concentrated to an oil. Crystallization from CH₂Cl₂/Et₂O/hexane gives 19 mg (31%) of the title compound as a white solid (mp 136-137 °C).

IR (mineral oil) 3316, 3087, 3065, 3027, 1702, 1634, 1563, 1498, 1420, 1229,
20 1213, 1164, 1083, 1048, 698 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.10-7.40, 5.63, 3.50, 2.65-2.90, 2.71, 2.54, 1.45-1.90, 0.92, 0.87;

MS (EI) m/z 332, 300, 276, 259, 241, 212, 196, 184, 142, 109, 105, 104, 103, 91.

25 **EXAMPLE 36** Preparation of N-Hydroxy-3-methyl-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-4-imidazolidineacetamide.



35 **Step 1.** Preparation of 3-Methyl-1-(2-phenylethyl)hydantoin.

Sodium hydride (921 mg, 23.0 mmol, 60% mineral oil dispersion) is added to

a solution of 1-methylhydantoin (2.19 g, 19.2 mmol) and DMF (40 mL) at 0 °C. The mixture was stirred for 1 hour and then (2-bromoethyl)benzene (3.14 mL, 23.0 mmol) is added. The mixture is stirred at 0 °C for 1 hour and 16 hours at room temperature. Aqueous workup (EtOAc, MgSO₄) and trituration with ether provides
5 2.21 g (53%) of the title compound as a white solid (mp 113-114 °C).

IR (mineral oil) 1768, 1758, 1748, 1713, 1488, 1441, 1403, 1340, 1290, 1243, 1134, 995, 989, 748, 704 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.15-7.35, 3.82, 3.70-3.80, 2.99, 2.85-3.00;

MS (EI) *m/z* 218, 105, 104, 99, 91, 78, 65, 57, 56, 51.

10 Step 2. Preparation of 3-Methyl-4-(2-methylpropyl)-1-(2-phenylethyl)hydantoin.

Lithium diisopropylamide (3.45 mL, 6.90 mmol, 2.0 M, heptane/THF/ethylbenzene) is added to a mixture of 3-methyl-1-(2-phenylethyl)hydantoin (1.50 g, 6.87 mmol) and THF (27 mL) at -78 °C. After
15 stirring for 30 minutes at -78 °C, 1-iodo-2-methylpropane (0.93 mL, 8.08 mmol) is added. The mixture is stirred at -78 °C for 30 minutes and is allowed to gradually warm to room temperature. After stirring at room temperature for 1 hour, aqueous workup (EtOAc, MgSO₄) and purification by flash chromatography (1:1 hexane:EtOAc) gives 467 mg of the title compound (25%) as an oil. Further elution
20 provides 704 mg of recovered starting material (47% of product based on recovered starting material). Spectral data for the title compound.

IR (liq.) 2958, 2936, 2871, 1771, 1712, 1498, 1454, 1429, 1412, 1389, 1368, 1142, 1030, 753, 701 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.15-7.35, 3.65-3.85, 2.85-3.00, 2.93, 1.50-1.90,
25 0.91;

MS (EI) *m/z* 274, 218, 127, 114, 105, 104, 91, 43, 41.

Step 3. Preparation of 3-Methyl-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-4-imidazolidineacetic Acid.

Lithium diisopropylamide (0.84 mL, 1.7 mmol, 2.0 M, heptane/THF/ethylbenzene) is added to a solution of 3-methyl-4-(2-methylpropyl)-1-(2-phenylethyl)hydantoin (464 mg, 1.69 mmol) and THF (7.0 mL) at -78 °C. After
30 stirring the partial solution for 30 minutes at -78 °C, ethyl bromoacetate (0.23 mL, 2.1 mmol) is added. The mixture is stirred for 1 hour at -78 °C and is then allowed to warm to room temperature. After stirring at room temperature for 1 hour,
35 aqueous workup (EtOAc, MgSO₄) and purification by flash chromatography (3:1 hexane:EtOAc) gives 407 mg of a 1.25:1 mixture of starting material and the ester

intermediate. The mixture could not be purified by chromatography and is carried on crude. Key spectral features for the ester intermediate: ^1H NMR (300 MHz, CDCl_3) δ 4.00-4.15, 2.84, 1.19, 0.81.

A mixture of the crude ester (407 mg), MeOH (12 mL), H_2O (2.5 mL) and
5 NaOH (213 mg, 5.33 mmol) is stirred at room temperature for 16 hours and is concentrated. The residue is partitioned between EtOAc and 10% NaOH. The organic layer is dried (MgSO_4), filtered, and concentrated to give 250 mg of starting material. The basic layer is acidified (10% HCl) and extracted several times with CH_2Cl_2 . The CH_2Cl_2 layers are dried (MgSO_4), filtered, and concentrated to give
10 117 mg (21%, 45% based on recovered starting material) of the title compound as a white solid (mp 64-67 °C).

IR (mineral oil) 3505, 3374, 1761, 1699, 1499, 1414, 1404, 1336, 1325, 1230, 1136, 1036, 1031, 736, 697 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.15-7.35, 3.70-3.80, 2.80-3.00, 2.85, 2.78, 1.73,
15 1.55, 1.20-1.40, 0.84, 0.78;

MS (EI) m/z 332, 276, 275, 273, 241, 231, 105, 104, 91, 56.

Step 4. Preparation of N-Benzyl-3-methyl-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-4-imidazolidineacetamide.

CDI (57.0 mg, 0.352 mmol) is added to a solution of 3-methyl-4-(2-
20 methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-4-imidazolidineacetic acid (113 mg, 0.340 mmol) and CH_2Cl_2 (2.5 mL). The solution is stirred for 1 hour at room temperature and then O-benzyl hydroxylaminehydrochloride (67.0 mg, 0.420 mmol) and N-methylmorpholine (46 μL , 0.42 mmol) are added. The solution is stirred for 60 hours at room temperature. Basic workup (CH_2Cl_2 , NaHCO_3 , MgSO_4) and
25 purification by flash chromatography (1:1 hexane:EtOAc) provides 94.8 mg (64%) of the title compound as a white solid.

IR (mineral oil) 3198, 3012, 1771, 1713, 1681, 1653, 1522, 1498, 1432, 1414, 1394, 1359, 758, 738, 696 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 8.35-8.55, 7.15-7.50, 4.70-4.90, 3.74, 2.96, 2.84,
30 2.60-2.90, 2.38, 1.69, 1.45-1.65, 1.20-1.40, 0.80, 0.65-0.85;

MS (EI) m/z 437, 363, 273, 231, 169, 105, 104, 92, 91, 56.

Step 5. Preparation of N-Hydroxy-3-methyl-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-4-imidazolidineacetamide.

Ammonium formate (59.0 mg, 0.936 mmol) is added to a mixture of N-
35 benzyloxy-3-methyl-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-4-


imidazolidineacetamide (91.0 mg, 0.208 mmol), EtOH (2.5 mL), and 10% Pd/C (15 mg). The mixture is stirred at room temperature for 5.5 hours. Additional ammonium formate (35.0 mg, 0.555 mmol) is added after 2.5 hours. The mixture is filtered, the solids washed with MeOH (3 X 15 mL) and CHCl₃ (3 X 15 mL), and the filtrate concentrated. The residue was taken up into CHCl₃ (40 mL), dried (MgSO₄), filtered, and concentrated to give 64.7 mg (90%) of the title compound as an oil. Crystallization from ether/hexane provided 46.4 mg (64%) of the title compound as a white powder (mp 127-129 °C).

IR (mineral oil) 3223, 3025, 1771, 1701, 1690, 1661, 1497, 1416, 1394, 1359, 1136, 1027, 742, 737, 698 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 9.55, 7.10-7.30, 3.60-3.85, 2.92, 2.81, 2.55, 1.45-1.75, 1.15-1.35, 0.76, 0.73;

MS (EI) *m/z* 347, 274, 273, 231, 169, 105, 104, 56.

EXAMPLE 37 Preparation of N-Hydroxy-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-4-imidazolidineacetamide.



25

Step 1. Preparation of 4-(2-Methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-4-imidazolidineacetic Acid.

Sodium hydroxide (300 mg, 7.50 mmol) is added to a solution of 2-(2-methylpropyl)-2-(propen-2-yl)glycine trifluoroacetic acid (856 mg, 3.00 mmol) which is prepared by the method described in J. Org. Chem., 1988, Vol. 53, p. 5607 and H₂O (10 mL). Phenethyl isocyanate (541 mg, 3.00 mmol) is added after 5 minutes and the mixture stirred for 1 hour at room temperature under N₂. The solution is diluted with more H₂O (5 mL) and acidified with 6 N HCl. The resultant solution is heated at reflux for 2 hours. Upon cooling to room temperature, the desired product is extracted into CH₂Cl₂ (3 x 50 mL) and EtOAc (2 x 50 mL). The combined organic layers are dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced

pressure to yield 619 mg of a golden oil. The oil is purified by silica gel chromatography (50 g SG, packed and eluted with a gradient of 0-40% EtOAc/hexane) to give 162 mg (18%) of the hydantoin intermediate as an oil. The material is sufficiently pure to be carried on: ^1H NMR (300 MHz, CDCl_3) δ 7.90-8.60, 7.20-7.40, 5.75-5.95, 5.25-5.40, 3.15-3.30, 3.05-3.15, 2.60-2.90, 1.80-2.00, 0.90-1.05.

Sodium periodate (NaIO_4 , 883 mg, 4.13 mmol) is added to a mixture of $\text{H}_2\text{O}/\text{CH}_3\text{CN}/\text{CCl}_4$ (3/3/2 mL, respectively) and treated with ruthenium oxide monohydrate (14 mg, 20 mole %). Once the black solution has turned green, NaHCO_3 (2.17 g, 25.8 mmol) is added, followed by the further addition of NaIO_4 until the solution became green again. A solution of the hydantoin intermediate (155 mg, 0.516 mmol) in 3 mL CH_3CN is added to the green mixture. After 5 minutes, the reaction mixture is quenched with H_2O and extracted with EtOAc several times. The aqueous layer is acidified with 6 N HCl and then extracted twice with CH_2Cl_2 (2 x) and EtOAc (2 x). The organic layers are combined, washed again with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure to yield 79 mg of the title compound as a solid. Additional title compound is recovered by washing the original EtOAc extracts with 10% NaOH, acidifying the aqueous with 6 N HCl, and re-extracting with CH_2Cl_2 (3 x). These extracts are also combined, washed again with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure to yield an additional 64 mg of the title compound. Both crops are dissolved in CH_2Cl_2 , combined, filtered through a fine frit, and concentrated under reduced pressure to give a total of 143 mg (87%) of the title compound as a solid.

^1H NMR (300 MHz, CDCl_3) δ 7.10-7.35, 3.70-3.80, 2.95, 2.66, 1.65-1.80, 1.40-1.55, 0.88, 0.80.

Step 2. Preparation of N-Benzyloxy-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-4-imidazolidineacetamide.

A solution of 4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-4-imidazolidineacetic acid (126 mg, 0.379 mmol) in dry THF (5 mL) is treated with CDI (74.0 mg, 0.455 mmol). After 1 hour, 4-methylmorpholine (417 μL , 3.79 mmol) and O-benzyhydroxylamine hydrochloride (91.0 mg, 0.569 mmol) are added. The mixture is stirred for 12 hours at room temperature and is diluted with EtOAc. The solution is washed with saturated NaHCO_3 , 1 N HCl, saturated NaHCO_3 , and brine. The organic layer is dried over anhydrous Na_2SO_4 , filtered, and concentrated

under reduced pressure to yield 156 mg of a black oil. The oil is purified by silica gel chromatography (25 g SG, packed with hexane, eluted with 50% EtOAc/hexane) to give 47 mg (28%) of the title compound as an amorphous white solid.

^1H NMR (300 MHz, CDCl_3) δ 8.89, 7.15-7.45, 6.67, 4.70-5.00, 3.60-3.90, 2.95, 2.15-2.40, 1.50-1.70, 1.35-1.50, 0.84, 0.75;

MS (FAB) m/z 424, 334, 318, 259, 105, 91.

Step 3. Preparation of N-Hydroxy-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-4-imidazolidineacetamide.


A solution of N-benzyloxy-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-4-imidazolidineacetamide (85.0 mg, 0.201 mmol) in 25% MeOH/EtOAc is purged with N_2 , treated with palladium hydroxide on carbon (17 mg, 20% by weight), and placed under a H_2 atmosphere (balloon). After 2.5 hours, the reaction mixture is filtered through celite and concentrated under reduced pressure to yield 70 mg of an off-white foam. The material is recrystallized from hot EtOAc/hexane to give 36 mg (54%) of the title compound as a white, powdery solid (mp 145-147 $^\circ\text{C}$).

IR (mineral oil) 3284, 3227, 1762, 1719, 1707, 1662, 1655, 1424, 1365, 699 cm^{-1} ,

^1H NMR (300 MHz, CDCl_3) δ 7.84, 7.15-7.40, 3.60-3.85, 2.65-3.10, 2.35-2.55, 1.45-1.75, 0.90, 0.83;

MS (EI) m/z 333, 277, 259, 243, 229, 217, 155, 105, 104, 91.

EXAMPLE 38 Preparation of N-Hydroxyl-4-(2-methylpropyl)-5-oxo-1-(2-phenylethyl)-4-pyrazolidineacetamide monohydrochloride.



Step 1. Preparation of 1-(Benzyloxycarbonyl)-2-(2-phenylethyl)pyrazolidin-3-one.

Sodium hydride (562 mg, 14.1 mmol, 60% mineral oil dispersion) is added to

a solution of 1-(benzyloxycarbonyl)pyrazolidin-3-one (2.81 g, 12.8 mmol, prepared similarly to that described in J. Org. Chem. 1990, 55, 6037) and DMF (37 mL) at 0 °C. The solution is stirred for 30 minutes and then (2-bromoethyl)benzene (1.90 mL, 13.9 mmol) is added. The solution is stirred at 0 °C for 1 hour and 16 hours at room temperature. Aqueous workup (EtOAc, brine, MgSO₄) and purification by flash chromatography (2:1 → 1:1 hexane:EtOAc) gives 1.58 g (38%) of the title compound as an oil.

IR (liq.) 3029, 2954, 1709, 1498, 1455, 1412, 1378, 1314, 1214, 1184, 1110, 1086, 1027, 748, 699 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.38, 7.10-7.30, 5.23, 4.02, 3.80, 2.87, 2.44; MS (EI) *m/z* 324, 190, 189, 106, 105, 104, 92, 91, 79, 77, 65.

Step 2. Preparation of 1-(Benzyloxycarbonyl)-4-(2-methylpropen-2-yl)-2-(2-phenylethyl)pyrazolidin-3-one.

Lithium diisopropylamide (2.92 mL, 5.84 mmol, 2.0 M, heptane/THF/ethylbenzene) is added to a solution of 1-(benzyloxycarbonyl)-2-(2-phenylethyl)pyrazolidin-3-one (1.58 g, 4.87 mmol), THF (15 mL), and HMPA (1.04 mL) at -78 °C. After stirring for 35 minutes at -78 °C, a solution of 3-bromo-2-methylpropene (0.54 mL, 5.4 mmol) and THF (2.6 mL) is added. The solution is allowed to stir for 6 hours at -78 °C and is then quenched with aqueous ammonium chloride (25 mL). After warming to room temperature, aqueous workup (EtOAc, MgSO₄) and purification by flash chromatography (3:1 hexane:EtOAc) gives 1.21 g of the title compound (66%) as an oil. Further elution provides 201 mg of recovered starting material (75% of product based on recovered sm). Spectral data for the title compound:

IR (liq.) 2945, 1710, 1498, 1455, 1416, 1377, 1318, 1232, 1206, 1172, 1121, 1028, 897, 748, 698 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.38, 7.10-7.40, 5.23, 4.71, 4.53, 4.10-4.30, 4.01, 3.80-3.95, 3.09, 2.75-2.95, 2.60-2.80, 2.35-2.45, 1.63, 1.53;

MS (EI) *m/z* 378, 244, 243, 105, 104, 92, 91, 79, 77, 65.

Step 3. Preparation of *tert*-Butyl 2-(Benzyloxycarbonyl)-4-(2-methylpropen-2-yl)-5-oxo-1-(2-phenylethyl)-4-pyrazolidinacetate.

Lithium diisopropylamide (1.70 mL, 3.40 mmol, 2.0 M, heptane/THF/ethylbenzene) is added to a solution of 1-(benzyloxycarbonyl)-4-(2-methylpropen-2-yl)-2-(2-phenylethyl)pyrazolidin-3-one (1.20 g, 3.17 mmol), THF (15.6 mL), and HMPA (0.69 mL) at -78 °C. After stirring for 30 minutes at -78 °C, a solution of *tert*-butyl bromoacetate (0.57 mL, 3.5 mmol) and THF (1.5 mL) is added.

The solution is allowed to stir for 6 hours at -78 °C and is then quenched with aqueous ammonium chloride (25 mL). After warming to room temperature, aqueous workup (EtOAc, MgSO₄) and purification by flash chromatography (4:1 → 3:1 hexane:EtOAc) gives 410 mg of the title compound (26%) as an oil. Further elution provides 624 mg of recovered starting material (55% of product based on recovered sm). Spectral data for the title compound.

IR (neat) 1723, 1696, 1320, 1286, 1263, 1242, 1201, 1186, 1165, 1123, 906, 764, 749, 697, 604 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.35-7.45, 7.10-7.30, 5.19, 4.74, 4.68, 4.15-4.30, 3.88, 3.75-3.95, 2.80-2.95, 2.19, 2.17, 1.62, 1.41;

MS (EI) *m/z* 492, 302, 301, 283, 255, 105, 92, 91, 57.

Step 4. Preparation of 2-(Benzyloxycarbonyl)-4-(2-methylpropen-2-yl)-5-oxo-1-(2-phenylethyl)-4-pyrazolidineacetic Acid.

TFA (8.0 mL) is added to a solution of *tert*-butyl 2-(benzyloxycarbonyl)-4-(2-methylpropen-2-yl)-5-oxo-1-(2-phenylethyl)-4-pyrazolidineacetate (546 mg, 1.11 mmol) and CH₂Cl₂ (20 mL) at 0 °C. The solution is stirred for 1.5 hours at 0 °C and is concentrated. Aqueous workup (CH₂Cl₂, MgSO₄) provides 456 mg (94%) of the title compound which is isolated as an oil.

IR (mineral oil) 3069, 3061, 3031, 1719, 1651, 1422, 1405, 1329, 1238, 1207, 1134, 1027, 905, 755, 699, cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.39, 7.10-7.30, 5.19, 4.75, 4.68, 4.20-4.35, 3.80-3.95, 3.77, 2.75-3.00, 2.10-2.40, 1.61;

MS (EI) *m/z* 436, 301, 255, 105, 104, 92, 91, 79, 77, 65, 57.

Step 5. Preparation of N-Benzyloxy-2-(benzyloxycarbonyl)-4-(2-methylpropen-2-yl)-5-oxo-1-(2-phenylethyl)-4-pyrazolidineacetamide.

CDI (204 mg, 1.26 mmol) is added to a solution of 2-(benzyloxycarbonyl)-4-(2-methylpropen-2-yl)-5-oxo-1-(2-phenylethyl)-4-pyrazolidineacetic acid (453 mg, 1.04 mmol) and CH₂Cl₂ (10 mL). The solution is stirred for 1 hour at room temperature and then O-benzylhydroxylamine hydrochloride (293 mg, 1.84 mmol) and N-methylmorpholine (0.23 mL, 2.1 mmol) are added. The solution is stirred for 60 hours at room temperature. Aqueous workup (CH₂Cl₂, MgSO₄) and purification by flash chromatography (1:1 hexane:EtOAc) provides 468 mg (83%) of the title compound as an oil.

IR (liq.) 3031, 1724, 1701, 1498, 1455, 1379, 1320, 1217, 1182, 1134, 1044, 1028, 749, 698, cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 8.72, 7.05-7.45, 5.18, 4.88, 4.73, 4.66, 4.05-4.30,

3.80-3.95, 3.57, 2.75-2.95, 1.95-2.20, 1.78, 1.57;

MS (EI) m/z 541, 407, 406, 106, 105, 104, 92, 91, 79, 77, 65.

Step 6. Preparation of N-Hydroxyl-4-(2-methylpropyl)-5-oxo-1-(2-phenylethyl)-4-pyrazolidineacetamide monohydrochloride.

5 An atmosphere of hydrogen is placed over a mixture of N-benzyloxy-2-(benzyloxycarbonyl)-4-(2-methylpropen-2-yl)-5-oxo-1-(2-phenylethyl)-4-pyrazolidineacetamide (462 mg, 0.853 mmol), MeOH (34 mL) and Pearlman's catalyst (85 mg). After stirring for 8 hours at room temperature, the mixture is filtered, the solids washed with MeOH (3 X 10 mL), CH₂Cl₂ (10 mL), and the
10 filtrates concentrated to provide 220 mg (81%) of the title compound as an oil.

¹H NMR (300 MHz, CDCl₃) δ 10.3-10.5, 7.10-7.40, 3.45-3.80, 3.37, 2.80-3.00, 2.35, 1.45-1.90, 1.10-1.30, 0.88, 0.82.


The hydrochloride salt is formed (EtOAc/MeOH) and triturated with ether to provide the hydrochloride salt of the title compound as a solid (mp 51-54°C).

15 IR (mineral oil) 3172, 3061, 3028, 2724, 1714, 1655, 1604, 1585, 1556, 1498, 1414, 1282, 1227, 750, 701 cm⁻¹;

MS (EI) m/z 319, 263, 245, 228, 172, 105, 104, 91, 57, 55.

Following the general procedures outlined in EXAMPLES 28,29 and making non-critical variations, the following compounds are prepared.

- EXAMPLE 39 Preparation of [S-(R*,R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo-N¹-phenyl- α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide.



mp 169-172 °C;


$[\alpha]_D^{25}$ -43° (c 0.54, MeOH);

- IR (mull) 3246, 3193, 3135, 3059, 3029, 1658, 1600, 1547, 1493, 1444, 1358, 1322, 1311, 759, 698 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.48, 7.10-7.35, 7.06, 4.74, 3.30-3.55, 3.05-3.25, 1.90-2.40, 1.40-1.65, 1.20-1.35, 0.83, 0.75;

MS (EI) *m/e* 364, 321, 273, 244, 228, 200, 132.

- EXAMPLE 40 Preparation of [S-(R*,R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-N¹-(2-pyridinylmethyl)-1,3-pyrrolidinediacetamide.




mp 68-71 °C;

- IR (mull) 3244, 3062, 3027, 1658, 1598, 1572, 1540, 1497, 1439, 1354, 1296, 1271, 751, 701, 620 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 8.40-8.55, 7.90-8.00, 7.75, 7.50, 7.05-7.35, 4.35-4.70, 4.10-4.25, 3.25-3.50, 2.75-2.90, 2.15-2.40, 1.75-1.90, 1.40-1.65, 1.00-1.15, 0.86, 0.81;

MS (EI) *m/z* 436, 379, 336, 301, 244, 200, 147, 135, 92.

EXAMPLE 41 Preparation of [S-(R*,R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.



10

mp 121-123 °C;


IR (mull) 3240, 3178, 3086, 3064, 3028, 1664, 1593, 1512, 1498, 1422, 1331, 1294, 1210, 749, 701 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 9.98, 8.25, 7.65-7.85, 7.15-7.35, 4.15-4.25, 3.25-3.65, 2.65-2.85, 2.37, 1.70-1.85, 1.45-1.70, 1.10-1.20, 0.90, 0.84;

15

MS (EI) m/z 438 (M⁺) 317, 316, 301, 284, 200, 132, 105, 95, 91, 55.

EXAMPLE 42 Preparation of [S-(R*,R*)]-N¹-(4-Fluorophenyl)-N³-hydroxy-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide.



20

mp 181-182.5;

IR (mull) 3254, 3154, 3066, 1658, 1614, 1552, 1511, 1499, 1409, 1309, 1299, 1230, 1213, 836, 699 cm⁻¹;


¹H NMR (300 MHz, CDCl₃) δ 8.20-8.50, 7.46, 7.15-7.40, 6.90-7.05, 4.65-4.80, 3.15-3.50, 1.90-2.45, 1.40-1.70, 1.20-1.35, 0.87, 0.79;

30

MS (EI) m/z 455 (M⁺) 345, 344, 317, 316, 284, 200, 132, 131, 91, 55.

35


EXAMPLE 43 Preparation of [*S*-(*R*^{*},*R*^{*})]-*N*³-Hydroxy-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-*N*¹-[1-(phenylmethyl)-4-piperdiny]-1,3-pyrrolidinediacetamide.



mp 108-110 °C;

IR (mull) 3276, 3107, 3085, 3062, 3027, 2764, 1658, 1540, 1496, 1296, 1271, 744, 721, 700 cm⁻¹; MS (FAB) *m/z* 535 (MH⁺), 534, 533, 519, 172, 91, 82.


EXAMPLE 44 Preparation of [*S*-(*R*^{*},*R*^{*})]-*N*³-Hydroxy-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-*N*¹-(4-piperdiny)-1,3-pyrrolidinediacetamide.



mp 160-165 °C;

IR (mull) 3283, 3085, 3062, 3028, 1661, 1584, 1544, 1497, 1311, 1297, 1271, 1213, 1154, 748, 700 cm⁻¹; MS (EI) *m/z* 444 (M⁺), 302, 301, 284, 132, 91, 84, 83, 82, 56, 55.


EXAMPLE 45 Preparation of [*S*-(*R**,*R**)]-*N*³-Hydroxy-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-*N*¹-(4-pyridinylmethyl)-1,3-pyrrolidinediacetamide.



mp 140.5-142 °C

¹H NMR (300 MHz, CDCl₃) δ 8.49, 8.35, 7.95-8.10, 7.10-7.35, 4.50-4.60, 4.20-4.45, 3.25-3.55, 2.80-3.10, 2.15-2.60, 1.95-2.10, 1.75-1.90, 1.40-1.70, 1.05-1.35, 0.89, 0.83;
MS (FAB) *m/z* 453 (MH⁺), 452, 437, 284, 132, 105, 93, 91.


EXAMPLE 46 Preparation of [*S*-(*R**,*R**)]-*N*¹-(4-Fluorophenylmethyl)-*N*³-hydroxy-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide.



mp 64-66 °C

¹H NMR (300 MHz, CDCl₃) δ 7.05-7.35, 6.90-7.05, 4.50-4.70, 4.20-4.45, 3.10-3.45, 2.29, 1.80-2.10, 1.40-1.70, 1.10-1.30, 0.86, 0.80.

EXAMPLE 47 Preparation of [*S*-(*R**,*R**)]-*N*³-Hydroxy-*N*¹-methyl-3-(2-methylpropyl)-2-oxo- α ¹-(2-phenylethyl)-1,3-pyrrolidinediacetamide.



5

mp 148-148.5 °C;


$[\alpha]_D^{25}$ -31° (c 0.68, MeOH);

IR (mull) 3227, 3092, 3084, 3024, 1678, 1667, 1658, 1644, 1569, 1503, 1496, 1297, 1282, 1206, 703 cm^{-1} ;

¹H NMR (300 MHz, CDCl₃) δ 7.10-7.35, 6.29, 4.30, 3.35-3.50, 2.75, 2.45-2.65, 2.35, 2.00-2.30, 1.60-1.80, 1.35-1.60, 0.91, 0.86;

MS (EI) *m/e* 316, 273, 258, 91, 44.

EXAMPLE 48 Preparation of [*S*-(*R**,*R**)]-*N*³-Hydroxy-3-(2-methylpropyl)-2-oxo- α ¹-(2-phenylethyl)-*N*¹-(phenylmethyl)-1,3-pyrrolidinediacetamide.



20

mp 59-61°C;


$[\alpha]_D^{25}$ -57° (c 0.39, CHCl₃);

IR (mull) 3234, 3086, 3062, 3027, 1652, 1605, 1585, 1540, 1497, 1295, 1269, 1213, 1030, 739, 699 cm^{-1} ;

¹H NMR (300 MHz, CDCl₃) δ 7.10-7.40, 6.40-6.55, 4.25-4.50, 3.25-3.50, 2.00-2.70, 1.25-1.75, 0.87, 0.83; MS (EI) *m/z* 465 (*M*⁺) 361, 332, 331, 330, 316, 298, 182, 117, 91.

25

EXAMPLE 49 Preparation of $[S-(R^*,R^*)]-N^3$ -Hydroxy- $\alpha^1,3$ -bis(2-methylpropyl)-2-oxo- N^1 -2-pyridinyl-1,3-pyrrolidinediacetamide.



5

mp 73-75°C;


IR (mull) 3203, 2728, 1663, 1600, 1579, 1532, 1494, 1435, 1298, 1279, 1181, 1152, 780, 741 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 8.10-8.35, 7.72, 7.05, 4.25-4.40, 3.30-3.65, 2.35-2.60, 2.00-2.20, 1.35-1.95, 1.20-1.35, 0.75-1.10;

15

MS (EI) m/z 404 (M^+), 284, 283, 267, 250, 208, 149, 98, 56, 55.

EXAMPLE 50 Preparation of $[S-(R^*,R^*)]-\alpha^1$ -Cyclohexyl- N^3 -hydroxy- N^1 -methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide.



20

mp 199-200 °C;

IR (mull) 3310, 3232, 3105, 1647, 1565, 1536, 1498, 1415, 1297, 1277, 1258, 1236, 1223, 1047, 722 cm^{-1} ;


^1H NMR (300 MHz, CDCl_3) δ 6.15-6.35, 4.01, 3.30-3.60, 2.76, 2.44, 2.20-2.40, 1.90-2.15, 1.10-1.80, 0.90, 0.83;

30

MS (EI) m/z 367 (M^+) 336, 310, 309, 308, 277, 276, 154, 95, 58, 55.

25

EXAMPLE 51 Preparation of [*S*-(*R**,*R**)]- α^1 -Cyclohexyl-*N*³-hydroxy-3-(2-methylpropyl)-2-oxo-*N*¹-2-pyridinyl-1,3-pyrrolidinediacetamide.



10

mp 119-121 °C;


IR (mull) 3254, 1665, 1596, 1579, 1532, 1497, 1434, 1301, 1279, 1270, 1186, 1172, 1151, 779, 740 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 8.25-8.35, 8.17, 7.65-7.80, 7.00-7.15, 4.20-4.35, 3.35-3.60, 2.00-2.75, 0.70-1.85;

MS (EI) *m/z* 430 (M⁺), 309, 294, 293, 276, 218, 154, 95, 78, 67, 55.

EXAMPLE 52 Preparation of [*S*-(*R**,*R**)]-3-(Cyclopentylmethyl)-*N*³-hydroxy-*N*¹-methyl-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide.

20



25

mp 180-181.5 °C;

¹H NMR (300 MHz, CDCl₃) δ 7.10-7.40, 4.41, 3.10-3.45, 2.75, 2.70-3.05, 2.00-2.35,


1.85-2.00, 1.30-1.85, 0.85-1.15;

MS (EI) *m/z* 401, 343, 342, 328, 310, 200, 132, 91, 58.

EXAMPLE 53 Preparation of [3*S*-[1(*R**),3*R**(*R**)]]- α^3 -[2-(Benzoylamino)ethyl]-*N*³-hydroxy-*N*¹-methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide.

5

10




¹H NMR (300 MHz, CDCl₃) δ 7.70-7.85, 7.35-7.55, 7.05-7.35, 6.40, 4.80-5.00, 3.10-3.50, 2.76, 2.20-2.40, 1.20-2.00, 0.70-1.00, 0.30-0.45;

MS (FAB) *m/z* 523 (MH⁺), 522, 391, 371, 129, 105, 71, 57, 43.

EXAMPLE 54 Preparation of [*S*-(*R**,*R**)]-*N*³-Hydroxy-3-(2-methylpropyl)-*N*¹-[2-(4-morpholinyl)ethyl]-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide.

20

25



mp 66 °C;


[α]_D = -56° (c, 0.58; CHCl₃);

IR (mull) 3223, 3086, 3063, 3027, 1653, 1547, 1497, 1297, 1271, 1239, 1146, 1118, 1071, 748, 700 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.45-7.15, 3.80-3.60, 3.50-3.00, 2.70-2.00, 1.95-1.80, 1.75-1.45, 1.35-1.15, 0.88;

MS (EI) *m/z* 474 (M⁺), 418, 358, 345, 244, 200, 113, 100.

EXAMPLE 55 Preparation of [*S*-(*R**,*R**)]-*N*-Hydroxy-3-(2-methylpropyl)-1-[2-(4-morpholinyl)-2-oxo-1-(phenylmethyl)ethyl]-2-oxo-3-pyrrolidineacetamide.



mp 52-56 °C);

$[\alpha]_D = -82^\circ$ (c, 0.70; CHCl₃);


IR (mull) 3237, 3085, 3061, 3025, 1648, 1494, 1299, 1268, 1239, 1213, 1115, 1039, 1029, 751, 702 cm⁻¹;

MS (EI) *m/z* 431 (M⁺), 399, 375, 357, 344, 340, 317, 284, 114, 91;

¹H NMR (CDCl₃) δ 7.35-7.15, 5.30, 3.70-3.10, 3.10-2.90, 2.40-1.95, 1.85-1.15, 0.86;

HRMS (EI) 431.2436.

EXAMPLE 56 Preparation of [1(*1S*)-[1(*R**(*R**)), 3α,5α]-1-[2-(3,5-Dimethyl-1-piperazinyl)-2-oxo-1-(phenylmethyl)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetamide.



mp 106 °C;


$[\alpha]_D = -77^\circ$ (c, 0.6082; CHCl₃);

IR (mull) 3252, 3087, 3062, 3027, 1649, 1493, 1323, 1263, 1193, 1157, 1110, 1084, 1033, 751, 702 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.35-7.10, 5.40-5.25, 4.50-4.35, 3.95-3.65, 3.55-3.30, 3.30-2.95, 2.75-0.75;

MS (EI) *m/z* 458 (M⁺), 402, 317, 113, 84.

EXAMPLE 57 Preparation of [S-(R*,R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-N¹-2-pyridinyl-1,3-pyrrolidinediacetamide.



mp 171-174 °C;


$[\alpha]_D = -14^\circ$ (c, 0.67; CHCl₃);

IR (mull) 3057, 3030, 3010, 1706, 1661, 1642, 1614, 1586, 1558, 1315, 1282, 1205, 786, 753, 704 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 8.40-8.30, 8.25-8.15, 7.85-7.75, 7.40-7.20, 7.20-7.05, 4.26, 3.60-3.35, 2.80-2.65, 2.55-2.25, 1.90-1.40, 1.10-1.95, 0.87;

MS (EI) m/z 438 (M⁺), 406, 382, 364, 347, 317, 284, 226, 200, 132, 91.


EXAMPLE 58 Preparation of [3S-[1(R*),3R*(R*)]]- α^3 -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N³-hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide.



¹H NMR (300 MHz, CDCl₃) δ 7.65-7.95, 7.10-7.40, 6.20, 4.55-4.70, 3.05-3.75, 2.67, 1.15-2.30, 0.77, 0.68;

MS (FAB) m/z 549 (MH⁺), 550, 549, 517, 516, 429, 160, 69, 57, 55, 43.


EXAMPLE 59 Preparation of [*S*-(*R**,*R**)]- α^1 -Cyclohexyl-*N*¹-cyclopropylmethyl-*N*³-hydroxy-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide.



mp 140-144°C;

¹H NMR (300 MHz, CDCl₃) δ 6.40, 3.97, 3.50-3.65, 3.30-3.45, 2.50-2.70, 2.20-2.40, 1.90-2.15, 1.10-1.90, 0.65-1.00, 0.40-0.60.

EXAMPLE 60 Preparation of [*S*-(*R**,*R**)]- α^1 -Cyclohexyl-*N*¹-(4-fluorophenyl)-*N*³-hydroxy-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide.




mp 132-135 °C;

¹H NMR (300 MHz, CDCl₃) δ 8.47, 7.40-7.50, 6.99, 4.15, 3.35-3.65, 2.57, 2.30-2.45, 2.00-2.20, 0.95-1.85, 0.86, 0.77.

Following the general procedures outlined in EXAMPLES 30-34 and making non-critical variations, the following compounds are prepared.

EXAMPLE 61 Preparation of [S-(R*,R*)]- α ¹-*tert*-Butyl-*N*³-hydroxy-*N*¹-methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide.




mp 108-110 °C;

¹H NMR (300 MHz, CDCl₃) δ 5.80-6.00, 4.23, 4.15-4.35, 2.70-2.80, 2.45-2.70, 2.30-2.45, 1.85-2.30, 1.35-1.85, 1.05, 0.75-1.00;

MS (ESI) 340 (MH⁺).

Following the general procedures outlined in EXAMPLES 4-14 and making non-critical variations, the following compounds are prepared.

EXAMPLE 62 Preparation of *N*-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(5-propyloxy-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-pyrrolidineacetamide.



mp 137-138 °C;


IR (mineral oil) 3211, 3085, 3028, 1772, 1712, 1660, 1620, 1491, 1400, 1346, 1292,

1249, 1234, 749, 705 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.72, 7.05-7.40, 4.02, 3.35-3.80, 3.10-3.25, 2.78, 2.30-2.45, 2.05-2.30, 1.75-2.00, 1.35-1.70, 1.06, 0.83, 0.76;

MS (EI) m/z 549 (M^+), 493, 489, 262, 261, 245, 244, 218, 202, 176, 105.

EXAMPLE 63 Preparation of [R-(R*,S*)]-5-Fluoro-1,3-dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidiny]-1,3-dioxo-2*H*-isoindole-2-butanamide.




IR (mull) 3205, 3063, 3027, 1775, 1717, 1664, 1616, 1497, 1481, 1399, 1302, 1263, 1229, 747, 701 cm^{-1} ;

15 ^1H NMR (300 MHz, CDCl_3) δ 8.92, 7.83, 7.50, 7.00-7.45, 3.35-3.80, 3.25-3.35, 3.10-3.25, 2.79, 2.55-2.70, 2.30-2.50, 2.10-2.30, 1.70-2.00, 1.35-1.65, 0.70-1.00;

MS (EI) m/z 509 (M^+), 477, 453, 449, 345, 262, 261, 178, 105, 104.

EXAMPLE 64 Preparation of α -[2-(5,6-Difluoro-1,3-dihydro-1,3-dioxo-2*H*-isoindol-2-yl)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.

20



IR (mull) 3340, 3187, 3062, 3028, 1777, 1720, 1678, 1654, 1505, 1406, 1354, 1277, 1261, 746, 704 cm^{-1} ;


^1H NMR (300 MHz, CDCl_3) δ 7.55-7.70, 7.40-7.55, 7.05-7.40, 3.35-3.80, 3.10-3.35, 2.70-2.85, 2.55-2.70, 2.30-2.55, 2.05-2.30, 1.70-2.05, 1.35-1.70, 0.85, 0.79;

35 MS (EI) m/z 527 (M^+), 471, 467, 363, 262, 261, 202, 196, 105, 104.

EXAMPLE 65 Preparation of *N*-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(5-trifluoromethyl-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-pyrrolidineacetamide.

5

10



mp 137-138 °C;

IR (mull) 1715, 1659, 1494, 1444, 1398, 1348, 1323, 1307, 1295, 1266, 1184, 1140,


15 1101, 750, 694 cm^{-1} ;

^1H NMR (CDCl_3) δ 8.91, 8.05-8.15, 7.90-8.05, 7.37, 7.05-7.35, 3.35-3.85, 3.25-3.35, 3.10-3.25, 2.79, 2.55-2.70, 2.35-2.55, 2.10-2.35, 1.75-2.05, 1.30-1.70, 0.84, 0.78;

MS (EI) m/z 559 (M^+), 527, 503, 499, 395, 262, 261, 228, 105, 104.

EXAMPLE 66 Preparation of α -[2-(1,3,4,5,6,7-Hexahydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.

25



30 mp 118-119 °C;


IR (mull) 3167, 3088, 3065, 3028, 1703, 1668, 1497, 1443, 1393, 1346, 1331, 1306, 1296, 1279, 701 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 8.80, 7.45, 7.10-7.40, 3.35-3.65, 3.10-3.35, 2.70-2.95, 2.50-2.70, 2.10-2.50, 1.25-2.10, 0.85, 0.79;

35 MS (EI) m/z 497 (M^+), 465, 441, 437, 262, 261, 244, 105, 104, 81.

EXAMPLE 67 Preparation of α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(3-phenylpropyl)-3-pyrrolidineacetamide.

5



10

mp 163-165 °C):

IR (mineral oil) 3231, 3107, 3088, 3051, 3034, 1771, 1712, 1683, 1663, 1499, 1442,

15 1400, 1298 cm^{-1} ; 1


^1H NMR (300 MHz, CDCl_3) δ 7.75-7.90, 7.65-7.75, 7.10-7.30, 3.60-3.85, 3.10-3.40, 2.56, 1.35-2.45, 0.87, 0.80;

MS (EI) m/z 505 (M^+), 387, 386, 276, 259, 258, 216, 185, 130, 91, 56.

EXAMPLE 68 Preparation of 1-[2-(4-Fluorophenyl)ethyl]- α -[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetamide.

20

25




30 mp 142.5-144 °C;

IR (mineral oil) 3212, 3067, 1773, 1712, 1673, 1657, 1510, 1495, 1438, 1398, 1341, 1301, 1219, 1034 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.60-7.95, 7.05-7.25, 6.85-7.05, 3.20-3.85, 3.10-3.25, 2.76, 1.30-2.50, 1.21, 0.82, 0.75;

35 MS (EI) m/z 509 (M^+), 477, 453, 449, 400, 220, 160, 123.

EXAMPLE 69 Preparation of α -[2-(*o*-benzoic sulfimide)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



mp 144-144.5 °C;


IR (mull) 3257, 1739, 1656, 1492, 1334, 1326, 1298, 1279, 1264, 1181, 1178, 1163,

1126, 752, 674 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.75-8.15, 7.00-7.40, 3.35-4.05, 3.10-3.30, 2.70-2.90, 2.40-2.60, 1.20-2.35, 0.65-1.00;

MS (EI) m/z 527 (M^+) 495, 471, 261, 245, 244, 202, 105, 104, 81, 56.


EXAMPLE 70 Preparation of Ethyl Phenylmethyl [4-(hydroxyamino)-3-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-4-oxobutyl]imidodicarbonate.



MS (EI) m/e 568.

Following the general procedures outlined in EXAMPLES 4-14 and making non-critical variations, but starting with the diastereomer of *tert*-butyl α -(2-hydroxyethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (EXAMPLE 4, step 2), the following compounds are prepared.

- 5 **EXAMPLE 71** Preparation of [S-(R*,R*)]-1,3-Dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1,3-dioxo-2*H*-isoindole-2-butanamide.




IR (mull) 1716, 1660, 1644, 1401 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 9.84, 7.80-7.90, 7.65-7.80, 7.15-7.35, 3.70-3.80, 3.35-3.70, 3.05-3.25, 2.80, 2.40-2.55, 2.34, 1.85-2.10, 1.30-1.65, 0.79, 0.71;

- 20 MS (EI) *m/e* 491, 459, 373, 245, 202, 185, 105.


EXAMPLE 72 Preparation of 1,3-Dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-[2-(4-fluorophenyl)ethyl]-3-pyrrolidinyl]-1,3-dioxo-2*H*-isoindole-2-butanamide.



IR (mull) 3223, 1716, 1675, 1648, 1510, 1444, 1397, 1367, 1218, 722 cm^{-1} ;

- 35 MS (EI) *m/e* 509, 477, 453, 449, 400, 262, 220, 160, 123.

EXAMPLE 73 Preparation of α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



Step 1. Preparation of *tert*-Butyl α -(2-Aminoethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate.

DEAD (1.18 mL) is added to a solution of *tert*-butyl α -(2-hydroxyethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (EXAMPLE 4, step 2; 2.74 g, 6.79 mmol), dibenzyl iminodicarboxylate (2.14 g), triphenylphosphine (1.96 g) and THF (43 mL). The mixture is stirred for 16 hours at room temperature. The solution is concentrated and purified by flash chromatography (3:1 hexane EtOAc) to give 3.09 g (68%) of the imide as an oil:

IR (neat) 2957, 1799, 1751, 1723, 1686, 1498, 1455, 1387, 1367, 1335, 1331, 1287, 1213, 1188, 1153, 1108, 1092, 698 cm^{-1} ;
 ^1H NMR (300 MHz, CDCl_3) δ 7.15-7.40, 5.23, 3.55-3.90, 3.25-3.40, 3.19, 2.79, 2.47, 2.30-2.45, 1.75-1.95, 1.50-1.70, 1.39, 0.82, 0.79;
 MS (FAB) m/z 671 (MH^+), 616, 572, 420, 419, 105, 92, 91, 57.

A mixture of the imide (1.01 g, 1.51 mmol), EtOH (100 mL), and 10% Pd/C (250 mg) is hydrogenated at 32 psi for 16 hours. The mixture is filtered, the solids washed with EtOH (20 mL), CH_2Cl_2 (20 mL), and EtOH (20 mL). The combined filtrates are concentrated to provide 549 mg (91%) of the title compound as an oil:
 ^1H NMR (300 MHz, CDCl_3) δ 7.15-7.35, 3.55-3.70, 3.30-3.45, 3.15-3.30, 2.30-2.90, 1.92, 1.35-1.85, 0.87, 0.83.

Step 2. Preparation of *tert*-Butyl α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate.

To a solution of *tert*-butyl α -(2-aminoethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (549 mg, 1.36 mmol), CH_2Cl_2 (8.4 mL), and diisopropylethylamine (0.29 mL, 1.6 mmol) at 0 $^\circ\text{C}$ is added 3,4-difluorobenzoyl

chloride (0.21 mL, 1.6 mmol). The solution is stirred at 0 °C for 1 hour and 16 hours at room temperature. Basic workup (CH_2Cl_2 , NaHCO_3 , MgSO_4) and purification by flash chromatography (1:1 hexane:EtOAc) gives 477 mg (64%) of the title compound as a white solid (mp 147-148 °C):

- 5 IR (mull) 3365, 1717, 1657, 1606, 1549, 1509, 1497, 1319, 1295, 1282, 1229, 1199, 1152, 832, 774 cm^{-1} ;
 ^1H NMR (300 MHz, CDCl_3) δ 7.65-7.80, 7.50-7.60, 7.15-7.40, 6.55-6.70, 3.55-3.70, 3.20-3.50, 2.81, 2.50-2.60, 2.10-2.40, 1.75-1.90, 1.40-1.65, 1.43, 0.85, 0.79;
MS (EI) m/z 542 (M^+) 486, 396, 395, 260, 245, 202, 141, 105, 104, 57.

- 10 Step 3. Preparation of α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetic Acid.

A solution of *tert*-butyl α -[2-[(3,4-difluorobenzoyl)amino]ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (473 mg, 0.872 mmol), CH_2Cl_2 (5.0 mL), and TFA (5.0 mL) is stirred for 1 hour at 0 °C and 2 hours at room
15 temperature. The solution is concentrated and the residue resuspended in CH_2Cl_2 and reconstituted two additional times (2 x 20 mL). Aqueous workup (CH_2Cl_2 , MgSO_4) provides 420 mg (99%) of the title compound as an oil:

- IR (liq.) 2959, 1728, 1661, 1618, 1607, 1553, 1510, 1467, 1454, 1443, 1442, 1314, 1297, 1283, 1203 cm^{-1} ;
20 ^1H NMR (300 MHz, CDCl_3) δ 7.65-7.75, 7.50-7.60, 7.15-7.40, 6.75-6.90, 3.70-3.90, 3.60-3.70, 3.40-3.55, 3.20-3.40, 2.80-3.00, 2.52, 1.95-2.10, 1.50-1.90, 1.15-1.35, 0.91, 0.83;
MS (EI) m/z 486 (M^+), 395, 272, 259, 258, 247, 141, 113, 105, 104.

- Step 4. Preparation of α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.
25

EDC (193 mg) is added to a solution of α -[2-[(3,4-difluorobenzoyl)amino]ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetic acid (411 mg, 0.865 mmol), CH_2Cl_2 (8.7 mL), DMF (2.1 mL), HOBT (118 mg), and 4-methylmorpholine (0.11 mL) at 0 °C. The solution was stirred for 5
30 min at 0 °C and 50 min at room temperature. Hydroxylamine hydrochloride (121 mg) and 4-methylmorpholine (0.19 mL) are added and the solution stirred for 16 hours at room temperature. The solution is diluted with 20 mL of water and the mixture acidified to pH 5 with 1 N HCl. The mixture is extracted several times with CH_2Cl_2 (3 x 20 mL), the combined organic layers dried (MgSO_4), filtered, and
35 concentrated. The residue is purified by flash chromatography (10:1 CH_2Cl_2 :MeOH) to give 273 mg of an oil which is crystallized from EtOAc/hexane to give 164 mg

(38%) of the title compound as a white powder (mp 132.5-134 °C):


IR (mull) 3264, 1674, 1666, 1649, 1512, 1497 cm^{-1} ; ¹

H NMR (300 MHz, CDCl_3) δ 7.60-7.80, 7.50-7.60, 7.05-7.35, 3.15-3.65, 2.81, 2.48, 1.85-2.20, 1.40-1.75, 0.85, 0.79;

5 MS (EI) m/e 501, 469, 262, 245, 202, 141, 105.

Following the general procedures outlined in EXAMPLE 73 and making non-critical variations, the following compounds were prepared.

EXAMPLE 74 Preparation of [*R*-(*R*^{*},*S*^{*})- α -{2-[(3-Fluorobenzoyl)amino]ethyl}-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



15

mp 144-145 °C;

$[\alpha]_D^{25} +13^\circ$ (c 0.75, CHCl₃);


IR (mull) 3290, 3216, 3062, 3029, 1673, 1662, 1643, 1585, 1555, 1496, 1486, 1323, 1301, 1227, 698 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.45-7.60, 7.10-7.45, 6.97, 3.35-3.70, 3.15-3.30, 2.83, 2.40-2.55, 1.80-2.05, 1.40-1.70, 0.87, 0.80;

MS (EI) *m/z* 483 (M⁺), 451, 262, 245, 202, 154, 123, 105, 104, 95, 56.

EXAMPLE 75 Preparation of α -{2-[(4-Fluorobenzoyl)amino]ethyl}-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.


25



30

IR (mull) 2950, 2932, 1718, 1661, 1604, 1547, 1504, 1466, 1454, 1234 cm⁻¹.


EXAMPLE 76 Preparation of *N*-Hydroxy-3-(2-methylpropyl)- α -[2-[(3-nitrobenzoyl)amino]ethyl]-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



IR (mull) 3270, 1664, 1633, 1556, 1532, 1454, 1447, 1351, 1310, 698 cm^{-1} ;

MS (EI) m/e 510.

EXAMPLE 77 Preparation of α -[2-[(3-Fluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.




mp 157-159 $^{\circ}\text{C}$;

IR (mull) 2954, 2925, 2868, 2855, 1645, 1624, 1586, 1552, 1465, 1455 cm^{-1} ;


MS (EI) m/e 403.

EXAMPLE 78 Preparation of α -[2-[(3-Fluorobenzoyl)amino]ethyl]-1-[2-(4-fluorophenyl)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetamide.




IR (mull) 2954, 2924, 2855, 1662, 1586, 1544, 1510, 1484, 1462, 1224 cm^{-1} .

EXAMPLE 79 Preparation of α -[2-[(4-Biphenylcarbonyl)amino]ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



MS (EI) m/e MH^+ 542.

EXAMPLE 80 Preparation of *N*-Hydroxy- α -[2-[[4-(4-methylphenyl)sulfonyl]amino]ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



Step 1. Preparation of *tert*-Butyl α -[2-[[[4-Methylphenyl)sulfonyl]amino]ethyl]-
15 3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate.

Toluenesulfonyl chloride (372 mg) is added to a solution of *tert*-butyl α -(2-aminoethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (EXAMPLE 73, step 1; 654 mg, 1.62 mmol), CH_2Cl_2 (10.0 mL), and diisopropylethylamine (0.34 mL) at 0 °C. The solution is stirred at 0 °C for 1 hour and at room temperature for 16 hours. Basic workup (CH_2Cl_2 , NaHCO_3 , MgSO_4) and purification by flash chromatography gives 634 mg (70%) of the title compound as a white solid (mp 136-138 °C):

IR (mineral oil) 1710, 1674, 1366, 1329, 1303, 1156, 1101 cm^{-1} ;

¹H NMR (300 MHz, CDCl₃) δ 7.73, 7.15-7.35, 4.45-4.55, 3.50-3.70, 3.30-3.45, 3.15-3.30, 2.75-3.10, 2.42, 2.20-2.35, 1.80-1.95, 1.60-1.80, 1.30-1.60, 1.38, 0.84, 0.79;

MS (FAB) m/z 557 (MH^+), 503, 502, 501, 484, 483, 105, 91, 57.

Step 2. Preparation of α -[2-[[[4-Methylphenyl)sulfonyl]amino]ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetic Acid.

TFA (7.0 mL) is added to a solution of *tert*-butyl α -[2-[(4-methylphenyl)sulfonyl]amino]ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (616 mg, 1.11 mmol) and CH_2Cl_2 (7.0 mL) at 0 °C. The solution is stirred for 1 h at 0 °C and for 2 hours at room temperature. The solution is concentrated which is repeated twice more from CH_2Cl_2 (2 x 20 mL). Aqueous workup (CH_2Cl_2 , MgSO_4) provides 463 mg (84%) of the title compound as a white foam:

IR (mineral oil) 1733, 1615, 1503, 1498, 1481, 1330, 1305, 1288, 1160, 1094, 701

cm⁻¹, ¹H NMR (300 MHz, CDCl₃) δ 7.70-7.80, 7.15-7.40, 4.80-5.00, 3.70-3.90, 3.20-3.50, 2.65-3.10, 2.50-2.65, 2.42, 1.95-2.10, 1.80-1.95, 1.50-1.80, 1.00-1.20, 0.92, 0.85;

MS (EI) *m/z* 500 (M⁺), 426, 392, 391, 334, 327, 244, 155, 105, 104, 91.

- 5 Step 3. Preparation of *N*-Benzyloxy-α-[2-[(4-methylphenyl)sulfonyl]amino]ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.

CDI (162 mg) is added to a solution of α-[2-[(4-methylphenyl)sulfonyl]amino]ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetic acid (453 mg) and CH₂Cl₂ (5.0 mL). The solution is stirred for 1
10 hour at room temperature and then *O*-benzylhydroxylamine hydrochloride (192 mg) and 4-methylmorpholine (0.13 mL) are added. The solution is stirred for 16 h at room temperature. The solution is diluted with 60 mL of EtOAc which is washed with 10% HCl, brine, dried (MgSO₄), filtered, and concentrated. Purification by
15 flash chromatography (1:1 hexane:EtOAc) provides a lactam intermediate with no evidence of *O*-benzylhydroxylamine incorporation:

¹H NMR (300 MHz, CDCl₃) δ 7.86, 7.15-7.45, 3.85-4.00, 3.45-3.70, 3.18, 2.85, 2.60-2.80, 2.43, 1.80-2.15, 1.35-1.55, 0.70-0.95.

A solution of the bis-lactam intermediate (317 mg, 0.657 mmol),
20 *O*-benzylhydroxylamine (500 mg) and THF (4.0 mL) is heated at reflux for 72 hours and then allowed to cool to room temperature. The residue is diluted with EtOAc which is washed with 10% HCl (2 x 10 mL) and brine (10 mL). The organic layer is dried (MgSO₄), filtered, and concentrated. Purification by flash chromatography (1:1 hexane:EtOAc) and crystallization from ether provides 139 mg (35%) of the title
25 compound as a white crystalline material (mp 155-157 °C):

IR (mull) 3162, 1664, 1650, 1332, 1154, 704 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.71, 7.15-7.40, 4.97, 4.81, 3.35-3.65, 3.17, 2.75-3.00, 2.55-2.75, 2.30-2.45, 2.39, 1.80-2.05, 1.35-1.70, 0.84, 0.77;

MS(EI) *m/e* 605, 483, 433, 327, 245, 202.

- 30 Step 4. Preparation of *N*-Hydroxy-α-[2-[(4-methylphenyl)sulfonyl]amino]ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.

A mixture of *N*-benzyloxy-α-[2-[(4-methylphenyl)sulfonyl]amino]ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (133 mg, 0.220 mmol),
35 MeOH (8.0 mL), and Pearlman's cat (25 mg) is hydrogenated (1 atm) for 8 h at room temperature. The mixture is filtered, the solids washed with MeOH (2 x 5 mL),

CH₂Cl₂ (5 mL), and MeOH (5 mL). The combined filtrates are concentrated and the residue crystallized from EtOAc/hexane to give 84 mg (74%) of the title compound as a white solid (mp 166.5-167 °C) :

IR (mull) 3278, 3202, 3028, 1659, 1636, 1496, 1329, 1298, 1291, 1160, 1093, 1061,


5 816, 702, 656 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.72, 7.30-7.60, 7.15-7.35, 5.82, 3.40-3.70, 3.15-3.35, 2.95-3.10, 2.70-2.95, 2.81, 2.57, 2.40, 2.10-2.25, 1.80-2.00, 1.30-1.75, 0.86, 0.80;

MS (EI) *m/z* 515 (M⁺), 483, 391, 343, 245, 244, 202, 155, 105, 104, 91.

Following the general procedures outlined in EXAMPLE 80 and making non-critical variations, the following compounds are prepared.

EXAMPLE 81 Preparation of α -[2-[[4-Fluorophenyl)sulfonyl]amino]ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



15


IR (mull) 3195, 3026, 1661, 1634, 1593, 1496, 1333, 1259, 1238, 1166, 1157, 1095, 1060, 844, 702 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 8.79, 7.75-7.90, 7.50-7.70, 7.43, 7.10-7.30, 3.10-3.50, 2.68, 2.40-2.75, 2.05-2.20, 1.85-2.00, 1.50-1.70, 1.30-1.50, 1.15-1.30, 0.75, 0.66;

MS (EI) m/z 519 (M^+), 395, 245, 202, 159, 154, 110, 105, 104, 95, 56.

EXAMPLE 82 Preparation of N-Hydroxy- α -[2-[[4-methoxyphenyl)sulfonyl]amino]ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.


25



30


MS (EI) m/e 532 (MH^+).

EXAMPLE 83 Preparation of *N*-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-[(phenylsulfonyl)amino]ethyl]-3-pyrrolidineacetamide.



IR (mull) 2954, 2924, 2862, 2855, 1663, 1610, 1569, 1453, 1446, 1429 cm^{-1} ;
MS (EI) m/e 502 (MH^+).

EXAMPLE 84 Preparation of [*R*-(*R*^{*},*S*^{*})]- α -[2-[(4-Fluorophenyl)sulfonyl]amino]ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



mp 67-70 °C;

IR (mull) 3196, 3107, 3065, 3027, 1662, 1592, 1495, 1332, 1292, 1237, 1166, 1154,

1093, 839, 701 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.80-7.95, 7.40-7.70, 7.10-7.40, 5.90, 3.10-3.70,


3.00-3.15, 2.70-3.00, 2.55, 2.05-2.20, 1.80-2.00, 1.20-1.80, 0.85, 0.80;

MS (FAB) m/z 520 (MH^+), 519, 504, 488, 487, 343, 202, 105.

EXAMPLE 85 Preparation of 5,6-Difluoro-1,3-dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1-oxo-2*H*-isoindole-2-butanamide.

5

10



Step 1. Preparation of *tert*-Butyl α -[2-(3-Acetoxy-5,6-difluoro-1,3-dihydro-1-oxo-2*H*-isoindol-2-yl)ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate.

Sodium borohydride (26 mg, 0.68 mmol) is added to a solution of *tert*-butyl α -[2-(5,6-difluoro-1,3-dihydro-1,3-dioxo-2*H*-isoindol-2-yl)ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (EXAMPLE 64; 384 mg, 0.675 mmol) and methanol (2.4 mL) at room temperature. The solution is stirred overnight at room temperature. Aqueous workup (EtOAc, MgSO₄) provides 386 mg (100%) of the diastereomeric mixture as a white foam. Solid 4-dimethylaminopyridine (14 mg, 0.12 mmol) is added to a solution of the crude alcohol (336 mg, 0.590 mmol), triethylamine (0.49 mL, 3.5 mmol), acetic anhydride (0.28 mL, 3.0 mmol) and CH₂Cl₂ (6.0 mL). The solution is stirred at room temperature for 2 hours. The reaction mixture was diluted with ether and the ether is washed with 10% HCl, saturated NaHCO₃, dried over MgSO₄, filtered, and concentrated. Column chromatography (20 → 50% EtOAc/hexane) provides 273 mg (76%) of the title compound as a diastereomeric mixture as an oil:

MS (EI) *m/z* 612 (M⁺) 497, 496, 440, 406, 405, 245, 236, 202, 105, 57.

Step 2. Preparation of *tert*-Butyl 5,6-Difluoro-1,3-dihydro- α -[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1-oxo-2*H*-isoindole-2-butyrate.

A mixture of *tert*-butyl α -[2-(3-acetoxy-5,6-difluoro-1,3-dihydro-1-oxo-2*H*-isoindol-2-yl)ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (236 mg, 0.386 mmol), palladium on carbon (10%, 60 mg) and acetonitrile (30 mL) is hydrogenated at 35 psi for 2 hours. The mixture was filtered and concentrated. Aqueous workup (EtOAc, MgSO₄) gave 200 mg (93%) of the title compound as an oil:

MS (EI) m/z 554 (M^+) 499, 498, 481, 408, 407, 247, 202, 182, 105, 57.

Step 3. Following the general procedure outlined in EXAMPLE 1, steps 4 and

5, and making non-critical variations, but starting with *tert*-butyl 5,6-difluoro-1,3-
5 dihydro- α -[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1-oxo-2*H*-
isoindole-2-butyrate, the title compound is obtained: (mp 175-176 °C):


IR (mull) 3186, 3060, 3022, 1702, 1659, 1511, 1436, 1307, 1290, 1265, 1219, 762,
757, 707, 699 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 8.80, 7.45-7.60, 7.05-7.35, 4.30-4.60, 3.05-3.75, 2.60-
10 2.80, 1.30-2.60, 0.87, 0.78;

MS (EI) m/z 513 (M^+) 514, 513, 480, 423, 262, 244, 236, 202, 182, 105.

Following the general procedures outlined in EXAMPLE 85 and making non-critical variations, the following compounds are prepared.

EXAMPLE 86 Preparation of 1,3-Dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidiny]-1-oxo-2*H*-isoindole-2-butanamide.




mp 140-144 °C;

IR (mull) 3165, 3085, 3058, 3020, 1683, 1669, 1653, 1616, 1487, 1424, 1349, 1335, 1295, 738, 699 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.80, 7.35-7.55, 7.00-7.35, 4.30-4.55, 3.10-3.85, 2.60-2.80, 1.90-2.40, 1.45-1.85, 0.87, 0.76;

MS (EI) m/z 477 (M^+), 202, 200, 189, 146, 134, 105, 104, 91, 56.

EXAMPLE 87 Preparation of [*R*-(*R*^{*},*S*^{*})]-6-Fluoro-1,3-dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidiny]-1-oxo-2*H*-isoindole-2-butanamide.




mp 167-170 °C;

^1H NMR (300 MHz, CDCl_3) δ 7.48, 7.35-7.45, 7.05-7.35, 4.30-4.50, 3.10-3.80, 2.55-2.95, 1.15-2.55, 0.87, 0.77;

MS (ESI) 496 (MH^+).

EXAMPLE 88 Preparation of [*R*-(*R*^{*},*S*^{*})]-5-Fluoro-1,3-dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1-oxo-2*H*-isoindole-2-butanamide.




mp 135-136 °C;

¹H NMR (300 MHz, CDCl₃) δ 7.70-7.85, 7.44, 7.00-7.35, 4.30-4.55, 3.05-3.80; 2.55-2.80, 2.35-2.55, 1.85-2.35, 0.87, 0.76;

15 MS (ESI) 496 (MH⁺).

EXAMPLE 89 Preparation of [*R*-(*R*^{*},*S*^{*})]-5,6-Difluoro-1,3-dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1-oxo-2*H*-isoindole-2-butanamide.



mp 153.5-155°C;


30 ¹H NMR (300 MHz, CDCl₃) δ 8.98, 7.50-7.65, 7.43, 7.00-7.35, 4.50, 3.10-3.75, 2.60-2.80, 2.45-2.60, 2.25-2.45, 1.85-2.25, 1.40-1.85, 0.87, 0.79;

MS (ESI) 514 (MH⁺).

EXAMPLE 90 Preparation of *N*-Hydroxy- α -[[[(4-methoxyphenyl)sulfonyl]amino]methyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (α R-diastereomer).

5

10



15 Step 1. Preparation of *tert*-Butyl α -(1-Hydroxymethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (α S-diastereomer).

A cold (-78 °C) solution of *tert*-butyl 3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (EXAMPLE 1, step 3; 2.00 g, 5.56 mmol) in dry THF (20 mL) is treated with the dropwise addition of LDA (3.20 mL, 6.40 mmol, 2.0 N). The solution is maintained at -78 °C for 30 min and then warmed to -30 °C. Gaseous formaldehyde (generated by heating 834 mg of paraformaldehyde at 160 °C to provide approximately 28 mmol) is bubbled through the enolate solution. The solution is maintained at -30 °C for 1 hour and then quenched with saturated aqueous NH₄Cl (5 mL) and diluted with H₂O (20 mL). The product is extracted into EtOAc (3 x 50 mL), dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure to provide 2.52 g of a yellow solid which is purified by silica gel chromatography (100 g SG; 25% EtOAc/hexane) to give 1.43 g (83%) of the title compound as a golden oil. Another fraction containing 375 mg of a mix of both diastereomers is also recovered. Spectral data for the title compound:

30 IR (liq.) 3417, 2957, 2931, 2869, 1722, 1669, 1497, 1465, 1455, 1392, 1368, 1274, 1252, 1155, 701 cm⁻¹;
¹H NMR (300 MHz, CDCl₃) δ 7.15-7.40, 3.90-4.05, 3.70-3.80, 3.55-3.70, 3.40-3.55, 3.20-3.30, 2.85, 2.75, 2.69, 2.00-2.20, 1.90-2.00, 1.65-1.70, 1.50-1.60, 1.44, 0.90, 0.84;
 MS (EI) *m/z* 389 (M⁺), 333, 316, 298, 277, 243, 242, 202, 105, 104, 57.

35

Step 2. Preparation of *tert*-Butyl α -(1-Hydroxymethyl)-3-(2-methylpropyl)-2-

oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (α R-diastereomer).

A cold (-78 °C) solution of oxalyl chloride (1.02 mL, 11.7 mmol) in dry CH_2Cl_2 (30 mL) is treated with DMSO (1.66 mL, 23.4 mmol, in 5 mL CH_2Cl_2). After 5 min, *tert*-butyl α -(1-hydroxymethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-

- 5 pyrrolidineacetate (S-isomer) (3.80 g, 9.76 mmol) is added. The solution is stirred for an additional 15 min and then quenched with triethylamine (6.8 mL, 48.8 mmol). The solution is maintained at -78 °C for 30 min and then allowed to warm to room temperature under N_2 . After 2.5 hours, the solution is diluted with H_2O (50 mL) and extracted into EtOAc (3 x 100 mL). The extracts are combined, dried over
10 anhydrous MgSO_4 , filtered, and concentrated under reduced pressure to provide a quantitative yield of the desired aldehyde as a ca. 1:2 mixture in favor of the *R* diastereomer. Key peaks of the NMR of the crude mixture:

^1H NMR (300 MHz, CDCl_3) δ 9.75, 9.48.

- A cold (0 °C) solution of the aldehyde mixture (1.68 g, 4.34 mmol) in MeOH
15 (30 mL) is treated with sodium borohydride (246 mg, 6.51 mmol). The solution is maintained at 0 °C for 1 h, and then allowed to warm to room temperature. After 3 hours, the solution is concentrated to a yellow foam. The foam is diluted with H_2O (25 mL) and extracted with EtOAc (3 x 50 mL). The extracts are combined, dried over anhydrous MgSO_4 , filtered, and concentrated under reduced pressure. The
20 material, 1.69 g, is purified by silica gel chromatography (100 g SG; 20% EtOAc/hexane) to provide 562 mg (33%) of the title compound, 467 mg (28%) of the *S* diastereomer and 331 mg of the unreduced aldehyde. Spectral data for the title compound:

IR (mineral oil) 3542, 3006, 1704, 1672, 1499, 1396, 1313, 1265, 1160, 1124, 1066,
25 1059, 1036, 738, 697 cm^{-1} ; 1

^1H NMR (300 MHz, CDCl_3) δ 7.15-7.35, 3.95, 3.75, 3.60-3.75, 3.40-3.65, 3.24, 2.87, 2.69, 1.80-2.15, 1.40-1.70, 1.45, 0.89, 0.87;

MS (FAB) m/z 390 (MH^+), 335, 334, 332, 316, 298, 242, 105, 57.

- Step 3. Preparation of *tert*-Butyl α -(1-Azidomethyl)-3-(2-methylpropyl)-2-oxo-1-
30 (2-phenylethyl)-3-pyrrolidineacetate.

Methanesulfonyl chloride (0.058 mL, 0.751 mmol) is added dropwise to a solution of *tert*-butyl α -(1-hydroxymethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (α R-diastereomer) (225 mg, 0.578 mmol) and triethylamine (105 mL, 0.751 mmol) in dry CH_2Cl_2 (3 mL). The solution is stirred overnight at room
35 temperature under N_2 . After diluting with CH_2Cl_2 (20 mL), the solution is washed with saturated NaHCO_3 (5 mL), H_2O (5 mL), and brine (5 mL). The organic layer is

dried over anhydrous MgSO_4 , filtered, and concentrated under reduced pressure to give 289 mg of a gold oil. The oil is purified by silica gel chromatography (10 g SG; 20% EtOAc/hexane) to provide 243 mg (90%) of the mesylate as an oil:

^1H NMR (300 MHz, CDCl_3) δ 7.10-7.40, 4.47, 4.17, 3.35-3.70, 3.05-3.30, 2.90-3.05,
5 2.97, 2.84, 2.10-2.30, 1.75-1.95, 1.30-1.70, 1.46, 0.88, 0.86.

A solution of the mesylate (795 mg, 1.70 mmol) and sodium azide (166 mg, 2.55 mmol) in DMSO (6 mL) is heated at 60 °C for 24 hours and then allowed to cool to room temperature under N_2 . The solution is diluted with Et_2O (40 mL) and washed with H_2O (3 x 15 mL) and brine (15 mL). The organic layer is dried over
10 anhydrous MgSO_4 , filtered, and concentrated under reduced pressure to give 679 mg (96%) of the title compound as a clear, colorless oil:

IR (liq.) 2958, 2932, 2870, 2101, 1725, 1682, 1498, 1455, 1393, 1368, 1276, 1152, 1122, 748, 700 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.15-7.35, 3.10-3.80, 3.00, 2.70-2.95, 2.15-2.30, 1.30-
15 1.90, 1.47, 0.85;

MS (EI) m/z 414 (M^+), 358, 268, 267, 246, 224, 212, 105, 104, 57.

Step 4. Preparation of *tert*-Butyl α -(1-Aminomethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate.

A mixture of *tert*-butyl α -(1-azidomethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (648 mg, 1.56 mmol) and 10% palladium on carbon (163 mg) in EtOH (25 mL) is hydrogenated at 30 psi in a Parr flask for 16 hours. The mixture is filtered, rinsing the residual solids with MeOH and CH_2Cl_2 . The filtrate is concentrated and purified by silica gel chromatography (15 g SG; EtOAc, 15% MeOH/EtOAc) to provide 356 mg (57%) of the title compound as a partially
25 crystalline solid:

IR (mull) 3004, 1718, 1672, 1498, 1394, 1311, 1296, 1263, 1223, 1156, 1149, 852, 738, 697, 620 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.15-7.35, 3.35-3.70, 3.05-3.30, 2.70-2.95, 2.60-2.70, 2.45-2.60, 2.20-2.40, 1.25-2.00, 1.46, 0.85 MS (FAB) m/z 389 (MH^+), 359, 334, 333,
30 316, 202, 105, 57.

Step 5. Preparation of *tert*-Butyl α -[[(4-Methoxyphenyl)sulfonyl]amino]methyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate.

35 A cold (0 °C) solution of *tert*-butyl α -(1-aminomethyl)-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (337 mg, 0.867 mmol) in dry CH_2Cl_2 (3

mL) is treated with diisopropylethylamine (240 μ L, 1.30 mmol) and 4-methoxybenzenesulfonyl chloride (215 mg, 1.30 mmol). The solution was allowed to slowly warm to room temperature, stirring overnight under N_2 . After diluting with CH_2Cl_2 (25 mL), the solution is washed with dilute $NaHCO_3$ (10 mL), H_2O (10 mL),
5 and brine (10 mL). The organic layer was dried over anhydrous $MgSO_4$, filtered, and concentrated under reduced pressure to give 460 mg of a yellow oil. The oil was purified by silica gel chromatography (20 g SG; 25% EtOAc/hexane) to provide 383 mg (79%) of the desired material as a white amorphous solid:

IR (liq.) 2958, 2932, 1725, 1668, 1598, 1499, 1455, 1444, 1368, 1334, 1304, 1279,
10 1260, 1160, 1097 cm^{-1} ;
 1H NMR (300 MHz, $CDCl_3$) δ 7.79, 7.10-7.35, 6.95, 5.45-5.60, 3.81, 3.30-3.65, 2.95-3.30, 2.60-2.90, 2.00-2.20, 1.70-1.90, 1.20-1.70, 1.43, 0.80;
MS (EI) m/z 558 (M^+), 411, 387, 287, 246, 245, 202, 171, 107, 105, 57.

Step 6. Preparation of α -[[[(4-Methoxyphenyl)sulfonyl]amino]methyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetic acid.
15

A cold (0 $^{\circ}C$) solution of *tert*-butyl α -[[[(4-methoxyphenyl)sulfonyl]amino]methyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (374 mg, 0.669 mmol) in CH_2Cl_2 (2 mL) is treated with TFA (2 mL). The solution is maintained at 0 $^{\circ}C$ for 40 min and then allowed to warm to room temperature under
20 N_2 . After 1.5 hours, the solution is diluted with CH_2Cl_2 and stripped (5 x). The residual foam is diluted with H_2O (5 mL) and extracted into CH_2Cl_2 (3 x 20 mL). The extracts are combined, dried over anhydrous $MgSO_4$, filtered, and concentrated under reduced pressure to provide 301 mg (90%) of the title compound as a white, amorphous solid:

25 IR (mull) 3062, 3026, 1713, 1647, 1597, 1580, 1498, 1332, 1304, 1261, 1180, 1158, 1096, 834, 701 cm^{-1} ;
 1H NMR (300 MHz, $CDCl_3$) δ 7.70-7.80, 7.15-7.35, 6.90-7.00, 5.45-5.55, 3.86, 3.45-3.75, 3.00-3.40, 2.89, 2.67, 1.95-2.25, 1.35-1.60, 0.84, 0.78;
MS (EI) m/z 502 (M^+), 411, 287, 246, 245, 244, 202, 171, 107, 105, 77.

30

Step 7. Preparation of *N*-Benzyloxy- α -[[[(4-methoxyphenyl)sulfonyl]amino]methyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.

A solution of α -[[[(4-methoxyphenyl)sulfonyl]amino]methyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetic acid (290 mg, 0.577 mmol)
35 in dry CH_2Cl_2 (5 mL) is treated with CDI (112 mg, 0.692 mmol). After 1 h, 4-

methylmorpholine (0.095 mL, 0.866 mmol) and *O*-benzyhydroxyamine HCl (138 mg, 0.866 mmol) are added. The solution is stirred at room temperature under N₂ for 65 h. The solvent had evaporated, and the residual gel is diluted with EtOAc (25 mL). The solution is washed with 1 N HCl (10 mL), 1 N NaOH (10 mL), and brine (10 mL). The organic layer is dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure to give 380 mg of an oil. The oil is purified by silica gel chromatography (30 g SG; 50% EtOAc/hexane) to provide 249 mg (71%) of the title compound as an oil:

IR (mull) 3205, 3028, 1658, 1597, 1498, 1331, 1304, 1287, 1261, 1157, 1096, 1027, 834, 749, 699 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.70-7.85, 7.10-7.45, 6.85-7.00, 5.70-5.80, 4.86, 3.76, 3.40-3.55, 3.00-3.25, 2.60-3.00, 2.30-2.50, 1.80-2.00, 1.30-1.60, 0.82, 0.75;

MS (FAB) *m/z* 608 (MH⁺), 485, 298, 286, 244, 171, 107, 105, 91.

Step 8. Preparation of *N*-Hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]amino]methyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.


A solution of *N*-benzyloxy-α-[[[(4-methoxyphenyl)sulfonyl]amino]methyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (218 mg, 0.359 mmol) in EtOH (7 mL) is treated with palladium hydroxide on carbon (55 mg) and placed under a H₂ atmosphere via a balloon. After 6.5 hours, the mixture is filtered, rinsing the residual solids with MeOH and CHCl₃. The filtrate is concentrated to give 182 mg of a white solid. The material is crystallized from hot EtOAc with a trace of MeOH, eventually diluting with hexane, to provide 136 mg of the title compound as a solid (mp 195-196 °C):

IR (mull) 3317, 3095, 1658, 1620, 1597, 1496, 1335, 1304, 1257, 1163, 1097, 833, 829, 805, 751 cm⁻¹;

¹H NMR (300 MHz, CDCl₃) δ 7.78, 7.05-7.35, 6.91, 6.20-6.35, 3.75, 3.35-3.60, 3.05-3.35, 2.60-2.90, 2.25-2.50, 1.80-2.00, 1.15-1.70, 0.83, 0.77; MS (EI) *m/z* 517 (M⁺), 261, 245, 244, 202, 171, 154, 107, 105.

EXAMPLE 91 Preparation of *N*-Hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]amino]methyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (α*S*-diastereomer).

5




10 mp 60-64 °C);

^1H NMR (300 MHz, CDCl_3) δ 7.70-7.90, 7.10-7.40, 6.85-7.05, 5.40-5.60, 3.86, 3.40-3.60, 2.95-3.30, 2.70-2.85, 2.05-2.25, 1.30-1.90, 0.65-0.90.

EXAMPLE 92 Preparation of α -[[4-Fluorophenyl)sulfonyl]amino]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (*R*-diastereomer).

15

20



25

Step 1. Preparation of *tert*-Butyl α -Azido-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (α *R*-diastereomer).

Potassium bis(trimethylsilyl)amide (0.5 M in toluene, 19.9 mL, 9.93 mmol) is added to a solution of *tert*-butyl 3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (EXAMPLE 1, step 3; 1.70 g, 4.73 mmol) and THF (57 mL) at -78 °C. The solution is allowed to stir at -78 °C for 25 min. A solution of trisylazide (3.66 g, 11.8 mmol) in THF (34.5 mL) is added dropwise over 5 min. The solution is stirred for an additional 2 min and acetic acid (1.2 mL) is added. The solution was allowed to warm slowly and stir at room temperature overnight. Aqueous workup (EtOAc, NaHCO_3 wash, brine wash, MgSO_4) and column chromatography (7.5 %

EtOAc/hexane) provides 1.34 g (71%) of the title compound as a yellow oil:

^1H NMR (300 MHz, CDCl_3) δ 7.15-7.35, 4.23, 4.12, 3.65-3.80, 3.50-3.65, 3.15-3.40, 2.75-2.90, 2.35-2.50, 2.10-2.30, 1.15-1.85, 0.75-0.95;

MS (ESI) 401 (MH^+).

- 5 Step 2. Preparation of *tert*-Butyl α -Amino-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (αR -diastereomer).

A mixture of *tert*-butyl α -azido-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (159 mg, 0.397 mmol), palladium on carbon (10%, 40 mg) and EtOH (2.0 mL) is hydrogenated overnight at 30 psi. The mixture is filtered and

- 10 concentrated to give 145 mg (97%) of the title compound as an oil:

^1H NMR (300 MHz, CDCl_3) δ 7.15-7.39, 3.55-3.75, 3.15-3.35, 2.84, 2.15-2.30, 1.85-1.95, 1.30-1.80, 1.46, 0.89, 0.84;

MS (ESI) 375 (MH^+).


- Following the procedures outlined in EXAMPLE 90 (steps 5-8) and making non-critical modifications, but starting with *tert*-butyl α -amino-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (αR -diastereomer), the title compound is obtained (mp 111-113 °C):
- 15

^1H NMR (300 MHz, CDCl_3) δ 9.05, 7.80-7.90, 7.05-7.35, 6.85, 5.25-5.50, 4.50-4.60, 3.80-3.90, 3.60-3.75, 3.05-3.60, 2.70-2.85, 2.10-2.35, 1.40-1.90, 1.55, 0.70-0.90;

- 20 MS (ESI) 492 (MH^+).

Following the general procedures outlined in EXAMPLE 92 and making non-critical variations, the following compounds were prepared.

EXAMPLE 93 Preparation of α -[[(4-Fluorophenyl)sulfonyl]amino]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (α S-diastereomer).




mp 99-102 °C;

^1H NMR (300 MHz, CDCl_3) δ 7.75-7.85, 7.10-7.35, 5.06, 3.45-3.60, 3.15-3.35, 2.85, 2.35-2.50, 1.95-2.10, 1.15-1.60, 0.78, 0.74;

MS (ESI) 492 (MH^+).

EXAMPLE 94 Preparation of α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(3-hydroxypropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



Step 1. Preparation of *tert*-Butyl α -(2-Chloroethyl)-2-oxo-1-(2-phenylethyl)-3-(propen-2-yl)-3-pyrrolidineacetate

A cold (-78 °C) solution of *tert*-butyl 2-oxo-1-(2-phenylethyl)-3-(propen-2-yl)-3-pyrrolidineacetate (prepared similarly to that described in EXAMPLE 1, step 3; 5.52

- g, 16.1 mmol) in dry THF (100 mL) is treated with the dropwise addition of LDA (9.66 mL, 19.3 mmol, 2.0 N). The solution is stirred for 30 min, and then treated with the dropwise addition of 1-bromo-2-chloroethane (1.61 mL, 19.3 mmol). The solution is maintained at -78°C for 5 hours and then allowed to slowly warm to room temperature under N₂ overnight. The solution is quenched with saturated NH₄Cl (10 mL) and diluted with H₂O (25 mL). The product is extracted with EtOAc (3 x 100 mL), dried over anhydrous MgSO₄, filtered, and concentrated to give 6.6 g of a brown oil. The oil is purified by silica gel chromatography (275 g SG; 10% EtOAc/hexane) to provide 5.07 g (78%) of the title compound as a clear, yellow oil:
- 10 IR (liq.) 2977, 2931, 1721, 1685, 1496, 1455, 1440, 1393, 1367, 1282, 1257, 1149, 917, 748, 701 cm⁻¹;
¹H NMR (300 MHz, CDCl₃) δ 7.15-7.35, 5.45-5.65, 4.95-5.15, 3.25-3.80, 3.05-3.25, 2.81, 2.71, 1.90-2.45, 1.65-1.85, 1.43;
MS (EI) *m/z* 405 (M⁺), 370, 351, 349, 332, 314, 260, 259, 258, 105, 104, 57.
- 15 Step 2. Preparation of *tert*-Butyl α-(2-Azidoethyl)-2-oxo-1-(2-phenylethyl)-3-(propen-2-yl)-3-pyrrolidineacetate

- A solution of *tert*-butyl α-(2-chloroethyl)-2-oxo-1-(2-phenylethyl)-3-(propen-2-yl)-3-pyrrolidineacetate (2.10 g, 5.17 mmol) in DMSO (15 mL) is treated with sodium azide (504 mg, 7.74 mmol). The mixture is heated to 60 °C (oil bath) for 17 hours.
- 20 The resultant solution was cooled to room temperature, diluted with Et₂O (100 mL), washed with H₂O (3 x 50 mL) and brine (50 mL). The organic layer is dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure to provide a quantitative yield of the title compound as a yellow oil:
- ¹H NMR (300 MHz, CDCl₃) δ 7.15-7.35, 5.40-5.65, 4.95-5.15, 3.60-3.80, 3.05-3.40, 2.81, 2.60, 2.10-2.40, 1.65-2.05, 1.43.
- 25

- Step 3. Preparation of *tert*-Butyl α-(2-Aminoethyl)-2-oxo-1-(2-phenylethyl)-3-(propen-2-yl)-3-pyrrolidineacetate.

- A solution of *tert*-butyl α-(2-azidoethyl)-2-oxo-1-(2-phenylethyl)-3-(propen-2-yl)-3-pyrrolidineacetate (2.12 g, 5.14 mmol) and triphenylphosphine (1.48 g, 5.65 mmol) in THF (15 mL) is stirred under N₂ for 7 hours. Water (1 mL) is added and the solution stirred overnight at room temperature under N₂. The solution is concentrated and purified by silica gel chromatography (75 g SG; EtOAc, 20% MeOH/EtOAc) to provide 1.94 g (97%) of the title compound as a yellow oil:
- 30 ¹H NMR (300 MHz, CDCl₃) δ 7.15-7.35, 5.45-5.65, 4.95-5.15, 3.60-3.80, 3.05-3.40, 2.80, 2.50-2.80, 2.10-2.45, 1.60-1.90, 1.42.
- 35

- Step 4. Preparation of *tert*-Butyl α-[2-[(3,4-Difluorobenzoyl)amino]ethyl]-2-oxo-

1-(2-phenylethyl)-3-(propen-2-yl)-3-pyrrolidineacetate

A cold (0 °C) solution of *tert*-butyl α -(2-aminoethyl)-2-oxo-1-(2-phenylethyl)-3-(propen-2-yl)-3-pyrrolidineacetate (1.93 g, 4.99 mmol) in dry CH_2Cl_2 (20 mL) is treated with diisopropylethylamine (1.04 mL, 5.99 mmol) and 3,4-difluorobenzoyl chloride (691 μL , 5.49 mmol). The solution is allowed to warm to room temperature, stirring under N_2 overnight. The solution is diluted with EtOAc (100 mL) and washed with 1 N HCl (25 mL), 1 N NaOH (25 mL), and brine (25 mL). The organic layer is dried over anhydrous MgSO_4 , filtered, and concentrated under reduced pressure to give 3.60 g of a brown oil. The oil is purified by silica gel chromatography (50 g SG; 25% EtOAc/hexane) to provide 2.10 g (80%) of the title compound as a yellow, amorphous solid:

IR (mineral oil) 3360, 1717, 1660, 1606, 1550, 1509, 1497, 1436, 1315, 1295, 1281, 1199, 1154, 831, 775 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.65-7.75, 7.50-7.60, 7.15-7.35, 6.70, 5.45-5.65, 4.90-5.10, 3.55-3.85, 3.10-3.45, 2.70-2.90, 2.62, 2.10-2.35, 1.65-1.90, 1.43;

MS (ESI) m/z 549 (MNa^+).

Step 5. Preparation of *tert*-Butyl α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-3-(3-hydroxypropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate.

A cold (0 °C) solution of *tert*-butyl α -[2-[(3,4-difluorobenzoyl)amino]ethyl]-2-oxo-1-(2-phenylethyl)-3-(propen-2-yl)-3-pyrrolidineacetate (1.62 g, 3.07 mmol) in dry THF (10 mL) is treated with monochloroborane methylsulfide complex (640 μL , 6.14 mmol). The ice bath is removed, and after 4.5 h, 3 N NaOH (7.4 mL, 22.1 mmol) is added dropwise, followed by 30% H_2O_2 (2.5 mL). The solution is stirred for 1 hour at room temperature and then for 1 hour at 50 °C. After cooling to room temperature and dilution with saturated NH_4Cl (5 mL) and H_2O (15 mL), the product is extracted into EtOAc (3 x 50 mL). The extracts are combined, dried over anhydrous MgSO_4 , filtered, and concentrated under reduced pressure to give 1.6 g of a yellow gel. The material is purified by silica gel chromatography (75 g SG; 75% EtOAc/hexane) to provide 713 mg (43%) of the title compound as a white, amorphous solid:

IR (liq.) 3335, 2934, 1721, 1666, 1606, 1554, 1511, 1455, 1368, 1316, 1296, 1283, 1250, 1204, 1153 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.65-7.75, 7.45-7.60, 7.15-7.35, 6.60-6.75, 3.75-3.95, 3.10-3.70, 2.70-2.90, 2.65, 2.20-2.40, 2.00-2.20, 1.42, 1.05-1.90;

MS (ESI) m/z 567 (MNa^+).

Step 6. Preparation of α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-3-(3-hydroxypropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetic acid.

- A cold (0°C) solution of *tert*-butyl α -[2-[(3,4-difluorobenzoyl)amino]ethyl]-3-(3-hydroxypropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetate (655 mg, 1.20 mmol) in
5 CH_2Cl_2 (3 mL) is treated with TFA (2 mL) and maintained at 0°C for 30 min. The ice bath is removed, and after 2 hours, the solution is diluted with CH_2Cl_2 and concentrated (3 X). The residual oil is diluted with H_2O (10 mL) and extracted into CH_2Cl_2 (3 X 50 mL). The extracts are combined, dried over anhydrous MgSO_4 , filtered, and concentrated under reduced pressure to provide a quantitative yield of
10 the title compound as a white, amorphous solid:
IR (liq.) 1785, 1724, 1644, 1619, 1605, 1557, 1511, 1455, 1442, 1322, 1297, 1284, 1207, 1171, 701 cm^{-1} ;
 ^1H NMR (300 MHz, CDCl_3) δ 7.60-7.75, 7.50-7.60, 7.15-7.40, 6.85-7.00, 4.10-4.35, 3.50-3.80, 3.20-3.45, 2.80-3.00, 2.54, 1.20-2.00;
15 MS (EI) m/z 488, 470, 397, 379, 260, 246, 141, 113.

Step 7. Preparation of α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-*N*-benzyloxy-3-(3-hydroxypropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.

- A cold (0 °C) solution of α -[2-[(3,4-difluorobenzoyl)amino]ethyl]-3-(3-hydroxypropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetic acid (586 mg, 1.20 mmol)
20 in 2:1 $\text{CH}_2\text{Cl}_2/\text{DMF}$ (7.5 mL) is treated with HOBT (195 mg, 1.44 mmol), EDC (276 mg, 1.44 mmol), and 4-methylmorpholine (158 μL , 1.44 mmol). The ice bath is removed, and after 1 hour, *O*-benzylhydroxylamine HCl (287 mg, 1.80 mmol) and a second portion of 4-methylmorpholine (198 μL , 1.80 mmol) are added. The solution is stirred overnight at room temperature under N_2 . The solution is diluted with
25 H_2O (25 mL) and extracted into CH_2Cl_2 (3 X 50 mL). The extracts are combined, dried over anhydrous MgSO_4 , filtered, and concentrated under reduced pressure to provide an oil. The residual oil is reconstituted in EtOAc (50 mL) and washed with 1 N HCl (10 mL), 1 N NaOH (10 mL), H_2O (10 mL), and brine (10 mL). The organic layer is dried over anhydrous MgSO_4 , filtered, and concentrated under reduced
30 pressure to give 603 mg of a white foam. The material is purified by silica gel chromatography (25 g SG; EtOAc) to provide 433 mg (62%) of the title compound as a white, amorphous solid:
IR (liq.) 3328, 2941, 1664, 1619, 1605, 1554, 1511, 1454, 1438, 1319, 1298, 1283, 1205, 750, 700 cm^{-1} ;
35 ^1H NMR (300 MHz, CDCl_3) δ 7.60-7.75, 7.45-7.60, 7.10-7.45, 6.75-6.85, 4.86, 3.35-

3.70, 3.10-3.30, 2.75-2.90, 2.30-2.45, 1.10-2.15;

MS (FAB) m/z 594 (MH^+), 593, 592, 531, 489, 472, 471, 453, 313, 57.

Step 8. Preparation of α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(3-hydroxypropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.

5 A solution of α -[2-[(3,4-difluorobenzoyl)amino]ethyl]-*N*-benzyloxy-3-(3-hydroxypropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (215 mg, 0.368 mmol) is dissolved in EtOH (5 mL) and purged with N_2 . Pearlman's catalyst (22 mg) is added and the atmosphere was replaced with H_2 . After 7 hours, the mixture is filtered through celite, washing the residual solids with MeOH, EtOH, and CH_2Cl_2 .
10 The filtrate is concentrated to give 171 mg of a slightly brown foam. The material is crystallized from hot EtOAc (diluting with hexane). The product is isolated and dried in the vacuum oven (45 °C) overnight to provide 117 mg (63%) of the title compound as a cream-colored, powdery solid (mp 118 °C, dec.):

IR (mineral oil) 3274, 3225, 3064, 3027, 1656, 1620, 1606, 1559, 1512, 1359, 1319,


15 1290, 1282, 1060, 701 cm^{-1} ;

1H NMR (300 MHz, $CDCl_3$) δ 7.45-7.80, 7.10-7.40, 3.10-3.75, 2.70-2.90, 2.40-2.60, 1.15-2.25;

MS (FAB) m/z 504 (MH^+), 503, 502, 488, 471, 313, 246, 141, 105.

EXAMPLE 95 Preparation of α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-*N*-

20 hydroxy-3-(2-hydroxyethyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



25

Step 1. Preparation of α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-2-oxo-1-(2-phenylethyl)-3-(propen-2-yl)-3-pyrrolidineacetic acid
30

A cold (0 °C) solution of *tert*-butyl α -[2-[(3,4-difluorobenzoyl)amino]ethyl]-2-oxo-1-(2-phenylethyl)-3-(propen-2-yl)-3-pyrrolidineacetate (EXAMPLE 94, step 4; 505 mg, 0.959 mmol) in CH_2Cl_2 (2 mL) is treated with TFA (2 mL) and maintained at 0 °C for 30 min. The ice bath is removed, and after 1 h, the solution was diluted with
35 CH_2Cl_2 and concentrated (3 x). The residual oil is diluted with H_2O (10 mL) and extracted into CH_2Cl_2 (3 x 25 mL). The extracts are combined, dried over

anhydrous MgSO_4 , filtered, and concentrated under reduced pressure to provide 430 mg (95%) of the title compound as a slightly yellow, amorphous solid:

IR (liq.) 1727, 1662, 1641, 1619, 1606, 1554, 1510, 1454, 1441, 1316, 1298, 1283, 1203, 775, 700 cm^{-1} ;

5 ^1H NMR (300 MHz, CDCl_3) δ 7.60-7.75, 7.50-7.60, 7.15-7.40, 6.75-6.90, 5.45-5.65, 5.10-5.20, 3.50-3.75, 3.15-3.35, 2.88, 2.52, 2.34, 1.70-2.05, 1.20-1.45;

MS (ESI) m/z 469 (M^+).

Step 2. Preparation of α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-*N*-benzyloxy-2-oxo-1-(2-phenylethyl)-3-(propen-2-yl)-3-pyrrolidineacetamide.

10 A cold (0 °C) solution of α -[2-[(3,4-difluorobenzoyl)amino]ethyl]-2-oxo-1-(2-phenylethyl)-3-(propen-2-yl)-3-pyrrolidineacetic acid (427 mg, 0.908 mmol) in 2:1 $\text{CH}_2\text{Cl}_2/\text{DMF}$ (6 mL) is treated with HOBT (147 mg, 1.09 mmol), EDC (209 mg, 1.09 mmol), and 4-methylmorpholine (120 μL , 1.09 mmol). The ice bath is removed, and after 1 hour, a second portion of 4-methylmorpholine (150 μL , 1.36 mmol) and *O*-
15 benzylhydroxylamine HCl (217 mg, 1.36 mmol) are added. The solution is stirred overnight at room temperature under N_2 . The solution is diluted with EtOAc (25 mL) and washed with 1 N HCl (10 mL), 1 N NaOH (10 mL), H_2O (2 x 10 mL), and brine (10 mL). The organic layer is dried over anhydrous MgSO_4 , filtered, and concentrated under reduced pressure to give 530 mg of a yellow solid. The solid is
20 purified by silica gel chromatography (30 g SG; 50% EtOAc/hexane) to provide 373 mg (71%) of the title compound as a white, amorphous solid:

IR (mineral oil) 3336, 3193, 1679, 1669, 1641, 1608, 1544, 1509, 1495, 1442, 1311, 1296, 1275, 747, 696 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.05-7.75, 6.65-6.85, 5.40-5.60, 4.80-5.15, 3.35-3.70,
25 3.05-3.30, 2.81, 1.35-2.45;

MS (ESI) m/z 574 (M^+).

Step 3. Preparation of α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-*N*-benzyloxy-3-(2-hydroxyethyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.

α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-*N*-benzyloxy-2-oxo-1-(2-phenylethyl)-3-
30 (propen-2-yl)-3-pyrrolidineacetamide (365 mg, 0.634 mmol) is dissolved in warm EtOH (10 mL) and cooled to -78 °C. The solution is subjected to ozone for 3.5 min and then purged with N_2 for 15 min. The ozonide is quenched with NaBH_4 (36 mg, 0.951 mmol) and allowed to slowly warm to room temperature under N_2 . After 5 hours, additional NaBH_4 (36 mg, 0.951 mmol) is added and the mixture allowed to
35 stir overnight. The mixture is concentrated, diluted with H_2O (20 mL) and

extracted into EtOAc (3 x 50 mL). The extracts are dried over anhydrous MgSO_4 , filtered, and concentrated under reduced pressure to give 306 mg of a white foam. The foam is purified by silica gel chromatography (25 g SG; EtOAc) to provide 123 mg (34%) of the title compound as a white, amorphous solid:

5 IR (mineral oil) 3321, 1664, 1619, 1605, 1554, 1510, 1318, 1297, 1283, 1205, 1028, 776, 750, 699, 626 cm^{-1} ;

^1H NMR (300 MHz, CDCl_3) δ 7.10-7.75, 6.65-6.75, 4.85, 3.10-3.70, 2.70-2.90, 2.45-2.60, 2.10-2.30, 1.50-1.95;

MS (ESI) m/z 580 (M^+), 578 (M^-).

10 Step 4. Preparation of α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(2-hydroxyethyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.


A solution of α -[2-[(3,4-difluorobenzoyl)amino]ethyl]-*N*-benzyloxy-3-(2-hydroxyethyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (117 mg, 0.202 mmol) is dissolved in EtOH (3 mL) and purged with N_2 . Pearlman's catalyst (10 mg) is
15 added and the atmosphere is replaced with H_2 . After 6 hours, the mixture is filtered through celite, washing the residual solids with MeOH, EtOH, and CH_2Cl_2 . The filtrate is concentrated and resubjected to the same procedure. The recovered material (99 mg) is purified by silica gel chromatography (8 g SG; 5, 10% MeOH/ CHCl_3) to give 45 mg of a white, amorphous solid. The solid is triturated
20 with Et_2O /hexane, filtered, and dried. This provides 39 mg (40%) of the title compound as a white, powdery solid (mp 135-137 $^\circ\text{C}$):

IR (mineral oil) 3202, 3089, 3063, 3029, 1670, 1648, 1633, 1601, 1564, 1515, 1499, 1435, 1331, 1320, 1299 cm^{-1} ;

^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 8.77, 8.40-8.55, 7.80-7.90, 7.65-7.75, 7.45-7.60,
25 7.10-7.30, 4.30-4.40, 3.00-3.50, 2.60-2.75, 2.10-2.45, 1.50-1.90;

MS (FAB) m/z 490 (MH^+), 489, 474, 457, 439, 299, 246, 141, 105.

EXAMPLE 96 Preparation of [R-(R^* , S^*)]- α -[2-[(3-Fluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(3-hydroxypropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.



$[\alpha]_D^{25} = +13^\circ$ (c 0.71, CHCl_3);

IR (mineral oil) 3233, 3085, 3064, 3026, 1662, 1586, 1547, 1497, 1484, 1319, 1299, 1271, 1225, 751, 701 cm^{-1} ;


^1H NMR (300 MHz, CDCl_3) δ 7.45-7.60, 7.05-7.45, 3.10-3.65, 2.70-2.90, 2.45-2.60,

5 1.15-2.25;


MS (EI) m/z 485 (M^+), 248, 247, 202, 178, 156, 123, 105, 104, 95, 56.

Following the general procedures outlined in EXAMPLES 28-29 or 30-34 and making non-critical variations, the following compounds may be prepared.


10 **EXAMPLE 97** Preparation of [*S*-(*R**,*R**)]-*N*³-hydroxy-*N*¹-methyl- α^1 -(1-methylethyl)-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide.




EXAMPLE 98 Preparation of [*S*-(*R**,*R**)]-*N*¹-cyclopropyl-*N*³-hydroxy- α^1 -(1-methylethyl)-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide.




EXAMPLE 99 Preparation of $[S-(R^*,R^*)]-N^3$ -hydroxy- α^1 -(1-methylethyl)-3-(2-methylpropyl)-2-oxo- N^1 -phenyl-1,3-pyrrolidinediacetamide.




EXAMPLE 100 Preparation of $[S-(R^*,R^*)]-N^1$ -(4-fluorophenyl)- N^3 -hydroxy- α^1 -(1-methylethyl)-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide.




EXAMPLE 101 Preparation of $[S-(R^*,R^*)]-N^3$ -hydroxy- α^1 -(1-methylethyl)-3-(2-methylpropyl)-2-oxo- N^1 -(4-pyridinyl)-1,3-pyrrolidinediacetamide.




EXAMPLE 102 Preparation of [*S*-(*R*^{*},*R*^{*})]- α ¹-*tert*-butyl-*N*¹-cyclopropyl-*N*³-hydroxy-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide.




EXAMPLE 103 Preparation of [*S*-(*R*^{*},*R*^{*})]- α ¹-*tert*-butyl-*N*³-hydroxy-3-(2-methylpropyl)-2-oxo-*N*¹-phenyl-1,3-pyrrolidinediacetamide.




EXAMPLE 104 Preparation of [*S*-(*R*^{*},*R*^{*})]- α ¹-*tert*-butyl-*N*¹-(4-fluorophenyl)-*N*³-hydroxy-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide.




EXAMPLE 105 Preparation of [*S*-(*R**,*R**)]- α ¹-*tert*-butyl-*N*³-hydroxy-3-(2-methylpropyl)-2-oxo-*N*¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.



EXAMPLE 106 Preparation of [*S*-(*R**,*R**)]- α ¹-cyclohexyl-*N*³-hydroxy-3-(2-methylpropyl)-2-oxo-*N*¹-phenyl-1,3-pyrrolidinediacetamide.




EXAMPLE 107 Preparation of [*S*-(*R**,*R**)]- α ¹-cyclohexyl-*N*³-hydroxy-3-(2-methylpropyl)-2-oxo-*N*¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.



EXAMPLE 108 Preparation of [*S*-(*R**,*R**)]-3-(cyclopentylmethyl)-*N*³-hydroxy-*N*¹-methyl- α ¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide.


5



10

EXAMPLE 109 Preparation of [*S*-(*R**,*R**)]-3-(cyclopentylmethyl)-*N*¹-cyclopropyl-*N*³-hydroxy- α ¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide.


15



20

EXAMPLE 110 Preparation of [*S*-(*R**,*R**)]-3-(cyclopentylmethyl)-*N*³-hydroxy- α ¹-(1-methylethyl)-2-oxo-*N*¹-phenyl-1,3-pyrrolidinediacetamide.


25




30

35


EXAMPLE 111 Preparation of [S-(R*,R*)]-3-(cyclopentylmethyl)-N¹-(4-fluorophenyl)-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide.



EXAMPLE 112 Preparation of [S-(R*,R*)]-3-(cyclopentylmethyl)-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.




EXAMPLE 113 Preparation of [S-(R*,R*)]-α¹-tert-butyl-3-(cyclopentylmethyl)-N³-hydroxy-N¹-methyl-2-oxo-1,3-pyrrolidinediacetamide.



EXAMPLE 114 Preparation of [S-(R*,R*)]- α^1 -tert-butyl-3-(cyclopentylmethyl)-N¹-cyclopropyl-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide.


5



10

EXAMPLE 115 Preparation of [S-(R*,R*)]- α^1 -tert-butyl-3-(cyclopentylmethyl)-N³-hydroxy-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide.


15



20


EXAMPLE 116 Preparation of [S-(R*,R*)]- α^1 -tert-butyl-3-(cyclopentylmethyl)-N¹-(4-fluorophenyl)-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide.

25




30


EXAMPLE 117 Preparation of [*S*-(*R*^{*},*R*^{*})]- α ¹-*tert*-butyl-3-(cyclopentylmethyl)-*N*³-hydroxy-2-oxo-*N*¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.



EXAMPLE 118 Preparation of [*S*-(*R*^{*},*R*^{*})]- α ¹-cyclohexyl-3-(cyclopentylmethyl)-*N*³-hydroxy-*N*¹-methyl-2-oxo-1,3-pyrrolidinediacetamide.




EXAMPLE 119 Preparation of [*S*-(*R*^{*},*R*^{*})]- α ¹-cyclohexyl-3-(cyclopentylmethyl)-*N*¹-cyclopropyl-*N*³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide.



EXAMPLE 120 Preparation of [S-(R*,R*)]- α^1 -cyclohexyl-3-(cyclopentylmethyl)-
N³-hydroxy-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide.


5



10

EXAMPLE 121 Preparation of [S-(R*,R*)]- α^1 -cyclohexyl-3-(cyclopentylmethyl)-
N¹-(4-fluorophenyl)-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide.


15



20

EXAMPLE 122 Preparation of [S-(R*,R*)]- α^1 -cyclohexyl-3-(cyclopentylmethyl)-
N³-hydroxy-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.


25




30

35


EXAMPLE 123 Preparation of $[S-(R^*,R^*)]$ - N^3 -hydroxy- N^1 -methyl- α^1 -(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide.




EXAMPLE 124 Preparation of $[S-(R^*,R^*)]$ - N^1 -cyclopropyl- N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide.




EXAMPLE 125 Preparation of $[S-(R^*,R^*)]$ - N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo- N^1 -phenyl-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide.




EXAMPLE 126 Preparation of [*S*-(*R*^{*},*R*^{*})]-*N*¹-(4-fluorophenyl)-*N*³-hydroxy- α ¹-(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide.




EXAMPLE 127 Preparation of [*S*-(*R*^{*},*R*^{*})]-*N*³-hydroxy- α ¹-(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-*N*¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.




EXAMPLE 128 Preparation of [*S*-(*R*^{*},*R*^{*})]- α ¹-*tert*-butyl-*N*³-hydroxy-*N*¹-methyl-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide.




EXAMPLE 129 Preparation of $[S-(R^*,R^*)]-\alpha^1$ -*tert*-butyl- N^1 -cyclopropyl- N^3 -hydroxy-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide.



EXAMPLE 130 Preparation of $[S-(R^*,R^*)]-\alpha^1$ -*tert*-butyl- N^3 -hydroxy-2-oxo- N^1 -phenyl-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide.




EXAMPLE 131 Preparation of $[S-(R^*,R^*)]-\alpha^1$ -*tert*-butyl- N^1 -(4-fluorophenyl)- N^3 -hydroxy-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide.



EXAMPLE 132 Preparation of [*S*-(*R**,*R**)]- α ¹-*tert*-butyl-*N*³-hydroxy-2-oxo-3-(3-phenylpropyl)-*N*¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.


5



10

EXAMPLE 133 Preparation of [*S*-(*R**,*R**)]- α ¹-cyclohexyl-*N*³-hydroxy-*N*¹-methyl-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide.


15



20


EXAMPLE 134 Preparation of [*S*-(*R**,*R**)]- α ¹-cyclohexyl-*N*¹-cyclopropyl-*N*³-hydroxy-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide.

25




30


EXAMPLE 135 Preparation of $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl- N^3 -hydroxy-2-oxo- N^1 -phenyl-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide.



EXAMPLE 136 Preparation of $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl- N^1 -(4-fluorophenyl)- N^3 -hydroxy-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide.




EXAMPLE 137 Preparation of $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl- N^3 -hydroxy-2-oxo-3-(3-phenylpropyl)- N^1 -(4-pyridinyl)-1,3-pyrrolidinediacetamide.



EXAMPLE 138 Preparation of $[S-(R^*,R^*)]$ -3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy- N^1 -methyl- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide.


5



10

EXAMPLE 139 Preparation of $[S-(R^*,R^*)]$ - N^1 -cyclopropyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide.


15



20

EXAMPLE 140 Preparation of $[S-(R^*,R^*)]$ -3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo- N^1 -phenyl-1,3-pyrrolidinediacetamide.


25



30

EXAMPLE 141 Preparation of [S-(R*,R*)]-N¹-(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]-N³-hydroxy- α ¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide.


5



10

EXAMPLE 142 Preparation of [S-(R*,R*)]-3-[3-(4-fluorophenyl)propyl]-N³-hydroxy- α ¹-(1-methylethyl)-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.


15



20

EXAMPLE 143 Preparation of [S-(R*,R*)]- α ¹-tert-butyl-3-[3-(4-fluorophenyl)propyl]-N³-hydroxy-N¹-methyl-2-oxo-1,3-pyrrolidinediacetamide.

25




30

35

EXAMPLE 144 Preparation of $[S-(R^*,R^*)]-\alpha^1$ -*tert*-butyl- N^1 -cyclopropyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide.


5



10

EXAMPLE 145 Preparation of $[S-(R^*,R^*)]-\alpha^1$ -*tert*-butyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo- N^1 -phenyl-1,3-pyrrolidinediacetamide.


15



20


EXAMPLE 146 Preparation of $[S-(R^*,R^*)]-\alpha^1$ -*tert*-butyl- N^1 -(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide.

25




30


EXAMPLE 147 Preparation of $[S-(R^*,R^*)]-\alpha^1$ -*tert*-butyl-3-[3-(4-fluorophenyl)propyl]-*N*³-hydroxy-2-oxo-*N*¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.




EXAMPLE 148 Preparation of $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl-3-[3-(4-fluorophenyl)propyl]-*N*³-hydroxy-*N*¹-methyl-2-oxo-1,3-pyrrolidinediacetamide.




EXAMPLE 149 Preparation of $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl-*N*¹-cyclopropyl-3-[3-(4-fluorophenyl)propyl]-*N*³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide.




EXAMPLE 150 Preparation of [S-(R*,R*)]- α^1 -cyclohexyl-3-[3-(4-fluorophenyl)propyl]-N³-hydroxy-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide.




EXAMPLE 151 Preparation of [S-(R*,R*)]- α^1 -cyclohexyl-N¹-(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide.




EXAMPLE 152 Preparation of [S-(R*,R*)]- α^1 -cyclohexyl-3-[3-(4-fluorophenyl)propyl]-N³-hydroxy-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.




EXAMPLE 153 Preparation of [*S*-(*R*^{*},*R*^{*})]-3-[3-(biphen-4-yl)propyl]-*N*³-hydroxy-*N*¹-methyl- α ¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide.



EXAMPLE 154 Preparation of [*S*-(*R*^{*},*R*^{*})]-3-[3-(biphen-4-yl)propyl]-*N*¹-cyclopropyl-*N*³-hydroxy- α ¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide.




EXAMPLE 155 Preparation of [*S*-(*R*^{*},*R*^{*})]-3-[3-(biphen-4-yl)propyl]-*N*³-hydroxy- α ¹-(1-methylethyl)-2-oxo-*N*¹-phenyl-1,3-pyrrolidinediacetamide.



EXAMPLE 156 Preparation of [*S*-(*R*^{*},*R*^{*})]-3-[3-(biphen-4-yl)propyl]-*N*¹-(4-fluorophenyl)-*N*³-hydroxy- α ¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide.

5


10



EXAMPLE 157 Preparation of [*S*-(*R*^{*},*R*^{*})]-3-[3-(biphen-4-yl)propyl]-*N*³-hydroxy- α ¹-(1-methylethyl)-2-oxo-*N*¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.

15


20



EXAMPLE 158 Preparation of [*S*-(*R*^{*},*R*^{*})]-3-[3-(biphen-4-yl)propyl]- α ¹-*tert*-butyl-*N*³-hydroxy-*N*¹-methyl-2-oxo-1,3-pyrrolidinediacetamide.


30

35



EXAMPLE 159 Preparation of [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]- α^1 -tert-butyl-N¹-cyclopropyl-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide.


5



10

EXAMPLE 160 Preparation of [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]- α^1 -tert-butyl-N³-hydroxy-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide.


15



20

EXAMPLE 161 Preparation of [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]- α^1 -tert-butyl-N¹-(4-fluorophenyl)-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide.

25




30

35

EXAMPLE 162 Preparation of [*S*-(*R*^{*},*R*^{*})]-3-[3-(biphen-4-yl)propyl]- α^1 -*tert*-butyl-*N*³-hydroxy-2-oxo-*N*¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.

5


10



EXAMPLE 163 Preparation of [*S*-(*R*^{*},*R*^{*})]-3-[3-(biphen-4-yl)propyl]- α^1 -cyclohexyl-*N*³-hydroxy-*N*¹-methyl-2-oxo-1,3-pyrrolidinediacetamide.

15


20



25 EXAMPLE 164 Preparation of [*S*-(*R*^{*},*R*^{*})]-3-[3-(biphen-4-yl)propyl]- α^1 -cyclohexyl-*N*¹-cyclopropyl-*N*³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide.

30


35



EXAMPLE 165 Preparation of [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]- α^1 -cyclohexyl-*N*³-hydroxy-2-oxo-*N*¹-phenyl-1,3-pyrrolidinediacetamide.

5


10



EXAMPLE 166 Preparation of [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]- α^1 -cyclohexyl-*N*¹-(4-fluorophenyl)-*N*³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide.

15

20




25


EXAMPLE 167 Preparation of [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]- α^1 -cyclohexyl-*N*³-hydroxy-2-oxo-*N*¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.

30


35




EXAMPLE 168 Preparation of [*S*-(*R*^{*},*R*^{*})]-3-[3-(4'-fluorobiphen-4-yl)propyl]-*N*³-hydroxy-*N*¹-methyl- α ¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide.



EXAMPLE 169 Preparation of [*S*-(*R*^{*},*R*^{*})]-3-[3-(4'-fluorobiphen-4-yl)propyl]-*N*³-cyclopropyl-hydroxy- α ¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide.




EXAMPLE 170 Preparation of [*S*-(*R*^{*},*R*^{*})]-3-[3-(4'-fluorobiphen-4-yl)propyl]-*N*³-hydroxy- α ¹-(1-methylethyl)-2-oxo-*N*¹-phenyl-1,3-pyrrolidinediacetamide.



EXAMPLE 171 Preparation of [S-(R*,R*)]-3-[3-(4'-fluorobiphen-4-yl)propyl]-N¹-(4-fluorophenyl)-N³-hydroxy- α ¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide.

5


10



EXAMPLE 172 Preparation of [S-(R*,R*)]-3-[3-(4'-fluorobiphen-4-yl)propyl]-N³-hydroxy- α ¹-(1-methylethyl)-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.

15

20




25

EXAMPLE 173 Preparation of [S-(R*,R*)]- α ¹-tert-butyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-N³-hydroxy-N¹-methyl-2-oxo-1,3-pyrrolidinediacetamide.

30


35



EXAMPLE 174 Preparation of [*S*-(*R*^{*},*R*^{*})]- α^1 -*tert*-butyl-*N*¹-cyclopropyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-*N*³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide.

5


10



EXAMPLE 175 Preparation of [*S*-(*R*^{*},*R*^{*})]- α^1 -*tert*-butyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-*N*³-hydroxy-2-oxo-*N*¹-phenyl-1,3-pyrrolidinediacetamide.

15


20



EXAMPLE 176 Preparation of [*S*-(*R*^{*},*R*^{*})]- α^1 -*tert*-butyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-*N*¹-(4-fluorophenyl)-*N*³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide.


25

30



EXAMPLE 177 Preparation of [*S*-(*R**,*R**)]- α^1 -*tert*-butyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-*N*³-hydroxy-2-oxo-*N*¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.


5



10

EXAMPLE 178 Preparation of [*S*-(*R**,*R**)]- α^1 -cyclohexyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-*N*³-hydroxy-*N*¹-methyl-2-oxo-1,3-pyrrolidinediacetamide.


15



20

EXAMPLE 179 Preparation of [*S*-(*R**,*R**)]- α^1 -cyclohexyl-*N*¹-cyclopropyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-*N*³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide.

25




30

35

EXAMPLE 180 Preparation of [*S*-(*R*^{*},*R*^{*})]- α ¹-cyclohexyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-*N*³-hydroxy-2-oxo-*N*¹-phenyl-1,3-pyrrolidinediacetamide.


5



10

EXAMPLE 181 Preparation of [*S*-(*R*^{*},*R*^{*})]- α ¹-cyclohexyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-*N*¹-(4-fluorophenyl)-*N*³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide.


15



20

EXAMPLE 182 Preparation of [*S*-(*R*^{*},*R*^{*})]- α ¹-cyclohexyl-3-[3-(4'-fluorobiphen-4-yl)propyl]-*N*³-hydroxy-2-oxo-*N*¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.

25




30

35

EXAMPLE 183 Preparation of [S-(R*,R*)]-3-heptyl-N³-hydroxy-N¹-methyl- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide.


5



10

EXAMPLE 184 Preparation of [S-(R*,R*)]-N¹-cyclopropyl-3-heptyl-N³-hydroxy- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide.


15



20

EXAMPLE 185 Preparation of [S-(R*,R*)]-3-heptyl-N³-hydroxy- α^1 -(1-methylethyl)-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide.

25




30

EXAMPLE 186 Preparation of [*S*-(*R*^{*},*R*^{*})]-3-heptyl-*N*¹-(4-fluorophenyl)-*N*³-hydroxy- α ¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide.

5


10



EXAMPLE 187 Preparation of [*S*-(*R*^{*},*R*^{*})]-3-heptyl-*N*³-hydroxy- α ¹-(1-methylethyl)-2-oxo-*N*¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.

15


20




EXAMPLE 188 Preparation of [*S*-(*R*^{*},*R*^{*})]- α ¹-*tert*-butyl-3-heptyl-*N*³-hydroxy-*N*¹-methyl-2-oxo-1,3-pyrrolidinediacetamide.

25


30




EXAMPLE 189 Preparation of [S-(R*,R*)]- α^1 -*tert*-butyl-*N*¹-cyclopropyl-3-heptyl-*N*³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide.




EXAMPLE 190 Preparation of [S-(R*,R*)]- α^1 -*tert*-butyl-3-heptyl-*N*³-hydroxy-2-oxo-*N*¹-phenyl-1,3-pyrrolidinediacetamide.




EXAMPLE 191 Preparation of [S-(R*,R*)]- α^1 -*tert*-butyl-*N*¹-(4-fluorophenyl)-3-heptyl-*N*³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide.




EXAMPLE 192 Preparation of [*S*-(*R**,*R**)]- α^1 -*tert*-butyl-3-heptyl-*N*³-hydroxy-2-oxo-*N*¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.



EXAMPLE 193 Preparation of [*S*-(*R**,*R**)]- α^1 -cyclohexyl-3-heptyl-*N*³-hydroxy-*N*¹-methyl-2-oxo-1,3-pyrrolidinediacetamide.




EXAMPLE 194 Preparation of [*S*-(*R**,*R**)]- α^1 -cyclohexyl-*N*¹-cyclopropyl-3-heptyl-*N*³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide.



EXAMPLE 195 Preparation of $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl-3-heptyl- N^3 -hydroxy-2-oxo- N^1 -phenyl-1,3-pyrrolidinediacetamide.


5



10

EXAMPLE 196 Preparation of $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl-3-heptyl- N^1 -(4-fluorophenyl)- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide.


15




20

25 EXAMPLE 197 Preparation of $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl-3-heptyl- N^3 -hydroxy-2-oxo- N^1 -(4-pyridinyl)-1,3-pyrrolidinediacetamide.

30



SCHEME A-1




SCHEME A-2

5




10




11

10




12




13

15




14



15

20




16

25


30

35


SCHEME A-3



SCHEME A-4




SCHEME A-5



SCHEME B

5




4

10



15




42

20



25




43

30

35


SCHEME C-1

5




44

10




45

15



46


20



47

25





30



48


35

SCHEME C-2




35


SCHEME D




53




54




55



56



57



58


CLAIMS

We claim:

1. A compound of formula I

5

10



I

- 15 or pharmaceutical acceptable salts thereof wherein

X is

- a) $-(CH_2)-$,
- b) $-NR_5-$, or
- c) $-C(=O)-$;

20 Y is


- a) $-(CH_2)-$, or
- b) $-NR_5$;

with the proviso that when X is $-NR_5-$, then Y is $-(CH_2)-$;

R₁ is

- 25 a) H,
- b) C₁₋₂₀ alkyl,
- c) $-(CH_2)_i$ -Aryl,
- d) $-(CH_2)_i$ -O-R₅,
- e) $-(CH_2)_i$ -Het,
- 30 f) $-(CH_2)_i$ -CO₂ R₅,
- g) $-(CH_2)_i$ -C(=O)NHR₅,
- h) $-(CH_2)_i$ -NR₆R₇,
- i) $-(CH_2)_i$ -SO₂-Aryl,
- j) $-(CH_2)_j$ cycloalkyl, or
- 35 k) $-(CH_2)_j$ -Aryl-Aryl;

R₂ is



- 5
- a) H,
 - b) C₁₋₂₀ alkyl,
 - c) -(CH₂)_j -R₈,
 - d) -(CH₂)_j -OR₅,
 - e) -CHCR₅=CR₅R₅,
 - f) -NHR₅,
 - g) -(CH₂)_jNR₆R₇,
 - h) -NHSO₂R₅,
 - i) -(CH₂)_j -C(=O)NR₆R₇,
 - 10 j) -(CH₂)_j -NR₅C(=O)R₅,
 - k) -(CH₂)_j -NR₅SO₂R₅, or
 - l) -(CH₂)_j -N(COR₅)₂;
- R₃ is
- 15
- a) H,
 - b) C₁₋₆ alkyl,
 - c) -(CH₂)_j -Aryl,
 - d) -(CH₂)_j -Het,
 - e) -(CH₂)_j -C₃₋₆ cycloalkyl, or
 - f) -C(=O)NHR₅;
- 20 R₄ is
- a) H,
 - b) -C(=O)NHR₅,
 - c) -C(=O)NR₆R₇,
 - d) -C(=O)NH(CH₂)_kNR₆R₇,
 - 25 e) -C(=O)NH(CH₂)_j -Aryl,
 - f) -C(=O)NH(CH₂)_k-O-(CH₂)_kNR₆R₇,
 - g) -C(=O)NH(CH₂)_k-S-(CH₂)_jNR₆R₇,
 - h) -C(=O)NH(CH₂)_k-NHSO₂-Aryl,
 - i) C(=O)NH(CH₂)_k-NHSO₂-NR₆R₇, or
 - 30 j)  ;
- R₅ is
- 35
- a) H,
 - b) C₁₋₆ alkyl,
 - c) -(CH₂)_j -Aryl,

- d) $-(CH_2)_j$ -Aryl - Aryl,
 e) $-(CH_2)_j$ -Aryl $-(CH_2)_j$ -Aryl,
 f) $(CH_2)_j$ -Het, or
 g) $-(CH_2)_j$ -cycloalkyl
- 5 R_6 and R_7 may be the same or differently
- a) H,
 b) C_{1-6} alkyl,
 c) $-(CH_2)_j$ -Aryl,
 d) Q, or
- 10 e) R_6 and R_7 taken together with the linking N-atom form azetidiny, pyrrolidinyl, piperazinyl, piperidinyl, or morpholinyl, optionally substituted with one or more C_{1-4} alkyl;

R_8 is

- a) $-S-R_5$,
 15 b) $-SO-R_5$,
 c) $-SO_2-R_5$,
 d) $-S-(CH_2)_j$ -Het,
 e) $-NHCO_2R_5$,
 f) piperidinyl,


20




30




35




5




10



15



20



25

 R_9 is

- a) halogen,
 b) C_{1-6} alkyl,
 c) $-OR_5$,
 d) $-NR_5R_5$,
 e) $-CONHR_5$,
 f) $-SO_2NHR_5$,
 g) $-NHSO_2R_5$,
 h) $-NO_2$,

30

35

i) $-\text{CO}_2\text{R}_5$, or

j) $-\text{CF}_3$;

R_{10} is

- 5 a) H,
 b) OH,
 c) OR_5 ,
 d) NHR_5 , or
 e) $-(\text{CH}_2)_j-\text{OR}_5$;

Aryl is phenyl, optionally substituted with one or more of the following:

- 10 a) halogen,
 b) C_{1-10} alkyl,
 c) $-\text{OR}_5$,
 d) $-\text{NR}_5\text{R}_5$,
 e) $-\text{CONHR}_5$,
 15 f) $-\text{SO}_2\text{NHR}_5$,
 g) $-\text{NHSO}_2\text{R}_5$,
 h) $-\text{NO}_2$,
 i) $-\text{CO}_2\text{R}_5$, or
 j) $-\text{CF}_3$;

20 Het is

a 5-, or 6-membered heteroaromatic moiety having one or more atoms selected from the group consisting of N, O, and S;

Q is

a saturated 5-, or 6-membered heterocyclic moiety having 1-2 atoms selected

25 from the group consisting of N, O, and S;

i is 1, 2, 3, 4, 5 or 6;


j is 0, 1, 2, 3, or 4;

k is 2, 3, or 4;

n is 0, 1, 2, 3, or 4;

30 C_{1-6} alkyl, C_{1-10} alkyl, or C_{1-20} alkyl in each of the above definitions, may be each and independently substituted with one to three halogen, hydroxy, or cyano; and with the proviso that when R_1 is methylbutyl R_4 is other than H.


2. A compound of formula I according to claim 1 which is an optically pure
 35 enantiomer having structure II.



5

II


3. A compound of formula I according to claim 1 which is an optically pure
10 enantiomer having structure III.



15

III

- 20 4. A compound of formula I according to claim 1 which is an optically pure
enantiomer having structure IV.




25

IV

5. A compound of formula I according to claim 1 which is an optically pure
enantiomer having structure V.


35



5

6. A compound of formula I according to claim 1 which is an optically pure enantiomer having structure VI.

10




15

VI

7. A compound of formula I according to claim 1 which is an optically pure enantiomer having structure VII.

20



25

VII

8. A compound of claim 1 wherein R_1 is 2-methylpropyl, or 3-methylbutyl.

30

9. A compound of claim 1 wherein R_2 is selected from the group consisting of H, methyl, 2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(1,3-dihydro-1,3-dioxo-2H-naphthoisoindol-2-yl)ethyl, 2-(4,5,6,7-tetrafluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(5,6-dichloro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(5-amino-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(4-nitro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(5-nitro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(4-fluoro-1,3-

35

dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(4,7-difluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(5-fluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl, 2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl, 2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl, 2-(2-thienylthio)propyl, and 2-(2-thienylthio)methyl.

5

10. A compound of claim 1 wherein R_3 is selected from the group consisting of H, 2-methylpropyl, cyclohexylmethyl, benzyl, and phenyl.

11. A compound of claim 1 wherein R_4 is H or acetamide.

10

12. A compound of claim 1 wherein said compound of formula I is

1a) N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,

1b) (3S)-N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,

1c) N-Hydroxy- α -methyl-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,

1d) α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,

1e) (3S)- α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,

1f) α -[2-(1,3-Dihydro-1,3-dioxo-2H-naphthoisoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,

1g) N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(4,5,6,7-tetrafluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-pyrrolidineacetamide,

1h) α -[2-(5,6-Dichloro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,

1i) α -[2-(5-Amino-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,

1j) N-Hydroxy-3-(2-methylpropyl)- α -[2-(4-nitro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,

1k) N-Hydroxy-3-(2-methylpropyl)- α -[2-(5-nitro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,

1l) α -[2-(4-Fluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,

1m) α -[2-(4,7-Difluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-

- hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 1n) α -[2-(5-Fluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 1o) α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 5 1p) α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 1q) N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(2-thienylthio)ethyl]-3-pyrrolidineacetamide,
- 10 1r) N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(2-thienylthio)propyl]-3-pyrrolidineacetamide,
- 1s) N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(2-thienylthio)methyl]-3-pyrrolidineacetamide,
- 1t) N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 15 1u) N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 1v) N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)-3-pyrrolidineacetamide,
- 20 1w) α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)-3-pyrrolidineacetamide,
- 1x) N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)- α -[2-(4,5,6,7-tetrafluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-pyrrolidineacetamide,
- 1y) 1-(3-Fluorophenyl)methyl)- α -[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetamide,
- 25 1z) α ³-[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N³-hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 2a) N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α ³-[2-(4,5,6,7-tetrafluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-1,3-pyrrolidinediacetamide,
- 30 2b) [S-(R*, R*)]-N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 2c) [S,R-(R*, R*)]- α ³-[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N³-hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 35 2d) [S-(R*, R*)]-N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,

- 2e) [S-(R*, R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo-N¹-(2-phenethyl)-α¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 2f) [S-(R*, R*)]-N³-Hydroxy-N¹-methyl-α¹,3-bis (2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 5 2g) [S-(R*, R*)]-α¹-(Cyclohexylmethyl)-N³-hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 2h) [S-(R*, R*)]-N³-Hydroxy-N¹-methyl-3-(3-methylbutyl)-2-oxo-α¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 2i) N-Hydroxy-3-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-3-
10 pyrrolidineacetamide,
- 2j) N-Hydroxy-3-methyl-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-4-imidazolidineacetamide,
- 2k) N-Hydroxy-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)-4-imidazolidineacetamide,
- 15 2l) N-Hydroxyl-4-(2-methylpropyl)-5-oxo-1-(2-phenylethyl)-4-pyrazolidineacetamide monohydrochloride,
- 2m) [S-(R*, R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo-N¹-phenyl-α¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 2n) [S-(R*, R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo-α¹-(phenylmethyl)-
20 N¹-(2-pyridinylmethyl)-1,3-pyrrolidinediacetamide,
- 2o) [S-(R*, R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo-α¹-(phenylmethyl)-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 2p) [S-(R*, R*)]-N¹-(4-Fluorophenyl)-N³-hydroxy-3-(2-methylpropyl)-2-oxo-α¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 25 2q) [S-(R*, R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo-α¹-(phenylmethyl)-N¹-[1-(phenylmethyl)-4-piperdiny]-1,3-pyrrolidinediacetamide,
- 2r) [S-(R*, R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo-α¹-(phenylmethyl)-N¹-(4-piperdiny)-1,3-pyrrolidinediacetamide,
- 2s) [S-(R*, R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo-α¹-(phenylmethyl)-
30 N¹-(4-pyridinylmethyl)-1,3-pyrrolidinediacetamide,
- 2t) [S-(R*, R*)]-N¹-(4-Fluorophenylmethyl)-N³-hydroxy-3-(2-methylpropyl)-2-oxo-α¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 2u) [S-(R*, R*)]-N³-Hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo-α¹-(2-phenylethyl)-1,3-pyrrolidinediacetamide,
- 35 2v) [S-(R*, R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo-α¹-(2-phenylethyl)-N¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,

- 2w) [S-(R*,R*)]-N³-Hydroxy- α ¹,3-bis(2-methylpropyl)-2-oxo-N¹-2-pyridinyl-1,3-pyrrolidinediacetamide,
- 2x) [S-(R*,R*)]- α ¹-Cyclohexyl-N³-hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 5 2y) [S-(R*,R*)]- α ¹-Cyclohexyl-N³-hydroxy-3-(2-methylpropyl)-2-oxo-N¹-2-pyridinyl-1,3-pyrrolidinediacetamide,
- 2z) [S-(R*,R*)]-3-(Cyclopentylmethyl)-N³-hydroxy-N¹-methyl-2-oxo- α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 3a) [S-(R*,R*)]-3-(Cyclopentylmethyl)-N³-hydroxy-N¹-methyl-2-oxo- α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 10 3b) [3S-[1(R*),3R*(R*)]]- α ³-[2-(Benzoylamino)ethyl]-N³-hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 3c) [S-(R*,R*)]-N³-Hydroxy-3-(2-methylpropyl)-N¹-[2-(4-morpholinyl)ethyl]-2-oxo- α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 15 3d) [S-(R*,R*)]-N-Hydroxy-3-(2-methylpropyl)-1-[2-(4-morpholinyl)-2-oxo-1-(phenylmethyl)ethyl]-2-oxo-3-pyrrolidineacetamide,
- 3e) [1(1S)-[1(R*(R*)), 3 α ,5 α]]-1-[2-(3,5-Dimethyl-1-piperazinyl)-2-oxo-1-(phenylmethyl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetamide,
- 3f) [S-(R*,R*)]-N³-Hydroxy-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-N¹-2-pyridinyl-1,3-pyrrolidinediacetamide,
- 20 3g) [3S-[1(R*),3R*(R*)]]- α ³-[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N³-hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo- α ¹-(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 3h) [S-(R*,R*)]- α ¹-Cyclohexyl-N¹-cyclopropylmethyl-N³-hydroxy-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 25 3i) [S-(R*,R*)]- α ¹-Cyclohexyl-N¹-(4-fluorophenyl)-N³-hydroxy-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 3j) [S-(R*,R*)]- α ¹-*tert*-Butyl-N³-hydroxy-N¹-methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 30 3k) N-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(5-propyloxy-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-pyrrolidineacetamide,
- 3l) [R-(R*,S*)]-5-Fluoro-1,3-dihydro-N-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1,3-dioxo-2H-isoindole-2-butanamide,
- 3m) α -[2-(5,6-Difluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 35

- 3n) *N*-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(5-trifluoromethyl-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-pyrrolidineacetamide,
- 3o) α -[2-(1,3,4,5,6,7-Hexahydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 5 3p) α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(3-phenylpropyl)-3-pyrrolidineacetamide,
- 3q) 1-[2-(4-Fluorophenyl)ethyl]- α -[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetamide,
- 3r) α -[2-(*o*-benzoic sulfimide)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-
10 (2-phenylethyl)-3-pyrrolidineacetamide,
- 3s) Ethyl Phenylmethyl [4-(hydroxyamino)-3-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-4-oxobutyl]imidodicarbonate,
- 3t) *S*-(*R*^{*},*R*^{*})-1,3-Dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1,3-dioxo-2H-isoindole-2-butanamide,
- 15 3u) 1,3-Dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-[2-(4-fluorophenyl)ethyl]-3-pyrrolidinyl]-1,3-dioxo-2H-isoindole-2-butanamide,
- 3v) α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 3w) [*R*-(*R*^{*},*S*^{*})- α -[2-[(3-Fluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(2-
20 methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 3x) α -[2-[(4-Fluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 3y) *N*-Hydroxy-3-(2-methylpropyl)- α -[2-[(3-nitrobenzoyl)amino]ethyl]-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 25 3z) α -[2-[(3-Fluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 4a) α -[2-[(3-Fluorobenzoyl)amino]ethyl]-1-[2-(4-fluorophenyl)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetamide,
- 4b) α -[2-[(4-Biphenylcarbonyl)amino]ethyl]-*N*-hydroxy-3-(2-methylpropyl)-
30 2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 4c) *N*-Hydroxy- α -[2-[(4-methylphenyl)sulfonyl]amino]ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 4d) α -[2-[(4-Fluorophenyl)sulfonyl]amino]ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 35 4e) *N*-Hydroxy- α -[2-[(4-methoxyphenyl)sulfonyl]amino]ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,

- 4f) *N*-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -2-
[(phenylsulfonyl)amino]ethyl]-3-pyrrolidineacetamide,
- 4g) $[R-(R^*,S^*)]$ - α -2-[[4-Fluorophenyl)sulfonyl]amino]ethyl]-*N*-hydroxy-3-
(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 5 4h) 5,6-Difluoro-1,3-dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-(2-
phenylethyl)-3-pyrrolidinyl]-1-oxo-2*H*-isoindole-2-butanamide,
- 4i) 1,3-Dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-
pyrrolidinyl]-1-oxo-2*H*-isoindole-2-butanamide,
- 4j) $[R-(R^*,S^*)]$ -6-Fluoro-1,3-dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-
10 oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1-oxo-2*H*-isoindole-2-butanamide,
- 4k) $[R-(R^*,S^*)]$ -5-Fluoro-1,3-dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-
oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1-oxo-2*H*-isoindole-2-butanamide,
- 4l) $[R-(R^*,S^*)]$ -5,6-Difluoro-1,3-dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-
oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1-oxo-2*H*-isoindole-2-butanamide,
- 15 4m) *N*-Hydroxy- α -[[[4-methoxyphenyl)sulfonyl]amino]-methyl]-3-(2-
methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (α R-diastereomer),
- 4n) *N*-Hydroxy- α -[[[4-methoxyphenyl)sulfonyl]amino]-methyl]-3-(2-
methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (α S-diastereomer),
- 4o) α -[[[4-Fluorophenyl)sulfonyl]amino]-*N*-hydroxy-3-(2-methylpropyl)-2-
20 oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (R-diastereomer),
- 4p) α -[[[4-Fluorophenyl)sulfonyl]amino]-*N*-hydroxy-3-(2-methylpropyl)-2-
oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (α S-diastereomer),
- 4q) α -2-[(3,4-Difluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(3-hydroxypropyl)-
2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 25 4r) α -2-[(3,4-Difluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(2-hydroxyethyl)-
2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 4s) $[R-(R^*,S^*)]$ - α -2-[(3-Fluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(3-
hydroxypropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 4t) $S-(R^*,R^*)$ - N^3 -hydroxy- N^1 -methyl- α^1 -(1-methylethyl)-3-(2-
30 methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 4u) $[S-(R^*,R^*)]$ - N^1 -cyclopropyl- N^3 -hydroxy- α^1 -(1-methylethyl)-3-(2-
methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide.,
- 4v) $[S-(R^*,R^*)]$ - N^3 -hydroxy- α^1 -(1-methylethyl)-3-(2-methylpropyl)-2-oxo-
 N^1 -phenyl-1,3-pyrrolidinediacetamide,
- 35 4w) $[S-(R^*,R^*)]$ - N^1 -(4-fluorophenyl)- N^3 -hydroxy- α^1 -(1-methylethyl)-3-(2-
methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,

- 4x) [S-(R*,R*)]-N³-hydroxy- α ¹-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 4y) [S-(R*,R*)]- α ¹-*tert*-butyl-N¹-cyclopropyl-N³-hydroxy-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 5 4z) [S-(R*,R*)]- α ¹-*tert*-butyl-N³-hydroxy-3-(2-methylpropyl)-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 5a) [S-(R*,R*)]- α ¹-*tert*-butyl-N¹-(4-fluorophenyl)-N³-hydroxy-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 5b) [S-(R*,R*)]- α ¹-*tert*-butyl-N³-hydroxy-3-(2-methylpropyl)-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 10 5c) [S-(R*,R*)]- α ¹-cyclohexyl-N³-hydroxy-3-(2-methylpropyl)-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 5d) [S-(R*,R*)]- α ¹-cyclohexyl-N³-hydroxy-3-(2-methylpropyl)-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 15 5e) [S-(R*,R*)]-3-(cyclopentylmethyl)-N³-hydroxy-N¹-methyl- α ¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 5f) [S-(R*,R*)]-3-(cyclopentylmethyl)-N¹-cyclopropyl-N³-hydroxy- α ¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 5g) [S-(R*,R*)]-3-(cyclopentylmethyl)-N³-hydroxy- α ¹-(1-methylethyl)-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 20 5h) [S-(R*,R*)]-3-(cyclopentylmethyl)-N¹-(4-fluorophenyl)-N³-hydroxy- α ¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 5i) [S-(R*,R*)]-3-(cyclopentylmethyl)-N³-hydroxy- α ¹-(1-methylethyl)-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 25 5j) [S-(R*,R*)]- α ¹-*tert*-butyl-3-(cyclopentylmethyl)-N³-hydroxy-N¹-methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 5k) [S-(R*,R*)]- α ¹-*tert*-butyl-3-(cyclopentylmethyl)-N¹-cyclopropyl-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 5l) [S-(R*,R*)]- α ¹-*tert*-butyl-3-(cyclopentylmethyl)-N³-hydroxy-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 30 5m) [S-(R*,R*)]- α ¹-*tert*-butyl-3-(cyclopentylmethyl)-N¹-(4-fluorophenyl)-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 5n) [S-(R*,R*)]- α ¹-*tert*-butyl-3-(cyclopentylmethyl)-N³-hydroxy-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 35 5o) [S-(R*,R*)]- α ¹-cyclohexyl-3-(cyclopentylmethyl)-N³-hydroxy-N¹-methyl-2-oxo-1,3-pyrrolidinediacetamide,

- 5p) [S-(R*,R*)]- α^1 -cyclohexyl-3-(cyclopentylmethyl)-N¹-cyclopropyl-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 5q) [S-(R*,R*)]- α^1 -cyclohexyl-3-(cyclopentylmethyl)-N³-hydroxy-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 5 5r) [S-(R*,R*)]- α^1 -cyclohexyl-3-(cyclopentylmethyl)-N¹-(4-fluorophenyl)-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 5s) [S-(R*,R*)]- α^1 -cyclohexyl-3-(cyclopentylmethyl)-N³-hydroxy-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 5t) [S-(R*,R*)]-N³-hydroxy-N¹-methyl- α^1 -(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 10 5u) [S-(R*,R*)]-N¹-cyclopropyl-N³-hydroxy- α^1 -(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 5v) [S-(R*,R*)]-N³-hydroxy- α^1 -(1-methylethyl)-2-oxo-N¹-phenyl-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 15 5w) [S-(R*,R*)]-N¹-(4-fluorophenyl)-N³-hydroxy- α^1 -(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 5x) [S-(R*,R*)]-N³-hydroxy- α^1 -(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 5y) [S-(R*,R*)]- α^1 -tert-butyl-N³-hydroxy-N¹-methyl-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 20 5z) [S-(R*,R*)]- α^1 -tert-butyl-N¹-cyclopropyl-N³-hydroxy-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 6a) [S-(R*,R*)]- α^1 -tert-butyl-N³-hydroxy-2-oxo-N¹-phenyl-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 25 6b) [S-(R*,R*)]- α^1 -tert-butyl-N¹-(4-fluorophenyl)-N³-hydroxy-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 6c) [S-(R*,R*)]- α^1 -tert-butyl-N³-hydroxy-2-oxo-3-(3-phenylpropyl)-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamid,
- 6d) [S-(R*,R*)]- α^1 -cyclohexyl-N³-hydroxy-N¹-methyl-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 30 6e) [S-(R*,R*)]- α^1 -cyclohexyl-N¹-cyclopropyl-N³-hydroxy-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 6f) [S-(R*,R*)]- α^1 -cyclohexyl-N³-hydroxy-2-oxo-N¹-phenyl-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,
- 35 6g) [S-(R*,R*)]- α^1 -cyclohexyl-N¹-(4-fluorophenyl)-N³-hydroxy-2-oxo-3-(3-phenylpropyl)-1,3-pyrrolidinediacetamide,

- 6h) $[S-(R^*, R^*)]-\alpha^1$ -cyclohexyl- N^3 -hydroxy-2-oxo-3-(3-phenylpropyl)- N^1 -(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 6i) $[S-(R^*, R^*)]-3$ -[3-(4-fluorophenyl)propyl]- N^3 -hydroxy- N^1 -methyl- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 5 6j) $[S-(R^*, R^*)]-N^1$ -cyclopropyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 6k) $[S-(R^*, R^*)]-3$ -[3-(4-fluorophenyl)propyl]- N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo- N^1 -phenyl-1,3-pyrrolidinediacetamide,
- 6l) $[S-(R^*, R^*)]-N^1$ -(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 10 6m) $[S-(R^*, R^*)]-3$ -[3-(4-fluorophenyl)propyl]- N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo- N^1 -(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 6n) $[S-(R^*, R^*)]-\alpha^1$ -*tert*-butyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy- N^1 -methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 15 6o) $[S-(R^*, R^*)]-\alpha^1$ -*tert*-butyl- N^1 -cyclopropyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 6p) $[S-(R^*, R^*)]-\alpha^1$ -*tert*-butyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo- N^1 -phenyl-1,3-pyrrolidinediacetamide,
- 6q) $[S-(R^*, R^*)]-\alpha^1$ -*tert*-butyl- N^1 -(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 20 6r) $[S-(R^*, R^*)]-\alpha^1$ -*tert*-butyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo- N^1 -(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 6s) $[S-(R^*, R^*)]-\alpha^1$ -cyclohexyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy- N^1 -methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 25 6t) $[S-(R^*, R^*)]-\alpha^1$ -cyclohexyl- N^1 -cyclopropyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 6u) $[S-(R^*, R^*)]-\alpha^1$ -cyclohexyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo- N^1 -phenyl-1,3-pyrrolidinediacetamide,
- 6v) $[S-(R^*, R^*)]-\alpha^1$ -cyclohexyl- N^1 -(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 30 6w) $[S-(R^*, R^*)]-\alpha^1$ -cyclohexyl-3-[3-(4-fluorophenyl)propyl]- N^3 -hydroxy-2-oxo- N^1 -(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 6x) $[S-(R^*, R^*)]-3$ -[3-(biphen-4-yl)propyl]- N^3 -hydroxy- N^1 -methyl- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 35 6y) $[S-(R^*, R^*)]-3$ -[3-(biphen-4-yl)propyl]- N^1 -cyclopropyl- N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,

- 6z) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 7a) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-N¹-(4-fluorophenyl)-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 5 7b) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 7c) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-tert-butyl-N³-hydroxy-N¹-methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 7d) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-tert-butyl-N¹-cyclopropyl-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 10 7e) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-tert-butyl-N³-hydroxy-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 7f) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-tert-butyl-N¹-(4-fluorophenyl)-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 15 7g) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-tert-butyl-N³-hydroxy-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 7h) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-cyclohexyl-N³-hydroxy-N¹-methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 7i) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-cyclohexyl-N¹-cyclopropyl-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 20 7j) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-cyclohexyl-N³-hydroxy-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 7k) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-cyclohexyl-N¹-(4-fluorophenyl)-N³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 25 7l) [S-(R*,R*)]-3-[3-(biphen-4-yl)propyl]-α¹-cyclohexyl-N³-hydroxy-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 7m) [S-(R*,R*)]-3-[3-(4'-fluorobiphen-4-yl)propyl]-N³-hydroxy-N¹-methyl-α¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 7n) [S-(R*,R*)]-3-[3-(4'-fluorobiphen-4-yl)propyl]-N¹-cyclopropyl-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 30 7o) [S-(R*,R*)]-3-[3-(4'-fluorobiphen-4-yl)propyl]-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-N¹-phenyl-1,3-pyrrolidinediacetamide,
- 7p) [S-(R*,R*)]-3-[3-(4'-fluorobiphen-4-yl)propyl]-N¹-(4-fluorophenyl)-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 35 7q) [S-(R*,R*)]-3-[3-(4'-fluorobiphen-4-yl)propyl]-N³-hydroxy-α¹-(1-methylethyl)-2-oxo-N¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,

- 7r) $[S-(R^*,R^*)]-\alpha^1$ -*tert*-butyl-3-[3-(4'-fluorobiphen-4-yl)propyl]- N^3 -hydroxy- N^1 -methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 7s) $[S-(R^*,R^*)]-\alpha^1$ -*tert*-butyl- N^1 -cyclopropyl-3-[3-(4'-fluorobiphen-4-yl)propyl]- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 5 7t) $[S-(R^*,R^*)]-\alpha^1$ -*tert*-butyl-3-[3-(4'-fluorobiphen-4-yl)propyl]- N^3 -hydroxy-2-oxo- N^1 -phenyl-1,3-pyrrolidinediacetamide,
- 7u) $[S-(R^*,R^*)]-\alpha^1$ -*tert*-butyl-3-[3-(4'-fluorobiphen-4-yl)propyl]- N^1 -(4-fluorophenyl)- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 7v) $[S-(R^*,R^*)]-\alpha^1$ -*tert*-butyl-3-[3-(4'-fluorobiphen-4-yl)propyl]- N^3 -hydroxy-2-oxo- N^1 -(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 10 7w) $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl-3-[3-(4'-fluorobiphen-4-yl)propyl]- N^3 -hydroxy- N^1 -methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 7x) $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl- N^1 -cyclopropyl-3-[3-(4'-fluorobiphen-4-yl)propyl]- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 15 7y) $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl-3-[3-(4'-fluorobiphen-4-yl)propyl]- N^3 -hydroxy-2-oxo- N^1 -phenyl-1,3-pyrrolidinediacetamide,
- 7z) $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl-3-[3-(4'-fluorobiphen-4-yl)propyl]- N^1 -(4-fluorophenyl)- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 8a) $[S-(R^*,R^*)]-\alpha^1$ -cyclohexyl-3-[3-(4'-fluorobiphen-4-yl)propyl]- N^3 -hydroxy-2-oxo- N^1 -(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 20 8b) Preparation of $[S-(R^*,R^*)]$ -3-heptyl- N^3 -hydroxy- N^1 -methyl- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 8c) Preparation of $[S-(R^*,R^*)]$ - N^1 -cyclopropyl-3-heptyl- N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 25 8d) Preparation of $[S-(R^*,R^*)]$ -3-heptyl- N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo- N^1 -phenyl-1,3-pyrrolidinediacetamide,
- 8e) Preparation of $[S-(R^*,R^*)]$ -3-heptyl- N^1 -(4-fluorophenyl)- N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 8f) Preparation of $[S-(R^*,R^*)]$ -3-heptyl- N^3 -hydroxy- α^1 -(1-methylethyl)-2-oxo- N^1 -(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 30 8g) Preparation of $[S-(R^*,R^*)]-\alpha^1$ -*tert*-butyl-3-heptyl- N^3 -hydroxy- N^1 -methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 8h) Preparation of $[S-(R^*,R^*)]-\alpha^1$ -*tert*-butyl- N^1 -cyclopropyl-3-heptyl- N^3 -hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 35 8i) Preparation of $[S-(R^*,R^*)]-\alpha^1$ -*tert*-butyl-3-heptyl- N^3 -hydroxy-2-oxo- N^1 -phenyl-1,3-pyrrolidinediacetamide,

- 8j) Preparation of [S-(R*,R*)]- α^1 -*tert*-butyl-*N*¹-(4-fluorophenyl)-3-heptyl-*N*³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 8k) Preparation of [S-(R*,R*)]- α^1 -*tert*-butyl-3-heptyl-*N*³-hydroxy-2-oxo-*N*¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 5 8l) Preparation of [S-(R*,R*)]- α^1 -cyclohexyl-3-heptyl-*N*³-hydroxy-*N*¹-methyl-2-oxo-1,3-pyrrolidinediacetamide,
- 8m) Preparation of [S-(R*,R*)]- α^1 -cyclohexyl-*N*¹-cyclopropyl-3-heptyl-*N*³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide,
- 8n) Preparation of [S-(R*,R*)]- α^1 -cyclohexyl-3-heptyl-*N*³-hydroxy-2-oxo-*N*¹-phenyl-1,3-pyrrolidinediacetamide,
- 10 8o) Preparation of [S-(R*,R*)]- α^1 -cyclohexyl-3-heptyl-*N*¹-(4-fluorophenyl)-*N*³-hydroxy-2-oxo-1,3-pyrrolidinediacetamide, or
- 8p) Preparation of [S-(R*,R*)]- α^1 -cyclohexyl-3-heptyl-*N*³-hydroxy-2-oxo-*N*¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide.
- 15 13. A compound of claim 12 which is
- 1a) (3S)- α -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 1b) [S,S-(R*,R*)]- α^3 -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-*N*³-hydroxy-*N*¹-methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 20 1c) [S-(R*,R*)]-*N*³-Hydroxy-3-(2-methylpropyl)-2-oxo-*N*¹-(2-phenethyl)- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 1d) [S-(R*,R*)]- α^1 -(Cyclohexylmethyl)-*N*³-hydroxy-*N*¹-methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 25 1e) [S-(R*,R*)]-*N*³-Hydroxy-*N*¹-methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 1f) [S-(R*,R*)]-*N*³-Hydroxy-3-(2-methylpropyl)-2-oxo-*N*¹-phenyl- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 30 1g) [S-(R*,R*)]-*N*³-Hydroxy-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-*N*¹-(2-pyridinylmethyl)-1,3-pyrrolidinediacetamide,
- 1h) [S-(R*,R*)]-*N*³-Hydroxy-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-*N*¹-(4-pyridinyl)-1,3-pyrrolidinediacetamide,
- 1i) [S-(R*,R*)]-*N*¹-(4-Fluorophenyl)-*N*³-hydroxy-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide,
- 35 1j) [S-(R*,R*)]-*N*³-Hydroxy-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-

- N^1 -[1-(phenylmethyl)-4-piperdiny]-1,3-pyrrolidinediacetamide,
 1k) [S-(R^* , R^*)]- N^3 -Hydroxy-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)- N^1 -(4-piperdiny)-1,3-pyrrolidinediacetamide,
 1l) [S-(R^* , R^*)]- N^3 -Hydroxy-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-
 5 N^1 -(4-pyridinylmethyl)-1,3-pyrrolidinediacetamide,
 1m) [S-(R^* , R^*)]- N^1 -(4-Fluorophenylmethyl)- N^3 -hydroxy-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide,
 1n) [S-(R^* , R^*)]- N^3 -Hydroxy- N^1 -methyl-3-(2-methylpropyl)-2-oxo- α^1 -(2-phenylethyl)-1,3-pyrrolidinediacetamide,
 10 1o) [S-(R^* , R^*)]- N^3 -Hydroxy-3-(2-methylpropyl)-2-oxo- α^1 -(2-phenylethyl)- N^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide,
 1p) [S-(R^* , R^*)]- N^3 -Hydroxy- α^1 ,3-bis(2-methylpropyl)-2-oxo- N^1 -2-pyridinyl-1,3-pyrrolidinediacetamide,
 1q) [S-(R^* , R^*)]- α^1 -Cyclohexyl- N^3 -hydroxy- N^1 -methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
 15 1r) [S-(R^* , R^*)]- α^1 -Cyclohexyl- N^3 -hydroxy-3-(2-methylpropyl)-2-oxo- N^1 -2-pyridinyl-1,3-pyrrolidinediacetamide,
 1s) [S-(R^* , R^*)]-3-(Cyclopentylmethyl)- N^3 -hydroxy- N^1 -methyl-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide,
 20 1t) [S-(R^* , R^*)]-3-(Cyclopentylmethyl)- N^3 -hydroxy- N^1 -methyl-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide,
 1u) [3S-[1(R^*),3 R^* (R^*)]]- α^3 -[2-(Benzoylamino)ethyl]- N^3 -hydroxy- N^1 -methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide,
 1v) [S-(R^* , R^*)]- N^3 -Hydroxy-3-(2-methylpropyl)- N^1 -[2-(4-morpholinyl)ethyl]-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide,
 25 1w) [S-(R^* , R^*)]- N -Hydroxy-3-(2-methylpropyl)-1-[2-(4-morpholinyl)-2-oxo-1-(phenylmethyl)ethyl]-2-oxo-3-pyrrolidineacetamide,
 1x) [1(1S)-[1(R^* (R^*), 3 α ,5 α)]-1-[2-(3,5-Dimethyl-1-piperazinyl)-2-oxo-1-(phenylmethyl)ethyl]- N -hydroxy-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetamide,
 30 1y) [S-(R^* , R^*)]- N^3 -Hydroxy-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)- N^1 -2-pyridinyl-1,3-pyrrolidinediacetamide,
 1z) [3S-[1(R^*),3 R^* (R^*)]]- α^3 -[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]- N^3 -hydroxy- N^1 -methyl-3-(2-methylpropyl)-2-oxo- α^1 -(phenylmethyl)-1,3-pyrrolidinediacetamide,
 35 2a) [S-(R^* , R^*)]- α^1 -Cyclohexyl- N^1 -cyclopropylmethyl- N^3 -hydroxy-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,

- 2b) [S-(R*,R*)]- α ¹-Cyclohexyl-*N*¹-(4-fluorophenyl)-*N*³-hydroxy-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 2c) [S-(R*,R*)]- α ¹-*tert*-Butyl-*N*³-hydroxy-*N*¹-methyl-3-(2-methylpropyl)-2-oxo-1,3-pyrrolidinediacetamide,
- 5 2d) *N*-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(5-propyloxy-1,3-dihydro-1,3-dioxo-2*H*-isoindol-2-yl)ethyl]-3-pyrrolidineacetamide,
- 2e) [R-(R*,S*)]-5-Fluoro-1,3-dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1,3-dioxo-2*H*-isoindole-2-butanamide,
- 2f) α -[2-(5,6-Difluoro-1,3-dihydro-1,3-dioxo-2*H*-isoindol-2-yl)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 10 2g) *N*-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -[2-(5-trifluoromethyl-1,3-dihydro-1,3-dioxo-2*H*-isoindol-2-yl)ethyl]-3-pyrrolidineacetamide,
- 2h) α -[2-(1,3,4,5,6,7-Hexahydro-1,3-dioxo-2*H*-isoindol-2-yl)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 15 2i) α -[2-(1,3-Dihydro-1,3-dioxo-2*H*-isoindol-2-yl)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(3-phenylpropyl)-3-pyrrolidineacetamide,
- 2j) 1-[2-(4-Fluorophenyl)ethyl]- α -[2-(1,3-dihydro-1,3-dioxo-2*H*-isoindol-2-yl)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetamide,
- 2k) α -[2-(*o*-benzoic sulfimide)ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 20 2l) Ethyl Phenylmethyl [4-(hydroxyamino)-3-[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-4-oxobutyl]imidodicarbonate,
- 2m) S-(R*,R*)-1,3-Dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl]-1,3-dioxo-2*H*-isoindole-2-butanamide,
- 25 2n) 1,3-Dihydro-*N*-hydroxy- α -[3-(2-methylpropyl)-2-oxo-1-[2-(4-fluorophenyl)ethyl]-3-pyrrolidinyl]-1,3-dioxo-2*H*-isoindole-2-butanamide,
- 2o) α -[2-[(3,4-Difluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 2p) [R-(R*,S*)]- α -[2-[(3-Fluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 30 2q) α -[2-[(4-Fluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 2r) *N*-Hydroxy-3-(2-methylpropyl)- α -[2-[(3-nitrobenzoyl)amino]ethyl]-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 35 2s) α -[2-[(3-Fluorobenzoyl)amino]ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,

- 2t) α -{2-[(3-Fluorobenzoyl)amino]ethyl}-1-{2-(4-fluorophenyl)ethyl}-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-3-pyrrolidineacetamide,
- 2u) α -{2-[(4-Biphenylcarbonyl)amino]ethyl}-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 5 2v) *N*-Hydroxy- α -{2-[(4-methylphenyl)sulfonyl]amino}ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 2w) α -{2-[(4-Fluorophenyl)sulfonyl]amino}ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 2x) *N*-Hydroxy- α -{2-[(4-methoxyphenyl)sulfonyl]amino}ethyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 10 2y) *N*-Hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- α -{2-[(phenylsulfonyl)amino]ethyl}-3-pyrrolidineacetamide,
- 2z) [*R*-(*R**,*S**)]- α -{2-[(4-Fluorophenyl)sulfonyl]amino}ethyl]-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 15 3a) 5,6-Difluoro-1,3-dihydro-*N*-hydroxy- α -{3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl}-1-oxo-2*H*-isoindole-2-butanamide,
- 3b) 1,3-Dihydro-*N*-hydroxy- α -{3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl}-1-oxo-2*H*-isoindole-2-butanamide,
- 3c) [*R*-(*R**,*S**)]-6-Fluoro-1,3-dihydro-*N*-hydroxy- α -{3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl}-1-oxo-2*H*-isoindole-2-butanamide,
- 20 3d) [*R*-(*R**,*S**)]-5-Fluoro-1,3-dihydro-*N*-hydroxy- α -{3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl}-1-oxo-2*H*-isoindole-2-butanamide,
- 3e) [*R*-(*R**,*S**)]-5,6-Difluoro-1,3-dihydro-*N*-hydroxy- α -{3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidinyl}-1-oxo-2*H*-isoindole-2-butanamide,
- 25 3f) *N*-Hydroxy- α -{[(4-methoxyphenyl)sulfonyl]amino}-methyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (α *R*-diastereomer),
- 3g) *N*-Hydroxy- α -{[(4-methoxyphenyl)sulfonyl]amino}-methyl]-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (α *S*-diastereomer),
- 3h) α -{[(4-Fluorophenyl)sulfonyl]amino}-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (*R*-diastereomer),
- 30 3i) α -{[(4-Fluorophenyl)sulfonyl]amino}-*N*-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide (α *S*-diastereomer),
- 3j) α -{2-[(3,4-Difluorobenzoyl)amino]ethyl}-*N*-hydroxy-3-(3-hydroxypropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide,
- 35 3k) α -{2-[(3,4-Difluorobenzoyl)amino]ethyl}-*N*-hydroxy-3-(2-hydroxyethyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide, or

31) [R-(R*,S*)]- α -[2-[(3-Fluorobenzoyl)amino]ethyl]-N-hydroxy-3-(3-hydroxypropyl)-2-oxo-1-(2-phenylethyl)-3-pyrrolidineacetamide.

14. A method of inhibiting excess matrix metalloproteinase which comprises
5 administering to a patient in need thereof an effective amount of a compound of claim 1.

15. A method of claim 14 wherein matrix metalloproteinases comprises collagenases, stromelysins, or gelatinases.

10

16. A method of treating a human, suffering from or susceptible to a diseases involving connective tissue degradation which comprises administering to a patient in need thereof an effective amount of a compound of claim 1.

15 17. A method of 16 wherein the diseases related to connective tissue degradation is osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as osteoporosis, tumor metastasis (invasion and growth), periodontitis, gingivitis, corneal ulceration, dermal ulceration, or gastric ulceration.

20 18. A pharmaceutical composition which comprises an amount of the compound of claim 1 effective to inhibit excess matrix metalloproteinase and a pharmaceutically acceptable carrier.

19. The method of claim 14 wherein the effective inhibitory amount of the
25 compound of claim 1 is administered orally, parenterally, or topically in a pharmaceutical composition.

20. The method of claim 16 wherein the effective amount of the compound of claim 1 is administered orally, parenterally, or topically in a pharmaceutical
30 composition.

21. The method of claim 14 or 16 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.

35

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/02568

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D207/26 C07D403/06 C07D409/12 C07D207/40 C07D233/78
C07D231/08 C07D401/12 A61K31/40 A61K31/41 C07D413/12
C07D417/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 042 100 A (HOFFMANN-LA ROCHE AG) 23 December 1981 see page 5, line 7 - line 8; claim 1 ---	1-21
A	WO 94 22820 A (G. D. SEARLE SND CO.) 13 October 1994 see claims 1,16 ---	1-21
A	GB 2 282 598 A (MERCK & CO., INC.) 12 April 1995 cited in the application see claims 1,12 ---	1-21
A	EP 0 574 758 A (F. HOFFMANN-LA ROCHE AG) 22 December 1993 cited in the application see claims 1,25 -----	1-21

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

18 June 1997

Date of mailing of the international search report

09.07.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Herz, C

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. Application No

PCT/US 97/02568

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 42100 A	23-12-81	AU 7138281 A JP 57028057 A US 4399136 A US 4487929 A	17-12-81 15-02-82 16-08-83 11-12-84
WO 9422820 A	13-10-94	AU 6552294 A CA 2159450 A CN 1124957 A EP 0691953 A FI 954609 A JP 8508732 T NO 953844 A	24-10-94 13-10-94 19-06-96 17-01-96 23-10-95 17-09-96 20-11-95
GB 2282598 A	12-04-95	US 5403952 A	04-04-95
EP 574758 A	22-12-93	AU 659555 B BG 97857 A CA 2098168 A CN 1083062 A CZ 9301081 A HR 930978 A JP 6065196 A JP 7076210 B NO 932117 A NZ 247765 A PL 299261 A SI 9300289 A SK 57393 A US 5318964 A US 5447929 A ZA 9303957 A	18-05-95 15-11-94 12-12-93 02-03-94 16-02-94 30-04-97 08-03-94 16-08-95 13-12-93 27-11-95 10-01-94 31-12-93 11-05-94 07-06-94 05-09-95 13-12-93